var title_f43_43_44720="A haemolyticum rash";
var content_f43_43_44720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rash of Arcanobacterium haemolyticum infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Academy of Pediatrics. Red Book Online: Photo of the week. Available at: aapredbook.aappublications.org/week/iotw012808.shtml. Copyright &copy;2008 American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44720=[""].join("\n");
var outline_f43_43_44720=null;
var title_f43_43_44721="Approach to bone disorders in HIV";
var content_f43_43_44721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Approach to bone problems in patients with human immunodeficiency virus (HIV) infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 702px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Hx: history; BMD: bone minteral density; DXA: dual-energy x-ray absorptiometry; FRAX: Fracture Risk Assessment Tool; ART: antiretroviral therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937, by permission of Oxford University Press. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44721=[""].join("\n");
var outline_f43_43_44721=null;
var title_f43_43_44722="Menthol and zinc oxide (topical): Drug information";
var content_f43_43_44722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Menthol and zinc oxide (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/31/33267?source=see_link\">",
"    see \"Menthol and zinc oxide (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15573799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calmoseptine&reg; [OTC];",
"     </li>",
"     <li>",
"      Remedy&reg; Calazime&reg; [OTC];",
"     </li>",
"     <li>",
"      Risamine&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10117291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Protectant, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10117325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Protective barrier:",
"     </b>",
"     Topical: Apply thin layer to clean, dry skin 2-4 times/day or after each incontinent episode/diaper change",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10117324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10117328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calmoseptine&reg;: Menthol 0.44% and zinc oxide 20.625% (3.5 g/packet, 75 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Risamine&trade;: Menthol 0.44% and zinc oxide 20.625% (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remedy&reg; Calazime&reg;: Menthol 0.2% and zinc oxide 20% (4 g, 113 g) [contains aloe]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10117326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply thin layer and rub in well. Do not have to completely remove before reapplication. Not for use during radiation therapy; if used, complete removal is necessary before each radiation treatment. Can remove ointment from skin with baby or mineral oil.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10117292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provides a barrier to protect intact and/or injured skin from moisture, wound or fistula drainage, urine, or feces; diaper rash",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10117297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus, rash, stinging (temporarily on application)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10117293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to menthol, zinc oxide, or any components of the formulation; not for use during radiation treatment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10117294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiation therapy:  Zinc oxide cannot be used during radiation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Do not use in deep injury or puncture wounds. Do not use in or around eyes or mucous membranes. May be used safely around mouth, anal, and vaginal openings.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10149395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Calmoseptine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.44-20.625% (71 g): $4.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Risamine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.44-20.625% (113 g): $4.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (Remedy Calazime External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2-20% (4 g): $0.57",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9568 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44722=[""].join("\n");
var outline_f43_43_44722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15573799\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117291\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117325\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117324\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117328\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117326\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117292\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117297\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117293\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117294\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299667\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149395\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570427\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9568\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9568|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/31/33267?source=related_link\">",
"      Menthol and zinc oxide (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_43_44723="Nitazoxanide: Pediatric drug information";
var content_f43_43_44723=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitazoxanide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"    see \"Nitazoxanide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/3/5172?source=see_link\">",
"    see \"Nitazoxanide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alinia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"      see \"Nitazoxanide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Cryptosporidium parvum",
"     </i>",
"     or",
"     <i>",
"      Giardia lamblia",
"     </i>",
"     treatment of diarrhea (",
"     <b>",
"      Note:",
"     </b>",
"     May consider increasing duration up to 14 days in HIV-exposed/HIV-infected patients (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-3 years: 100 mg every 12 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-11 years: 200 mg every 12 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;12 years and Adults: 500 mg every 12 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Fasciola hepatica",
"     </i>",
"     (sheep liver fluke) (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-3 years: 100 mg every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 4-11years: 200 mg every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &ge;12 years and Adults: 500 mg every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hymenolepis nana",
"     </i>",
"     (dwarf tapeworm) (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-3 years: 100 mg twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 4-11 years: 200 mg twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 500 mg once or twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea: Adults: 500 mg every 12 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal and/or hepatic impairment:",
"     </b>",
"     Specific recommendations are not available; use with caution",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alinia&reg;: 100 mg/5 mL (60 mL) [contains sodium benzoate, sucrose 1.48 g/5 mL; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alinia&reg;: 500 mg [contains soy lecithin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minimize gastric irritation by administering with food; shake suspension well prior to use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Prior to and following reconstitution, store at  25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following reconstitution, discard unused portion of suspension after 7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store at  25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea caused by",
"     <i>",
"      Giardia lamblia",
"     </i>",
"     (FDA approved in ages &ge;1 year and adults); treatment of diarrhea caused by",
"     <i>",
"      Cryptosporidium parvum",
"     </i>",
"     in immunocompetent patients (FDA approved in ages &ge;1 year and adults); has also been used for the treatment of amebiasis, dwarf tapeworm infection, fluke infections, and refractory or recurrent",
"     <i>",
"      Clostridium difficile-",
"     </i>",
"     associated diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F201775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, ALT increased, anemia, anorexia, appetite increased, creatinine increased, diaphoresis, dizziness, eye discoloration (pale yellow), fever, flatulence, hypertension, infection, malaise, pruritus, rhinitis, salivary glands enlarged, tachycardia, urine discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitazoxanide or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal, hepatic, or biliary disease since pharmacokinetics of nitazoxanide have not been studied in these patients. Use suspension dosage form with caution in diabetic patients due to sucrose content.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of sodium benzoate containing products in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Administration with food increases AUC twofold and peak concentrations by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Administration with food increases AUC by 45% to 50% and peak concentrations by &le;10%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, stool frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Appears to interfere with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential for anaerobic energy metabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients (1-18 years of age), pharmacokinetic properties similar to adult  when dosed equivalently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Tizoxanide: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, to an active metabolite, tizoxanide. Tizoxanide undergoes conjugation to form tizoxanide glucuronide. Nitazoxanide is not detectable in the serum following oral administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Relative bioavailability of the suspension to the tablet is 70%; tablet and suspension are not bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Tizoxanide: 1-1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Tizoxanide: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Tizoxanide is excreted in urine (&lt;10%), bile, and feces (60%); tizoxanide glucuronide is excreted in urine and bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/3/5172?source=see_link\">",
"      see \"Nitazoxanide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor eyes or urine to a yellow tint",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The oral suspension contains sucrose 1.48 g/5 mL.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bobak DA, \"Use of Nitazoxanide for Gastrointestinal Tract Infections: Treatment of Protozoan Parasitic Infection and Beyond,\"",
"      <i>",
"       Curr Infect Dis Rep",
"      </i>",
"      , 2006, 8(2):91-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44723/abstract-text/16524544 /pubmed\" id=\"16524544 \" target=\"_blank\">",
"        16524544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44723/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Drugs for Parasitic Infections,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 783-816. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/4.10",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12904 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44723=[""].join("\n");
var outline_f43_43_44723=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201754\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048945\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048938\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201736\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201725\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048948\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048941\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048947\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201775\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048951\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048937\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048936\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299763\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221927\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048954\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201733\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201742\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048944\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048935\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048950\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048943\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048952\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=related_link\">",
"      Nitazoxanide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/3/5172?source=related_link\">",
"      Nitazoxanide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_43_44724="Coal tar: Drug information";
var content_f43_43_44724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Coal tar: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/51/13109?source=see_link\">",
"    see \"Coal tar: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/19/2356?source=see_link\">",
"    see \"Coal tar: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Balnetar&reg; [OTC];",
"     </li>",
"     <li>",
"      Betatar Gel&reg; [OTC];",
"     </li>",
"     <li>",
"      Cutar&reg; [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Therapeutic Protection 2-in-1 Shampoo + Conditioner [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Therapeutic Protection [OTC];",
"     </li>",
"     <li>",
"      DHS&reg; Tar [OTC];",
"     </li>",
"     <li>",
"      DHS&trade; Tar Gel [OTC];",
"     </li>",
"     <li>",
"      Exorex&reg; Penetrating Emulsion #2 [OTC];",
"     </li>",
"     <li>",
"      Exorex&reg; Penetrating Emulsion [OTC];",
"     </li>",
"     <li>",
"      ionil-T&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      ionil-T&reg; [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar Extra Strength [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar Intensive Strength [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; Stubborn Itch Control [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; [OTC];",
"     </li>",
"     <li>",
"      Oxipor&reg; VHC [OTC];",
"     </li>",
"     <li>",
"      Pentrax&reg; [OTC];",
"     </li>",
"     <li>",
"      Scytera&trade; [OTC];",
"     </li>",
"     <li>",
"      Tera-Gel&trade; [OTC];",
"     </li>",
"     <li>",
"      Thera-Gel [OTC];",
"     </li>",
"     <li>",
"      Zetar&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doak Oil Forte [OTC];",
"     </li>",
"     <li>",
"      Doak Oil [OTC];",
"     </li>",
"     <li>",
"      Emorex Gel [OTC];",
"     </li>",
"     <li>",
"      Neuotrogena T/Gel Therapeutic Shampoo [OTC];",
"     </li>",
"     <li>",
"      Odans Liquor Carbonis Detergens [OTC];",
"     </li>",
"     <li>",
"      Pentrax Gold Shampoo [OTC];",
"     </li>",
"     <li>",
"      Pentrax Tar Shampoo [OTC];",
"     </li>",
"     <li>",
"      Psoriasin [OTC];",
"     </li>",
"     <li>",
"      T/Gel Therapeutic Shampoo Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Targel&reg; [OTC];",
"     </li>",
"     <li>",
"      Tersa Tar Shp [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seborrhea, dermatitis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Skin:",
"     </i>",
"     Apply to the affected area 1-4 times/day; decrease frequency to 2-3 times/week once condition has been controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Soap:",
"     </i>",
"     Use on affected areas in place of regular soap. Work into a lather using warm water; massage into skin; rinse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Bath:",
"     </i>",
"     Add appropriate amount to bath water, for adults usually 60-90 mL of a 5% to 20% solution or 15-25 mL of 30% lotion; soak 5-20 minutes, then pat dry; use once daily to 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dandruff:",
"     </b>",
"     Shampoo: Rub shampoo onto wet hair and scalp, rinse thoroughly; repeat; leave on 5 minutes; rinse thoroughly; apply twice weekly for the first 2 weeks then once weekly or more often if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Scalp psoriasis:",
"     </i>",
"     Tar oil bath or coal tar solution may be painted sparingly to the lesions 3-12 hours before each shampoo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Psoriasis of the body, arms, legs:",
"     </i>",
"     Apply at bedtime; if thick scales are present, use product with salicylic acid and apply several times during the day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scytera&trade;: Coal tar solution 10% (100 g) [equivalent to coal tar 2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutar&reg;: Coal tar solution 7.5% (180 mL, 3840 mL) [equivalent to coal tar 1.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exorex&reg; Penetrating Emulsion: Coal tar 1% (100 mL, 250 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exorex&reg; Penetrating Emulsion #2: Coal tar 2% (100 mL, 250 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [shampoo]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DHS&trade; Tar Gel: Solubilized coal tar extract 2.9% (240 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thera-Gel: 0.5% (255 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MG217&reg; Medicated Tar: Coal tar solution 5% (120 mL) [contains jojoba; equivalent to coal tar 1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxipor&reg; VHC: Coal tar solution 25% (56 mL, 120 mL) [contains ethanol 79%; equivalent to coal tar 5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Balnetar&reg;: Coal tar 2.5% (221 mL) [for use in bath]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MG217&reg; Medicated Tar Intensive Strength: Coal tar solution 10% (107 g) [equivalent to coal tar 2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betatar Gel&reg;: Coal tar solution 12.5% (480 mL) [equivalent to coal tar 2.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denorex&reg; Therapeutic Protection: Coal tar solution 12.5% (118 mL, 240 mL, 300 mL) [contains ethanol 10.4%; equivalent to coal tar 2.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DHS&reg; Tar: Solubilized coal tar extract 2.9% (120 mL, 240 mL, 480 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ionil-T&reg;: Coal tar 1% (240 mL, 480 mL, 960 mL) [contains ethanol 12%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ionil-T&reg; Plus: Coal tar 2% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MG217&reg; Medicated Tar Extra Strength: Coal tar solution 15% (120 mL, 240 mL) [equivalent to coal tar 3%; with conditioners]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; T/Gel&reg;: Solubilized coal tar extract 2% (130 mL, 255 mL, 480 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; T/Gel&reg; Extra Strength: Solubilized coal tar extract 4% (177 mL) [equivalent to coal tar 1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; T/Gel&reg; Stubborn Itch Control: Coal tar extract 2% (130 mL) [contains menthol; equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentrax&reg;: Coal tar 5% (236 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tera-Gel&trade;: Solubilized coal tar extract 2% (120 mL, 255 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zetar&reg;: Coal tar 1% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo/Conditioner, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denorex&reg; Therapeutic Protection 2-in-1 Shampoo + Conditioner: Coal tar solution 12.5% (120 mL, 240 mL, 300 mL) [contains ethanol 10.4%; equivalent to coal tar 2.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 20% (473 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topically for controlling dandruff, seborrheic dermatitis, or psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pentrax [U.S., Canada, Great Britain, Ireland] may be confused with Permax brand name for pergolide [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Dermatologic: Dermatitis, folliculitis, irritation, photosensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to coal tar or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May increase photosensitivity; avoid exposure to direct sunlight for 24 hours following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with eyes, genital/rectal areas.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13862032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limited application of coal tar during pregnancy for the treatment of psoriasis appears to be safe in pregnant women (Gelmetti, 2009; Landau, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bar",
"     </b>",
"     (Polytar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.11-0.3-0.3% (1): $4.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bar",
"     </b>",
"     (Tegrin Medicated Soap External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (1): $3.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Elta Tar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (107 g): $9.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tegrin for Psoriasis External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 g): $9.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Balnetar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (221 mL): $23.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Scytera External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (100 g): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (MG217 Psoriasis Multi-Symptom External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (56 g): $5.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Psoriasin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25% (21.25 g): $5.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Neutrogena T/Gel Conditioner External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (130 mL): $4.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (MG217 Psoriasis Medicated External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (120 mL): $7.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Cutar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (180 mL): $16.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (MG217 Medicated Tar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (107.7 g): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (MG217 Psoriasis Multi-Symptom External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (107 g): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Psoriasin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (113 g): $7.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Beta Care Betatar Gel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (480 mL): $11.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (DHS Tar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (120 mL): $5.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (DHS Tar Gel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (240 mL): $8.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (MG217 Medicated Tar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (240 mL): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Neutrogena T/Gel Ex St External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (177 mL): $7.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Neutrogena T/Gel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (251 mL): $7.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Original Tegrin Medicated External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (210 mL): $4.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Pentrax Gold External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (168 mL): $6.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Tera-Gel Tar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (114 mL): $3.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Theraplex T External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (240 mL): $7.20",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F154025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Carbotural (MX);",
"     </li>",
"     <li>",
"      Coco-Scalp (NZ);",
"     </li>",
"     <li>",
"      Doak Tar (HK);",
"     </li>",
"     <li>",
"      Evorex Lotion (GR, IE, NL);",
"     </li>",
"     <li>",
"      Hi-Tar (SG);",
"     </li>",
"     <li>",
"      Linotar (ZA);",
"     </li>",
"     <li>",
"      Linotar Gel 1 (AU);",
"     </li>",
"     <li>",
"      Linotar Gel 2 (AU);",
"     </li>",
"     <li>",
"      Linotar Gel 3 (AU);",
"     </li>",
"     <li>",
"      Medic (AR);",
"     </li>",
"     <li>",
"      Polytar (AU, PL, ZA);",
"     </li>",
"     <li>",
"      Polytar Plus (AU);",
"     </li>",
"     <li>",
"      Tarmed (CN, CO, PE);",
"     </li>",
"     <li>",
"      Tarmed Shampoo (MX)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gelmetti C, \"Therapeutic Moisturizers as Adjuvant Therapy for Psoriasis Patients,\"",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      , 2009, 10(Suppl 1):7-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44724/abstract-text/19209948/pubmed\" id=\"19209948\" target=\"_blank\">",
"        19209948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Landau JL, Moody MN, Kazakevich N, et al, \"Psoriasis and the Pregnant Woman: What Are the Key Considerations?\"",
"      <i>",
"       Skin Therapy Lett",
"      </i>",
"      , 2011, 16(9):1-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44724/abstract-text/22089504/pubmed\" id=\"22089504\" target=\"_blank\">",
"        22089504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8878 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44724=[""].join("\n");
var outline_f43_43_44724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154028\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154036\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154029\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154030\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154021\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154010\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154022\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154040\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154034\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154024\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154013\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299071\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219451\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13862032\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323074\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154025\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8878|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/51/13109?source=related_link\">",
"      Coal tar: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/19/2356?source=related_link\">",
"      Coal tar: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_43_44725="Gram stain sputum 2A answer";
var content_f43_43_44725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69327%7EID%2F59890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69327%7EID%2F59890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sputum from pneumococcal pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows abundant inflammatory cells and Gram positive diplococci; Streptococcus pneumoniae was identified from this specimen by culture and by the optochin disk test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optochin disk test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Optochin disk test to differentiate alpha-hemolytic (green) streptococci. Streptococcus pneumoniae is susceptible to optochin as shown by the zone of inhibition around the disk of the culture on the right. Other alpha- hemolytic streptococci (example on left) are resistant to this compound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44725=[""].join("\n");
var outline_f43_43_44725=null;
var title_f43_43_44726="Cardiac cycle";
var content_f43_43_44726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The cardiac cycle and cardiac conduction system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 680px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The electrical impulse is initiated in the sinus node and then activates the right and left atria, generating the P wave. Impulse conduction through the atrioventricular (AV) node and bundle of His, which are small structures, does not generate any ECG activity; this period of \"electrical silence\" is the PR interval. The first part of the ventricle to be depolarized is the left side of the interventricular septum, producing a small septal Q wave, followed by depolarization of the remainder of the ventricular myocardium, generating the full QRS complex. The T wave represents ventricular repolarization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44726=[""].join("\n");
var outline_f43_43_44726=null;
var title_f43_43_44727="Prurigo nodularis";
var content_f43_43_44727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prurigo nodularis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/43/44727/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/43/44727/contributors\">",
"     Kalman Watsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/43/44727/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/43/44727/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/43/44727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/43/44727/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/43/44727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21099279\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prurigo nodularis (PN) is a chronic skin disorder characterized by multiple, firm, pruritic nodules typically localized to the extensor surface of the extremities (",
"    <a class=\"graphic graphic_picture graphicRef66268 graphicRef53475 \" href=\"mobipreview.htm?20/49/21271\">",
"     picture 1A-B",
"    </a>",
"    ). PN is frequently associated with a history of atopic dermatitis or chronic pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prurigo nodularis will be discussed in this topic. Other skin conditions associated with chronic pruritus, including atopic dermatitis, nodular scabies, lichen planus, and bullous pemphigoid, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10090?source=see_link\">",
"       \"Pruritus: Etiology and patient evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=see_link\">",
"       \"Pruritus: Overview of management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28712?source=see_link\">",
"       \"Scabies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=see_link\">",
"       \"Lichen planus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21099286\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of prurigo nodularis (PN) are not known. PN can occur in all age groups but primarily affects older adults. In a review of 108 cases of PN, the median age was 62 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/3\">",
"     3",
"    </a>",
"    ]. Both sexes are equally affected.",
"   </p>",
"   <p>",
"    In approximately half of cases, PN is associated with a history of atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with atopic dermatitis may have PN at an earlier age than nonatopic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/4\">",
"     4",
"    </a>",
"    ]. Prurigo nodularis occurs in approximately 5 percent of patients with HIV infection, particularly among individuals with a CD4+ count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/5\">",
"     5",
"    </a>",
"    ]. In tropical areas, PN may be the first manifestation of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21099293\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of prurigo nodularis is largely unknown. Earlier studies noted an increased number of nerves in the papillary dermis, suggesting a neurocutaneous component in the pathogenesis of PN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/7\">",
"     7",
"    </a>",
"    ]. Nerve growth factor (NGF) and its receptor tyrosine receptor kinase A (TrkA) are overexpressed in prurigo nodularis lesions and may be associated with increased release and accumulation of neuropeptides, such as substance P and calcitonin gene-related peptide (CGRP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Mast cells, which are known to release NGF, are seen in close vicinity to nerves expressing TrkA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, subsequent studies have not confirmed dermal nerve hyperplasia in PN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/13\">",
"     13",
"    </a>",
"    ]. An immunohistochemical study of 53 patients with PN found that intraepidermal nerve fibre density is reduced in lesional and nonlesional skin of patients with PN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/13\">",
"     13",
"    </a>",
"    ]. This finding suggests that PN may represent a form of subclinical cutaneous neuropathy or, alternatively, that the reduced nerve fiber density is a secondary effect of scratching.",
"   </p>",
"   <p>",
"    The role of Th1 and Th2 cytokines in the pathogenesis of PN also has been evaluated by examining the cytokine signatures in the epidermis of 22 cases of PN using the signal transducers and activators of transcription STAT 1, 3, and 6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/14\">",
"     14",
"    </a>",
"    ]. In 19 of 22 cases, the entire epidermis stained with anti-pSTAT 6, a marker for the Th2 cytokines IL-4, IL-5, and IL-13. Only eight cases showed scattered staining with anti-pSTAT 1, a marker for the Th1 cytokines IFN and IL-27. These findings suggest that Th2 cytokines play a principal role in the pathogenesis of PN.",
"   </p>",
"   <p>",
"    Allergic contact dermatitis, emotional stress, and psychologic factors may be contributing factors in the pathogenesis of PN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6984368\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathology of PN shows thick, compact ortho-hyperkeratosis; irregular epidermal hyperplasia or pseudoepitheliomatous hyperplasia; focal parakeratosis with irregular acanthosis; diminished nerve fiber density; and a nonspecific dermal infiltrate containing lymphocytes, macrophages, eosinophils, and neutrophils (",
"    <a class=\"graphic graphic_picture graphicRef86963 \" href=\"mobipreview.htm?32/45/33489\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. A hair follicle may be seen in the center of the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21099300\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prurigo nodularis (PN) typically presents with firm, dome-shaped, itchy nodules symmetrically distributed on the extensor surfaces of the arms and legs (",
"    <a class=\"graphic graphic_picture graphicRef86816 graphicRef66268 graphicRef53475 graphicRef86964 \" href=\"mobipreview.htm?33/41/34458\">",
"     picture 1A-D",
"    </a>",
"    ). Nodules can be flesh-colored, erythematous, or",
"    <span class=\"nowrap\">",
"     brown/black",
"    </span>",
"    and range in number from few to hundreds (",
"    <a class=\"graphic graphic_picture graphicRef86817 \" href=\"mobipreview.htm?15/48/16133\">",
"     picture 1E",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The extensor surfaces of the extremities are characteristically involved. The upper back, abdomen, and sacrum also can be involved whereas the difficult to reach upper mid-back area is usually spared (&ldquo;butterfly&rdquo; sign) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/21\">",
"     21",
"    </a>",
"    ]. The palms, soles, face, and flexural areas are rarely involved.",
"   </p>",
"   <p>",
"    Pruritus is always severe and distressing; it can be paroxysmal, sporadic, or continuous, and is worsened by heat, sweating, or irritation from clothing. In most cases, the cause of pruritus is unknown.",
"   </p>",
"   <p>",
"    In some patients, a coexistent pruritic skin condition (eg, atopic dermatitis, xerosis) may be the initial cause of pruritus. Rarely, PN may be the presenting symptom of a systemic disease, such as infection with HIV or mycobacteria, parasitic infestation, or lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/6,24-27\">",
"     6,24-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21099314\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of prurigo nodularis (PN) is clinical, based upon a history of chronic severe pruritus and the clinical finding of characteristic excoriated nodular lesions symmetrically distributed (",
"    <a class=\"graphic graphic_picture graphicRef86817 graphicRef53475 graphicRef66268 graphicRef86816 \" href=\"mobipreview.htm?38/63/39930\">",
"     picture 1A-C, 1E",
"    </a>",
"    ). However, several relatively rare skin conditions can mimic PN. Skin biopsy is indicated in cases where the clinical diagnosis is in question or there is a poor response to first line therapies. (See",
"    <a class=\"local\" href=\"#H21099300\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6984368\">",
"     'Histopathology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6984633\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with PN who do not have a history of atopic dermatitis or other pruritic skin condition, systemic causes of chronic pruritus should be investigated. Systemic causes of pruritus include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic renal failure",
"     </li>",
"     <li>",
"      Liver failure",
"     </li>",
"     <li>",
"      Hypo- or hyperthyroidism",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Parasitic infestation",
"     </li>",
"     <li>",
"      Malignancy &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10090?source=see_link&amp;anchor=H690781#H690781\">",
"     \"Pruritus: Etiology and patient evaluation\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial evaluation involves a detailed medical history, physical examination, and laboratory and imaging tests, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood cell count",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      BUN and creatinine",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone",
"     </li>",
"     <li>",
"      Stool examination for ova and parasites",
"     </li>",
"     <li>",
"      HIV test",
"     </li>",
"     <li>",
"      Chest radiograph",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10090?source=see_link\">",
"     \"Pruritus: Etiology and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6984633\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin diseases that may mimic PN include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acquired reactive perforating dermatoses",
"      </strong>",
"      &ndash; Acquired reactive perforating dermatoses are a group of skin disorders most commonly associated with chronic renal failure and diabetes mellitus, characterized by transepithelial elimination of dermal material. They present with pruritic dome-shaped, umbilicated papules with a central keratinous plug, located on the trunk and limbs (",
"      <a class=\"graphic graphic_picture graphicRef86478 graphicRef86829 graphicRef86830 graphicRef86831 \" href=\"mobipreview.htm?40/26/41386\">",
"       picture 3A-D",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/28\">",
"       28",
"      </a>",
"      ]. Histology reveals a cup-shaped depression of the epidermis filled with a plug consisting of keratin, collagen, and inflammatory debris. The underlying epidermis shows fine slits through which basophilic collagen fibers in vertical orientation are extruded.",
"     </li>",
"     <li>",
"      <strong>",
"       Pemphigoid nodularis",
"      </strong>",
"      &ndash; Pemphigoid nodularis is a rare variant of bullous pemphigoid characterized by pruritic nodules, papules or plaques that mimic clinically and histologically PN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/19\">",
"       19",
"      </a>",
"      ]. The diagnosis is confirmed by direct immunofluorescence, showing linear IgG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C3 staining along the basement membrane zone, and presence of circulating autoantibodies against BP antigens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link&amp;anchor=H53290498#H53290498\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nodular scabies",
"      </strong>",
"      &ndash; A history of exposure and histologic examination can usually differentiate PN from nodular scabies (",
"      <a class=\"graphic graphic_picture graphicRef60849 graphicRef75169 graphicRef83093 \" href=\"mobipreview.htm?14/16/14602\">",
"       picture 4A-C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28712?source=see_link&amp;anchor=H9#H9\">",
"       \"Scabies\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypertrophic lichen planus",
"      </strong>",
"      &ndash; Hypertrophic lichen planus is a variant of lichen planus characterized by the presence of thick hyperkeratotic plaques, often on the anterior aspect of the legs (",
"      <a class=\"graphic graphic_picture graphicRef54396 \" href=\"mobipreview.htm?23/6/23652\">",
"       picture 5",
"      </a>",
"      ). Histology can clarify the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=see_link\">",
"       \"Lichen planus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Multiple keratoacanthomas",
"      </strong>",
"      &ndash; Multiple keratoacanthomas are a feature of the rare Ferguson&ndash;Smith syndrome and Grzybowski syndrome (",
"      <a class=\"graphic graphic_picture graphicRef50780 \" href=\"mobipreview.htm?21/10/21668\">",
"       picture 6",
"      </a>",
"      ). Histology and clinical course differentiate multiple keratoacanthomas from PN. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4090?source=see_link&amp;anchor=H2295938#H2295938\">",
"       \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Multiple keratoacanthomas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermolysis bullosa pruriginosa",
"      </strong>",
"      &ndash; Epidermolysis bullosa (EB) pruriginosa is a rare localized variant of dystrophic EB characterized by skin fragility, intense pruritus, and skin lesions resembling hypertrophic lichen planus or prurigo nodularis. The clinical suspicion of inherited EB needs to be confirmed by appropriate immunofluorescence studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=see_link&amp;anchor=H476124#H476124\">",
"       \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Rare subtypes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21099321\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for prurigo nodularis (PN). Topical or systemic therapies are aimed at interrupting the itch-scratch cycle and flattening the skin lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6985246\">",
"    <span class=\"h2\">",
"     Topical and intralesional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical treatments for PN include superpotent topical corticosteroids with or without occlusion, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . None of these treatments has been evaluated in randomized trials and their use is based upon clinical experience and limited evidence from small observational studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Topical corticosteroids",
"      </strong>",
"      &ndash; Superpotent topical corticosteroids, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% ointment (group one (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )), with or without occlusion are often the first-line therapy for PN.",
"     </li>",
"     <li>",
"      <strong>",
"       Intralesional corticosteroids",
"      </strong>",
"      &ndash; Intralesional corticosteroids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide 10 to 40",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      suspension based upon the size of the lesion and response to treatment) are an alternative to superpotent topical corticosteroids. Based upon clinical experience, they are effective in reducing pruritus and flattening the nodules. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Topical",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      &ndash; Topical capsaicin exerts analgesic and antipruritic effect by inducing the depletion of the neuropeptide substance P from local sensory nerve terminals in the skin, degeneration of epidermal nerve fibers, and desensitization of nociceptive nerve endings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study, 33 patients with PN were treated with topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    0.025% to 0.3% four to six times per day for two weeks up to 33 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/31\">",
"     31",
"    </a>",
"    ]. Complete remission of pruritus was reported by all patients within 12 days of treatment. The nodules flattened and softened within two months in 24 patients. However, pruritus and skin nodules recurred in 16 patients upon discontinuation of treatment.",
"   </p>",
"   <p>",
"    There are isolated reports of successful treatment of PN with topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and topical vitamin D analogs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    , tacalcitol) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9315409\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy with psoralen plus ultraviolet A (PUVA), including",
"    <span class=\"nowrap\">",
"     bath/topical",
"    </span>",
"    PUVA, long-wavelength ultraviolet A (UVA1, 340-400 nm), narrowband UVB (311 to 312 nm), or monochromatic excimer light of 308 nm, has been used to control pruritus and improve the skin lesions in patients with PN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=see_link\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26775?source=see_link\">",
"     \"UVB therapy (broadband and narrowband)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited evidence for efficacy is derived from small observational studies and a single randomized trial, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 63 patients with prurigo nodularis were treated with topical PUVA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/39\">",
"       39",
"      </a>",
"      ]. Approximately 80 percent of patients improved after the first treatment cycle of two to four weeks.",
"     </li>",
"     <li>",
"      In another study, 22 patients with PN were randomized to use bath PUVA or bath PUVA plus targeted 308 nm excimer laser therapy. Six of 11 patients receiving bath PUVA alone and 7 of 10 receiving combined therapy had complete clearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients assigned to bath PUVA alone received an average of 20 treatment sessions, whereas patients assigned to combination therapy received an average of 10 bath PUVA sessions.",
"     </li>",
"     <li>",
"      Narrowband UVB therapy was used to treat 10 patients with recalcitrant PN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/40\">",
"       40",
"      </a>",
"      ]. Improvement of skin lesions was reported in all patients after a median number of 16 weekly treatments.",
"     </li>",
"     <li>",
"      Monochromatic excimer light (308 nm) laser therapy induced partial or complete remission in 11 patients with PN after an average of 7.5 treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6985292\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic treatments for prurigo nodularis (PN) include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and cyclosporin. Their efficacy in the treatment of PN has not been evaluated in randomized trials and there is only limited evidence derived from small observational studies. These treatments are associated with potential significant toxicity, and their efficacy in patients with PN has not been established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      - Thalidomide is thought to have sedative, immunomodulatory, antiinflammatory, and anti-angiogenic properties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/41\">",
"       41",
"      </a>",
"      ]. Thalidomide has been used for the treatment of prurigo nodularis in both immunocompetent patients and in patients with HIV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/42-45\">",
"       42-45",
"      </a>",
"      ]. However, the use of thalidomide is associated with a dose-dependent risk of peripheral neuropathy that may be nonreversible as well as serious birth defects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a retrospective study, 21 patients with PN were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/42\">",
"       42",
"      </a>",
"      ]. Of 12 patients who took the medication one month or longer, one had a complete response and four had no improvement.",
"     </li>",
"     <li>",
"      In a retrospective study, 42 patients with PN were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      at an average dose of 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for an average of two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/43\">",
"       43",
"      </a>",
"      ]. The average duration of thalidomide treatment before discontinuation due to neuropathy was 89 weeks (range one week to 7.5 years). There was moderate to marked improvement in 50 percent of the patients; 12 patients showed only slight improvement or no effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another small study, eight patients with HIV infection and PN were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      100 to 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/46\">",
"       46",
"      </a>",
"      ]. After an average of five months, seven patients had a greater than 50 percent reduction in skin lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      &ndash; Oral cyclosporine has been used to achieve rapid control of pruritus in patients with recalcitrant PN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. In one study including 14 patients treated with cyclosporine 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, 10 patients reported a &ldquo;very good response&rdquo; after an average treatment time of 2.7 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/48\">",
"       48",
"      </a>",
"      ]. However, long-term treatment with cyclosporine is limited by adverse effects such as elevation of blood pressure and serum creatinine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are isolated reports of successful treatment of PN with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (an analogue of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    with a reduced risk of peripheral neuropathy), the &mu;-opioid receptor antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    , and the neurokinin receptor 1 agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44727/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6985236\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of prurigo nodularis (PN) requires a multifaceted approach and response is frequently suboptimal. Any underlying causes of pruritus should be investigated and treated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be educated about adopting general measures to reduce scratching and excoriations, including keeping their nails short, wearing gloves at night, and occluding the involved areas with bandages (eg, Unna boots) or dressings.",
"     </li>",
"     <li>",
"      Sedating antihistamines at bedtime may be useful in controlling nocturnal pruritus. Both selective serotonin reuptake inhibitors and tricyclic antidepressants also are employed for chronic pruritus, especially when a component of depression is present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=see_link&amp;anchor=H8354417#H8354417\">",
"       \"Pruritus: Overview of management\", section on 'Antihistamines'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=see_link&amp;anchor=H8354438#H8354438\">",
"       \"Pruritus: Overview of management\", section on 'Antidepressants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any underlying compulsive behavior (eg, skin picking) should be treated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13080?source=see_link&amp;anchor=H15211851#H15211851\">",
"       \"Pathologic skin picking\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a limited number of small nodular lesions, we suggest superpotent topical corticosteroids (group one (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )). Topical corticosteroids, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      dipropionate 0.05% ointment, are applied under occlusion with plastic wrap once at nighttime for two to four weeks.",
"     </li>",
"     <li>",
"      For patients with a limited number of large hyperkeratotic lesions, we suggest intralesional corticosteroids.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      acetonide in concentrations of 10&nbsp;to 40",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (based on the size of the lesion and response to therapy) is injected in the single lesions every four weeks until pruritus subsides and the nodules are flattened.",
"     </li>",
"     <li>",
"      For motivated patients willing to adhere to a time-consuming schedule, topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      may be a treatment option. Topical capsaicin 0.025% cream is applied four to six times per day for two weeks to up to several months, as tolerated.",
"     </li>",
"     <li>",
"      We suggest a trial of narrowband UVB or PUVA therapy for patients with widespread disease or as second-line therapy for patients who do not respond to topical or intralesional treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21099351\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prurigo nodularis (PN) is a chronic and often intractable disease which may have a profound impact on the patient&rsquo;s quality of life. Complete resolution of lesions is rare, even after the",
"    <span class=\"nowrap\">",
"     itch/scratch",
"    </span>",
"    cycle has been successfully interrupted. Recurrence is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21099358\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prurigo nodularis is a chronic skin disorder characterized by multiple, firm, itchy nodules typically localized to the extensor surface of the extremities (",
"      <a class=\"graphic graphic_picture graphicRef66268 graphicRef53475 graphicRef86816 graphicRef86817 \" href=\"mobipreview.htm?38/62/39914\">",
"       picture 1A-C, 1E",
"      </a>",
"      ). Pruritus is always severe and distressing; it can be paroxysmal, sporadic, or continuous, and is worsened by heat, sweating, or irritation from clothing. (See",
"      <a class=\"local\" href=\"#H21099279\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21099300\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of prurigo nodularis is clinical, based upon a history of chronic severe pruritus and the clinical finding of characteristic excoriated nodular lesions symmetrically distributed. Cutaneous and systemic causes of chronic pruritus should be investigated. (See",
"      <a class=\"local\" href=\"#H21099314\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10090?source=see_link&amp;anchor=H690781#H690781\">",
"       \"Pruritus: Etiology and patient evaluation\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The approach to management of prurigo nodularis is multifaceted and may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient education about adopting general measures to reduce scratching and excoriations (eg, keeping the nail short, wearing gloves at night, occlusion of the involved areas with bandages).",
"     </li>",
"     <li>",
"      Symptomatic treatment of pruritus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=see_link\">",
"       \"Pruritus: Overview of management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of any underlying compulsive behavior. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13080?source=see_link&amp;anchor=H15211851#H15211851\">",
"       \"Pathologic skin picking\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a limited number of small nodular lesions, we suggest superpotent topical corticosteroids (group one (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical corticosteroids such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      dipropionate 0.05% ointment are applied under occlusion with plastic wrap once a day at nighttime for two to four weeks.",
"     </li>",
"     <li>",
"      For patients with a limited number of large hyperkeratotic lesions, we suggest intralesional corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      acetonide in concentrations of 10&nbsp;to 40",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      is injected in the single lesions every four weeks until pruritus subsides and the nodules are flattened.",
"     </li>",
"     <li>",
"      For motivated patients willing to adhere to a time-consuming schedule, topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      may be a treatment option. Topical capsaicin 0.025% cream is applied four to six times per day for two weeks to up to several months, as tolerated.",
"     </li>",
"     <li>",
"      For patients with widespread disease we suggest phototherapy with narrowband UVB or topical or oral PUVA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/1\">",
"      Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005; 46:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/2\">",
"      Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol 1981; 4:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/3\">",
"      Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/4\">",
"      Tanaka M, Aiba S, Matsumura N, et al. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology 1995; 190:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/5\">",
"      Zancanaro PC, McGirt LY, Mamelak AJ, et al. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 2006; 54:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/6\">",
"      Magand F, Nacher M, Cazorla C, et al. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. Trans R Soc Trop Med Hyg 2011; 105:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/7\">",
"      Harris B, Harris K, Penneys NS. Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis. J Am Acad Dermatol 1992; 26:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/8\">",
"      Liang Y, Marcusson JA, Johansson O. Light and electron microscopic immunohistochemical observations of p75 nerve growth factor receptor-immunoreactive dermal nerves in prurigo nodularis. Arch Dermatol Res 1999; 291:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/9\">",
"      Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002; 293:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/10\">",
"      Ikoma A, Steinhoff M, St&auml;nder S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/11\">",
"      Liang Y, Marcusson JA, Jacobi HH, et al. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol 1998; 25:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/12\">",
"      Perez GL, Peters MS, Reda AM, et al. Mast cells, neutrophils, and eosinophils in prurigo nodularis. Arch Dermatol 1993; 129:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/13\">",
"      Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol 2011; 165:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/14\">",
"      Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol 2011; 165:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/15\">",
"      Zelickson BD, McEvoy MT, Fransway AF. Patch testing in prurigo nodularis. Contact Dermatitis 1989; 20:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/16\">",
"      Schneider G, Hockmann J, St&auml;nder S, et al. Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: results of a case-control study. Br J Dermatol 2006; 154:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/17\">",
"      Dazzi C, Erma D, Piccinno R, et al. Psychological factors involved in prurigo nodularis: A pilot study. J Dermatolog Treat 2011; 22:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/18\">",
"      Weigelt N, Metze D, St&auml;nder S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol 2010; 37:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/19\">",
"      Powell AM, Albert S, Gratian MJ, et al. Pemphigoid nodularis (non-bullous): a clinicopathological study of five cases. Br J Dermatol 2002; 147:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/20\">",
"      Mattila JO, Vornanen M, Katila ML. Histopathological and bacteriological findings in prurigo nodularis. Acta Derm Venereol 1997; 77:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/21\">",
"      Rowland Payne CM, Wilkinson JD, McKee PH, et al. Nodular prurigo--a clinicopathological study of 46 patients. Br J Dermatol 1985; 113:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/22\">",
"      Doyle JA, Connolly SM, Hunziker N, Winkelmann RK. Prurigo nodularis: a reappraisal of the clinical and histologic features. J Cutan Pathol 1979; 6:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/23\">",
"      Miyauchi H, Uehara M. Follicular occurrence of prurigo nodularis. J Cutan Pathol 1988; 15:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/24\">",
"      Jacob CI, Patten SF. Strongyloides stercoralis infection presenting as generalized prurigo nodularis and lichen simplex chronicus. J Am Acad Dermatol 1999; 41:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/25\">",
"      Shelnitz LS, Paller AS. Hodgkin's disease manifesting as prurigo nodularis. Pediatr Dermatol 1990; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/26\">",
"      Torchia D, Caproni M, Del Bianco E, et al. Linear IgA disease presenting as prurigo nodularis. Br J Dermatol 2006; 155:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/27\">",
"      Savoia F, Casadio C, Tabanelli M, et al. Prurigo nodularis as the first manifestation of a chronic autoimmune cholestatic hepatitis. Int J Dermatol 2011; 50:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/28\">",
"      Saray Y, Se&ccedil;kin D, Bilezik&ccedil;i B. Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol 2006; 20:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/29\">",
"      Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/30\">",
"      Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010; 11:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/31\">",
"      St&auml;nder S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/32\">",
"      Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis. Arch Dermatol 2000; 136:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/33\">",
"      St&auml;nder S, Sch&uuml;rmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006; 2:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/34\">",
"      Katayama I, Miyazaki Y, Nishioka K. Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo. Br J Dermatol 1996; 135:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/35\">",
"      Saraceno R, Nistic&ograve; SP, Capriotti E, et al. Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis. Photodermatol Photoimmunol Photomed 2008; 24:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/36\">",
"      Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol 2010; 35:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/37\">",
"      Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/38\">",
"      Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/39\">",
"      Karvonen J, Hannuksela M. Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm Venereol Suppl (Stockh) 1985; 120:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/40\">",
"      Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol 2007; 34:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/41\">",
"      Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005; 153:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/42\">",
"      Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008; 7:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/43\">",
"      Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology 2011; 223:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/44\">",
"      Lan CC, Lin CL, Wu CS, et al. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol 2007; 34:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/45\">",
"      Taefehnorooz H, Truchetet F, Barbaud A, et al. Efficacy of thalidomide in the treatment of prurigo nodularis. Acta Derm Venereol 2011; 91:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/46\">",
"      Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol 2004; 140:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/47\">",
"      Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. Br J Dermatol 1995; 132:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/48\">",
"      Siepmann D, Luger TA, St&auml;nder S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges 2008; 6:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/49\">",
"      Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther 2010; 23:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/50\">",
"      Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol 2012; 148:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/51\">",
"      Phan NQ, Bernhard JD, Luger TA, St&auml;nder S. Antipruritic treatment with systemic &mu;-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/52\">",
"      Mazza M, Guerriero G, Marano G, et al. Treatment of prurigo nodularis with pregabalin. J Clin Pharm Ther 2013; 38:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44727/abstract/53\">",
"      St&auml;nder S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5:e10968.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13667 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44727=[""].join("\n");
var outline_f43_43_44727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21099358\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099279\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099286\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099293\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6984368\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099300\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099314\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6984633\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099321\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6985246\">",
"      Topical and intralesional therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9315409\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6985292\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6985236\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099351\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21099358\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13667|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/51/12083\" title=\"picture 1A\">",
"      Prurigo nodularis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/32/5633\" title=\"picture 1B\">",
"      Prurigo nodularis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/48/25350\" title=\"picture 1C\">",
"      Prurigo nodularis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/5/4176\" title=\"picture 1D\">",
"      Prurigo nodularis arms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/48/16133\" title=\"picture 1E\">",
"      Prurigo nodularis 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/45/33489\" title=\"picture 2\">",
"      Prurigo nodularis histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/6/42083\" title=\"picture 3A\">",
"      Perforating dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/62/13286\" title=\"picture 3B\">",
"      Perforating dermatosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/43/29365\" title=\"picture 3C\">",
"      Perforating dermatosis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/46/28387\" title=\"picture 3D\">",
"      Perforating dermatosis 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/38/23138\" title=\"picture 4A\">",
"      Scabies axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/30/9697\" title=\"picture 4B\">",
"      Scabies buttocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/57/39829\" title=\"picture 4C\">",
"      Scabies nodular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/6/23652\" title=\"picture 5\">",
"      Hypertrophic lichen planus lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/10/21668\" title=\"picture 6\">",
"      Multiple keratoacanthomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4090?source=related_link\">",
"      Keratoacanthoma: Epidemiology, risk factors, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13080?source=related_link\">",
"      Pathologic skin picking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10090?source=related_link\">",
"      Pruritus: Etiology and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26775?source=related_link\">",
"      UVB therapy (broadband and narrowband)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_43_44728="Paliperidone: Drug information";
var content_f43_43_44728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paliperidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/42/3750?source=see_link\">",
"    see \"Paliperidone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/51/36663?source=see_link\">",
"    see \"Paliperidone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3981432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Invega&reg;;",
"     </li>",
"     <li>",
"      Invega&reg; Sustenna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5941023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Invega&reg;;",
"     </li>",
"     <li>",
"      Invega&reg; Sustenna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3982373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3982410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Schizoaffective disorder:",
"     </b>",
"     Oral: Usual: 6 mg once daily in the morning; titration not required, though some may benefit from lower or higher doses (range: 3-12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended no more frequently than every 4 days, up to a maximum of 12 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Usual: 6 mg once daily in the morning; titration not required, though some may benefit from lower or higher doses (range: 3-12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended no more frequently than every 5 days, up to a maximum of 12 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation of I.M therapy, tolerability should be established with oral paliperidone or oral risperidone. Previous oral antipsychotics can be discontinued at the time of initiation of I.M. therapy.",
"     <b>",
"      Dosing based on paliperidone palmitate.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation of I.M therapy, tolerability should be established with oral paliperidone or oral risperidone. Previous oral antipsychotics can be discontinued at the time of initiation of I.M. therapy.",
"     <b>",
"      Dosing based on paliperidone palmitate.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Initiation of therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly timepoint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Maintenance: Following the 1-week initiation regimen, begin a maintenance dose of 117 mg every month administered in either the deltoid or gluteal muscle.  Some patients may benefit from higher or lower monthly maintenance doses (monthly maintenance dosage range: 39-234 mg). The monthly maintenance dose may be administered 7 days before or after the monthly timepoint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Conversion from oral paliperidone to I.M paliperidone:",
"     </i>",
"     Initiate I.M. therapy as described using the 1-week initiation regimen. Patients previously stabilized on oral doses can expect similar steady state exposure during maintenance treatment with I.M. therapy using the following conversion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Oral extended release dose of 12 mg, then I.M. maintenance dose of 234 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Oral extended release dose of 6 mg, then I.M. maintenance dose of 117 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Oral extended release dose of 3 mg, then I.M. maintenance dose of 39-78 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Switching from other long-acting injectable antipsychotics to I.M. paliperidone:",
"     </i>",
"     Initiate I.M. paliperidone in the place of the next scheduled injection and continue at monthly intervals. The 1-week initiation regimen is not required in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Dosage adjustments:",
"     </i>",
"     Adjustments may be made monthly (full effect from adjustments may not be seen for several months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Missed second initiation dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If &lt;4 weeks  have elapsed since the first injection: Administer the missed dose (156 mg) in the deltoid as soon as possible, followed by a third dose of 117 mg in either the deltoid or gluteal muscle 5 weeks after the first injection (regardless of when the second injection was administered), then begin normal monthly maintenance dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If &gt;4 weeks and &le;7 weeks have elapsed since the first injection: Administer a dose of 156 mg in the deltoid as soon as possible, followed by another 156 mg dose in the deltoid 1 week later, then begin normal monthly maintenance dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If &gt;7 weeks have elapsed since the first injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Missed maintenance dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If &lt;6 weeks have elapsed since the last monthly injection: Administer the missed dose as soon as possible and continue therapy at monthly intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If &gt;6 weeks and &le;6 months have elapsed since the last monthly injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     If the maintenance dose was &lt;234 mg: Administer  the same dose the patient was previously stabilized on in the deltoid as soon as possible, followed by a second equivalent dose in the deltoid 1 week later, then resume maintenance dose at monthly intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     If the maintenance dose was 234 mg: Administer a 156 mg dose in the deltoid as soon as possible, followed by a second dose of 156 mg in the deltoid  1 week later, then resume maintenance dose at monthly intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If &gt;6 months have elapsed since last monthly maintenance injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Usual: 6 mg once daily in the morning; titration not required, though some may benefit from lower or higher  doses (range: 3-12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended no more frequently than every 5 days in schizophrenia, up to a maximum of 12 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation of I.M therapy, tolerability should be established with oral paliperidone or oral risperidone. Previous oral antipsychotics can be discontinued at the time of initiation of I.M. therapy.",
"     <b>",
"      Dosing based on paliperidone.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Initiation of therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial: 150 mg on treatment day 1 followed by 100 mg 1 week later (day 8) with both doses administered in the deltoid. The second dose may be administered 2 days before or after the weekly timepoint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance: Following the 1-week initiation regimen, begin a maintenance dose of 75 mg every month administered in either the deltoid or gluteal muscle. Some patients may benefit from higher or lower monthly maintenance doses (monthly maintenance dosage range: 25-150 mg). The monthly maintenance dose may be administered 7 days before or after the monthly timepoint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Conversion from oral paliperidone to I.M paliperidone:",
"     </i>",
"     Initiate I.M. therapy as described using the 1-week initiation regimen. Patients previously stabilized on oral doses can expect similar steady state exposure during maintenance treatment with I.M. therapy using the following conversion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral extended release dose of 12 mg, then I.M. maintenance dose of 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral extended release dose of 6 mg, then I.M. maintenance dose of 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral extended release dose of 3 mg, then I.M. maintenance dose of 25-50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Switching from injectable risperidone (Risperdal&reg; Consta&reg;) to I.M. paliperidone:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Risperdal&reg; Consta&reg; dose of 25 mg every 2 weeks, then I.M. paliperidone maintenance dose of 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Risperdal&reg; Consta&reg; dose of 37.5 mg every 2 weeks, then I.M. paliperidone maintenance dose of 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Risperdal&reg; Consta&reg; dose of 50 mg every 2 weeks, then I.M. paliperidone maintenance dose of 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Switching from other long-acting injectable antipsychotics to I.M. paliperidone:",
"     </i>",
"     Initiate I.M. paliperidone in the place of the next scheduled injection and continue at monthly intervals. The 1-week initiation regimen is not required in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dosage adjustments:",
"     </i>",
"     Adjustments may be made monthly (full effect from adjustments may not be seen for several months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Missed maintenance dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If &lt;6 weeks have elapsed since the last monthly injection: Administer the missed dose as soon as possible and continue therapy at monthly intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If &gt;6 weeks and &le;6 months have elapsed since the last monthly injection: Therapy may be resumed at same dose (25-100 mg) the patient was previously stabilized on and then repeated 1 week later (day 8) with both doses administered in the deltoid. Resume usual monthly maintenance dosing cycle thereafter. If the dose was 150 mg, administer a 100 mg dose as soon as possible and repeat 1 week later (day 8) with both doses administered in the deltoid, then resume usual monthly maintenance dosing cycle 25-150 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If &gt;6 months have elapsed since last monthly maintenance injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12761050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/51/36663?source=see_link\">",
"      see \"Paliperidone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Adolescents 12-17 years: Oral: Initial: 3 mg once daily; titration not required (no known benefit to efficacy from higher doses [ie, 6 mg daily for patients &lt;51 kg and 12 mg daily for patients &ge;51 kg]). If exceeding 3 mg daily, increases of 3 mg daily are recommended no more frequently than every 5 days.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3982411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Additional monitoring of renal function and orthostatic blood pressure may be warranted.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3982412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     Clearance is decreased in renal impairment; adjust dose according to renal function:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-79 mL/minute): Initial dose: 3 mg once daily; maximum dose: 6 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate-to-severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-49 mL/minute): Initial dose: 1.5 mg once daily; maximum dose: 3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute): Use not recommended; not studied in this population",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-79 mL/minute): Initiation of therapy: 156 mg on treatment day 1, followed by 117 mg 1 week later with both doses administered in the deltoid, followed by a maintenance dose of 78 mg every month (administered in the deltoid or gluteal muscle)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Moderate-to-severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute): Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-79 mL/minute): Initiation of therapy: 100 mg on treatment day 1, followed by 75 mg 1 week later with both doses administered in the deltoid, followed by a maintenance dose of 50 mg every month (administered in the deltoid or gluteal muscle)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Moderate-to-severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute): Use not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3982413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.M.: No adjustment necessary for mild-to-moderate (Child-Pugh class A or B) impairment. Not studied in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3982430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, extended release, as palmitate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Invega&reg; Sustenna&reg;: 39 mg/0.25 mL (0.25 mL); 78 mg/0.5 mL (0.5 mL); 117 mg/0.75 mL (0.75 mL); 156 mg/mL (1 mL); 234 mg/1.5 mL (1.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Invega&reg;: 1.5 mg, 3 mg, 6 mg, 9 mg [osmotic controlled release]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Invega&reg; Sustenna&trade;: 25 mg/0.25 mL (0.25 mL), 50 mg/0.5 mL (0.5 mL), 75 mg/0.75 mL (0.75 mL), 100 mg/1 mL (1 mL), 150 mg/1.5 mL (1.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3981434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3982415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer in the morning without regard to meals. Extended release tablets should be swallowed whole with liquids; do not crush, chew, or divide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Invega&reg; Sustenna&trade; should be administered by I.M. route only as a single injection (do not divide); do not administer I.V. or subcutaneously. Avoid inadvertent injection into vasculature. Prior to injection, shake syringe for at least 10 seconds to ensure a homogenous suspension. The 2 initial injections should be administered in the deltoid muscle using a 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch, 22-gauge needle for patients &ge;90 kg, and a 1 inch, 23-gauge needle for patients &lt;90 kg. The 2 initial deltoid intramuscular injections help attain therapeutic concentrations rapidly. Alternate deltoid injections (right and left deltoid muscle). The second dose may be administered 4 days before or after the weekly timepoint (Canadian labeling suggests the second dose may be administered 2 days before or after the weekly timepoint). Monthly maintenance doses can be administered in either the deltoid or gluteal muscle. Administer injections in the gluteal muscle using a 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch, 22-gauge needle in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). The monthly maintenance dose may be administered 7 days before or after the monthly timepoint.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3982377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of schizophrenia; acute treatment of schizoaffective disorder (monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Treatment of schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5685246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14087817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3982387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unless otherwise noted, frequency of adverse effects is reported for the oral/I.M.  formulation in adults.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Tachycardia (1% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: EPS (&le;26%; dose dependent), insomnia (10% to 15%), headache (6% to 15%), parkinsonism (3% to 14%; dose dependent), somnolence (adolescents 9% to 26%; adults 1% to 12%; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Orthostatic hypotension (1% to 4%; dose dependent), bundle branch block (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Agitation (4% to 10%), akathisia (adolescents 4% to 17%; adults 1% to 10%; dose dependent), anxiety (adolescents &le;9%; adults 3% to 8%), dizziness (1% to 6%), dystonia (1% to 5%; dose dependent), dysarthria (1% to 4%; dose dependent), fatigue (adolescents &le;4%), sleep disorder (&le;3%), lethargy (adolescents &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine and metabolic: Amenorrhea (adolescents &le;6%), galactorrhea (adolescents &le;4%), gynecomastia (adolescents &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (1% to 9%; dose dependent), nausea (2% to 8%), dyspepsia (5% to 6%), vomiting (adolescents &le;11%; adults 2% to 5%), constipation (1% to 5%), salivation increased (adolescents &le;6%; adults &le;4%; dose dependent), appetite increased (2% to 3%), toothache (1% to 3%), abdominal pain (&le;3%), diarrhea (&le;3%), xerostomia (&le;3%); tongue swelling (adolescents &le;3%), tongue paralysis (adolescents &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: I.M. formulation: Injection site reaction (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia (2% to 10% dose dependent), dyskinesia (1% to 9%), weakness (&le;4%), myalgia (&le;4% dose dependent), back pain (1% to 3%), extremity pain (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (adolescents &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (&le;5%; dose dependent), upper respiratory tract infection (1% to 4%), cough (&le;3%; dose dependent), rhinitis (1% to 3%; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &le;2% (Limited to important or life-threatening): Agranulocytosis, ALT increased, amenorrhea, appetite decreased, anaphylactic reaction, angioedema, arrhythmia, arthralgia, aspiration pneumonia, AV block (first degree), blurred vision, bradycardia, breast abnormalities (includes discharge, engorgement, pain, tenderness), cerebrovascular accident, drooling, edema, erectile dysfunction, epistaxis (adolescents), fatigue, flatulence, galactorrhea, gynecomastia, hyper-/hypotension, hyperprolactinemia, hypertonia, intestinal obstruction, ischemia, lethargy, leukopenia, menstrual irregularities, nasal congestion, neuroleptic malignant syndrome, neutropenia, nightmares, oculogyric crisis, palpitation, peripheral edema, pharyngolaryngeal pain (dose dependent), postural dizziness, postural orthostatic tachycardia syndrome, priapism, pruritus, psychomotor hyperactivity, QT",
"     <sub>",
"      c",
"     </sub>",
"     -interval prolongation, rash, restlessness, retrograde ejaculation, seizure, sexual dysfunction, stiffness, suicidal ideation, syncope, thrombotic thrombocytopenic purpura (TTP), tongue swelling, transient ischemic attack, urinary incontinence, urinary retention, urinary tract infection, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3982382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paliperidone, risperidone, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3982383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction and prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Risk may be increased by conditions or concomitant medications which cause bradycardia, hypokalemia, and/or hypomagnesemia. Avoid use in combination with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs. Avoid use in patients with congenital long QT syndrome and in patients with history of cardiac arrhythmia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular effects: An increased incidence of cerebrovascular adverse effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of risperidone (paliperidone is the primary active metabolite of risperidone) for the unapproved use in elderly patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyslipidemia: Increased cholesterol and triglycerides and decreased HDL have been noted. Use with caution in patients with a pre-existing abnormal lipid profile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (eg, Alzheimer's disease). Do not use in patients unable to swallow the tablet whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics). Risk of tardive dyskinesia may be increased in the elderly, particularly women. Symptoms may be masked by antipsychotic treatment. Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes (or risk factors) or other disorders of glucose regulation; monitor for worsening of glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Use is associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension and syncope; use with caution in patients at risk of this effect (hemodynamic instability) or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, severe cardiovascular disease, prior myocardial infarction, ischemic heart disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Rare cases of priapism have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be low to moderately sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Paliperidone is not approved for the treatment of dementia-related psychosis. In addition, patients with Lewy body dementia (LBD) may be more sensitive to CNS-related and extrapyramidal effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; may be more sensitive to CNS-related and extrapyramidal effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with mild renal disease; dosage reduction is recommended. Not recommended in patients with moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Extended-release tablet: Use is not recommended in patients with pre-existing severe gastrointestinal narrowing disorders (nondeformable controlled release formulation). Patients with upper GI tract alterations in transit time may have increased or decreased bioavailability of paliperidone. Formulation consists of drug within a nonabsorbable shell; following drug release/absorption, the shell is expelled in the stool.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3982393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May decrease the metabolism of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: May enhance the adverse/toxic effect of Paliperidone. Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3982395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Paliperidone may increase the serotonergic effect of St John's wort; use caution and monitor for serotonin toxicity or NMS during concomitant use. St John&rsquo;s wort is also a strong CYP3A4 inducer; dose of paliperidone may need to be increased when St John&rsquo;s wort is coadministered and decreased when St. John&rsquo;s wort is discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3982378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3982379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization. Paliperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females. Paliperidone is the active metabolite of risperidone; refer to Risperidone monograph for additional information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll women 18-45 years of age exposed to paliperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3982381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15588158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paliperidone can be detected in breast milk following risperidone administration (paliperidone is the active metabolite of risperidone). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3982414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5165183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Invega Sustenna Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     39 mg/0.25 mL (0.25 mL): $343.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     78 mg/0.5 mL (0.5 mL): $687.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     117 mg/0.75 mL (0.75 mL): $1031.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     156 mg/mL (1 mL): $1374.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     234 mg/1.5 mL (1.5 mL): $2062.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Invega Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (30): $659.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (30): $659.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (30): $659.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 mg (30): $989.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3982417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; fasting lipid profile and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually), prolactin levels, CBC frequently during first few months of therapy in patients with pre-existing low WBC or a history of drug-induced leukopenia/neutropenia; BMI, personal/family history of obesity, diabetes, waist circumference; blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms; orthostatic blood pressure changes for 3-5 days after starting or increasing dose. Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Invega (AR, AT, AU, BE, CH, CL, CO, CZ, DE, DK, EE, GB, GR, HK, HN, ID, IE, IL, IT, KP, MY, NL, NZ, PH, PL, PT, RU, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Invega SR (KP);",
"     </li>",
"     <li>",
"      Invega Sustenna (AU, IL, MY, NZ, SG, TH);",
"     </li>",
"     <li>",
"      Xeplion (CH, CZ, DK, EE, GB, IE, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3982398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paliperidone is considered a benzisoxazole atypical antipsychotic as it is the primary active metabolite of risperidone. As with other atypical antipsychotics, its therapeutic efficacy is believed to result from mixed central serotonergic and dopaminergic antagonism. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects. Similar to risperidone, paliperidone demonstrates high affinity to &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     , D",
"     <sub>",
"      2",
"     </sub>",
"     , H",
"     <sub>",
"      1",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     receptors, and low affinity for muscarinic and 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors. In contrast to risperidone, paliperidone displays nearly 10-fold lower affinity for &alpha;",
"     <sub>",
"      2",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     receptors, and nearly three- to fivefold less affinity for 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     , respectively.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3982400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Slow release (begins on day 1 and continues up to 126 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 391-487 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 74%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2D6 and 3A4 (limited role in elimination); minor metabolism (&lt;10% each) via dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 28%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 23 hours; 24-51 hours with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (following a single-dose administration): Range: 25-49 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: ~24 hours; I.M.: 13 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80%); feces (11%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon L, Perkins D, and Calmes C,",
"      <i>",
"       Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia",
"      </i>",
"      , Arlington, Va: American Psychiatric Association, 2009. Available at file://www.psychiatryonline.com/content.aspx?aid=501001",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jung SM, Kim K-A, Cho H-K, et al, &ldquo;Cytochrome P450 3A Inhibitor Itraconazole Affects Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Schizophrenic Patients,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005, 78(5):520-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/16321618/pubmed\" id=\"16321618\" target=\"_blank\">",
"        16321618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richelson E and Souder T, &ldquo;Binding of Antipsychotic Drugs to Human Brain Receptors. Focus on Newer Generation Compounds,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 2000, 68(1):29-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/11132243/pubmed\" id=\"11132243\" target=\"_blank\">",
"        11132243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spina E, Avenoso A, Facciola G, et al, &ldquo;Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: Effect of Comedication with Carbamazepine or Valproate,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2000, 22:481-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/43/44728/abstract-text/10942191/pubmed\" id=\"10942191\" target=\"_blank\">",
"        10942191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10174 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44728=[""].join("\n");
var outline_f43_43_44728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709193\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3981432\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5941023\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982373\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982410\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12761050\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982411\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982412\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982413\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982430\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950134\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3981434\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982415\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982377\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5685246\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14087817\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982387\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982382\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982383\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838448\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982393\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982395\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982378\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982379\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982381\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15588158\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982414\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5165183\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982417\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539984\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982398\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982400\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10174|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/42/3750?source=related_link\">",
"      Paliperidone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/51/36663?source=related_link\">",
"      Paliperidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_43_44729="Biology of the graft-versus-tumor effect following hematopoietic cell transplantation";
var content_f43_43_44729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/43/44729/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/43/44729/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/43/44729/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/43/44729/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/43/44729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/43/44729/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/43/44729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with malignancy who undergo hematopoietic cell transplantation (HCT) are effectively treated, thereby resulting in minimal residual disease. However, this response is frequently not maintained since relapse ultimately occurs in 40 to 75 percent of patients who undergo an autologous transplant and 10 to 40 percent of those who undergo an allogeneic transplant. Further, with the development of non-myeloablative or reduced intensity allogeneic transplantation there is increased reliance on immune-mediated effects to control the underlying disease.",
"   </p>",
"   <p>",
"    The rationale for using immunotherapy to prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treat the reemergence of malignancy is based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence indicates that the graft-versus-tumor (GVT) effect plays a major role in reducing the risk of relapse following an allogeneic transplant.",
"     </li>",
"     <li>",
"      Significant advances have been made in our basic understanding of both the cellular populations responsible for potential antitumor activity and the cellular interactions and cytokines required for their activation and expansion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cell populations capable of recognizing and lysing malignant targets can be divided into two broad categories based upon the mechanism of cellular recognition: cytotoxic T cells (CTLs) and natural killer (NK) cells. Significant insights have been made into the functional mechanisms of these two populations.",
"   </p>",
"   <p>",
"    This topic review will discuss the basic principles underlying the pathogenesis of the GVT effect after HCT. An overview of some of the clinical trials examining immunotherapy to prevent and treat relapse following HCT is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CYTOTOXIC T CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing how cytotoxic T cells (CTLs) recognize and become activated in response to malignant cells, it is helpful to first briefly review the major histocompatibility complex (MHC), and how T cells recognize and are activated by any antigen. Genes of the MHC (called HLA in humans) encode two distinct classes of cell surface molecules, I and II. Class I MHC molecules are expressed on the surfaces of virtually all nucleated cells at varying densities, while class II MHC molecules are more restricted to cells of the immune system, primarily B lymphocytes, monocytes, and dendritic cells.",
"   </p>",
"   <p>",
"    The normal function of the MHC is now understood. Since the principal task of the immune system is to distinguish self from non-self, HLA molecules provide the crucial surface upon which the antigen receptors on T lymphocytes (T cell receptors or TCRs) recognize foreign (non-self) antigens. On antigen presenting cells (APCs), such as macrophages and dendritic cells, class II MHC molecules present antigenic fragments (in the form of linear peptides) to the CD4+ inducer (or helper) T cells, while class I MHC molecules function at the effector phase of immunity by presenting antigens to CD8+ T cells. This process of antigen presentation consists of the binding of a single T cell receptor to a complex on the surface of an antigen-presenting cell consisting of the MHC molecule and a peptide fragment derived from the foreign antigen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to engagement of the T cell receptor with the MHC molecule-antigenic peptide complex, several other signals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functions are required for full T cell activation and expansion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      APCs must express costimulatory molecules that provide a mandatory second signal to the T cell. The major pathways are an interaction of the B7 family of molecules (B7-1 [CD80] or B7-2 [CD86]) or of CD58 (LFA-3) on antigen presenting cells with CD28 or CD2 on T cells (",
"      <a class=\"graphic graphic_figure graphicRef63541 \" href=\"mobipreview.htm?6/23/6527\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Other co-stimulatory molecules (eg, CD30:CD30L, OX40) have also been identified. Anergy, a state in which T cells are unable to become activated in response to their normal target antigen, develops in the absence of costimulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Helper T cells are also necessary for a normal immune response. They are primarily CD3+CD4+CD8-, compared with the majority of CTLs which are CD3+CD8+CD16-. Helper T cells release cytokines and provide cellular interactions (via costimulatory molecules) necessary for the appropriate stimulation of APCs (",
"      <a class=\"graphic graphic_figure graphicRef63541 \" href=\"mobipreview.htm?6/23/6527\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traditional understanding dictated that CD4+ T cells were required to produce cytokines (principally IL-2) in the local environment of the CD8+ T cells, thereby allowing for clonal expansion. This hypothesis required two populations of effector cells to be present and bind to an APC. However, studies indicate that CD4+ T cells are capable of activating APCs via engagement of CD40, which primes the APCs for more effective stimulation of CD8+ cells. These observations simplify the role of helper T cells and do not require a physical presence at the time of CD8+ T cell activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Regulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other populations of T cells regulate immune responses. The best characterized population is that of regulatory T (Treg) cells, which express CD4 and CD25 as well as the transcription factor FoxP3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/6\">",
"     6",
"    </a>",
"    ]. Treg cells reduce T cell proliferation and may play a major role in controlling graft versus host disease (GVHD) in murine model systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/7\">",
"     7",
"    </a>",
"    ] as well as in man [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/8\">",
"     8",
"    </a>",
"    ]. Importantly, Treg cells did not inhibit graft versus tumor (GVT) reactions in a mouse model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of graft-versus-host disease\", section on 'Regulatory T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other populations of natural killer (NK) T cells also play an important immunoregulatory role under certain biological conditions. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Natural killer cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Recognition of malignant cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a donor CTL to recognize and lyse a malignant host target cell, antigen(s) expressed by the tumor must be recognized as foreign. Based upon the type of transplant, this identification principally occurs via the following two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donor CTLs recognize alloantigens, possibly minor histocompatibility antigens, on host cells. This is of principal importance with allogeneic transplants.",
"     </li>",
"     <li>",
"      CTLs also react against unique antigens expressed by the malignant host cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/10\">",
"       10",
"      </a>",
"      ]. This can occur with any donor-recipient pair, as well as outside the transplant setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Self versus non-self",
"    </span>",
"    &nbsp;&mdash;&nbsp;With nonidentical transplants, donor CTLs may recognize neoplastic (and normal) cells as foreign due to the expression of epitopes unique to the host. CTLs may subsequently become activated, lysing such cells.",
"   </p>",
"   <p>",
"    This mechanism for a GVT effect is very similar to that which underlies GVHD. When the recipient and nonidentical donor are not matched at the MHC, GVHD (or GVT) may result because of differences within the major MHC antigens. However, when the donor-recipient pair are matched for MHC antigens, GVHD (or GVT) is initiated and propagated via recognition by the T cell and its receptor of additional antigens called minor histocompatibility antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/11\">",
"     11",
"    </a>",
"    ]. A major question in the field is whether the repertoire of T cells responsible for GVHD is the same as those responsible for GVT, and if not how much overlap between these two populations exists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of this effect for the development of GVT is suggested by the different outcomes with grafts from identical twin and nonidentical donors. Patients who have an identical twin donor do not develop GVHD. However, they are at a higher risk of relapse of the underlying malignant disease than similar patients transplanted with HLA-matched but nonidentical sibling donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/12\">",
"     12",
"    </a>",
"    ]. This is presumably due to the lack of a GVT reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These relationships were illustrated in a review from 163 transplant centers that compared the results of 103 identical twin (syngeneic) and 1030 HLA-identical sibling (allogeneic) transplants for leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/14\">",
"     14",
"    </a>",
"    ]. The three-year probability of relapse of leukemia was substantially higher in the syngeneic than allogeneic transplants in acute myeloid leukemia (52 versus 16 percent) and chronic myeloid leukemia (40 versus 7 percent).",
"   </p>",
"   <p>",
"    The importance of the pathogenic link between GVT and GVHD is also suggested by the finding that GVHD can be induced by donor lymphocyte infusions. With this technique, lymphocytes from the original donor are administered to patients with relapsing disease to attempt to elicit a GVT reaction; this benefit is tempered by the enhanced risk of developing GVHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the observation that some patients clearly have GVT without GVHD suggests that these two processes may result via different mechanisms (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Possible separation of GVT from GVHD'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Expression of tumor specific antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;CTLs, independent of origin, can also recognize malignant cells as foreign when unique antigens are expressed by the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Potential antigenic targets include the following (",
"    <a class=\"graphic graphic_table graphicRef76786 \" href=\"mobipreview.htm?15/4/15435\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unique idiotypes or TCRs, which result from rearranged immunoglobulin or TCR genes, respectively; this may occur in some B and T cell malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Foreign proteins encoded by the viral genome in malignancies that occur in association with viral infections, such as EBV-associated B cell lymphomas.",
"     </li>",
"     <li>",
"      Specific peptides derived from proteins expressed on tumor cells such as the her-2 neu protein, a product expressed by a subset of breast cancers and neuroblastomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Products of specific oncogenes (the importance of which is unclear). Peptides derived from breakpoint regions of",
"      <span class=\"nowrap\">",
"       bcr/abl,",
"      </span>",
"      an oncogene found in the majority of patients with chronic myeloid leukemia, have been used to stimulate a productive T cell immune response in vitro [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A variety of lineage-specific antigens, including minor histocompatibility antigens (which are found on hematopoietic tumors), the MAGE proteins (on melanomas), proteinase III, WT-1 and Wnt (on certain leukemias), and carcinoembryonic antigen (on some solid tumors).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ongoing investigations are focusing on those characteristics of the antigen that would best enable CTLs to recognize and lyse malignant targets. No consensus has emerged concerning the optimal nature and source of these antigens, particularly whether they should be in the form of peptide(s), a whole protein, DNA, or cDNA, or whether they should be introduced into dendritic cells by gene transfer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapeutic maneuvers include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To expand dendritic cells from leukemic precursors; this is based upon the assumption that these cells will present leukemic specific antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      To utilize T cells that are activated and expanded using beads that provide binding through CD3 and CD28. These co-stimulated T cells have been shown to provide T cell help and possibly promote a cytolytic response against tumor cells. Early clinical trials have demonstrated the feasibility and tolerability of this approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/23\">",
"       23",
"      </a>",
"      ]. Expansion of these cells in the lymphopenic environment early after transplantation may be a particularly effective strategy in the induction of immune responses (eg, vaccination strategies) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Malignant cells and costimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor cells may lack the costimulatory molecules necessary for such an interaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/25\">",
"     25",
"    </a>",
"    ], which, as noted above, may lead to anergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. A variety of strategies have been employed in an attempt to overcome this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, follicular lymphoma cells were treated with CD40L, a protein known to upregulate the expression of costimulatory molecules of the B7 family [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/26\">",
"       26",
"      </a>",
"      ]. Using this approach, autologous tumor-infiltrating CTLs could be generated in the presence of interleukin (IL)-2; they could be further expanded in vitro with IL-4, IL-7 and interferon-gamma (IFNg).",
"     </li>",
"     <li>",
"      Another strategy has been to transfect tumor cells with costimulatory genes. In animal models, injection of transfected tumor cells resulted in an effective immune response against both the transfected and wild type tumor cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The identification of dendritic cells and their role in stimulating an immune response is a major scientific advance. Clearly, much work is required to identify not only the appropriate clinical situation but also to develop the necessary approach that is effective and technically feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL KILLER CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural killer (NK) cells are commonly referred to as nonspecific or MHC-nonrestricted. However, these terms are misnomers, since NK cells express receptors, which recognize MHC molecules.",
"   </p>",
"   <p>",
"    The cell surface phenotype of NK cells is CD3-CD56+CD16+, although other cell populations have been described. These cells can be activated by a variety of different cytokines, particularly IL-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cell receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of target cell recognition by NK cells is not completely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/31\">",
"     31",
"    </a>",
"    ]. Several groups have identified cell surface receptors expressed by NK cells, which recognize MHC molecules and, upon productive interaction, initiate an",
"    <strong>",
"     inhibitory",
"    </strong>",
"    signal that prevents lysis.",
"   </p>",
"   <p>",
"    In humans, two distinct families of inhibitory receptors have been characterized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One group of proteins is referred to as the killer inhibitory receptors (KIRs); they are composed of either two or three extracellular immunoglobulin-like domains, and recognize specific class I HLA molecules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. The role of peptides in class I recognition by KIRs has been controversial, although it appears that some peptide specificity exists.",
"     </li>",
"     <li>",
"      A second structurally distinct class of receptors",
"      <span class=\"nowrap\">",
"       (CD94/NKG2A)",
"      </span>",
"      has a C-lectin domain and recognizes peptides derived from certain class I alleles in the context of HLA-E [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NK cells also express activation receptors, which, upon triggering, engage the cytolytic machinery. The best characterized activation receptor is a molecule termed NKG2D. Ligands for NKG2D include molecules such as MICA, MICB and the ULB binding proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/38\">",
"     38",
"    </a>",
"    ]. NKG2D ligands are upregulated by cellular stress, including viral infection and transformation.",
"   </p>",
"   <p>",
"    In the setting of bone marrow transplantation, donor NK cells are inhibited upon interaction with an appropriate MHC class I molecule expressed by a normal host cell. As a result, all donor NK cells tolerate normal (eg, not malignant or infected) host cells expressing normal levels of MHC class I molecules. By comparison, tumor or virally infected cells, which either downregulate class I expression or have altered peptide expression, are recognized and killed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several aspects of NK function are unclear, including the exact requirements for an interaction to occur; whether there are specific activator receptors; and what role activator receptors play [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/40\">",
"     40",
"    </a>",
"    ]. Adhesion molecules appear to be required since monoclonal antibodies directed against LFA-1 and intercellular adhesion molecule (ICAM)-1 inhibit NK cytolytic activity.",
"   </p>",
"   <p>",
"    NK cells also express the Fc-gamma receptor (CD16); this allows cells bound by immunoglobulin to be lysed by antibody dependent cellular cytotoxicity mechanisms. This mechanism of tumor cell removal is thought to play an important role in the mechanism of therapeutic antibodies, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Individuals who express different polymorphisms of the Fc-gamma receptor may differ in their response to rituximab and presumably other therapeutic monoclonal antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Autologous and MHC-matched transplants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which tumor cells are recognized by NK effector cell populations with autologous and MHC-matched transplants are not completely understood. As previously mentioned, recognition and killing of such cells may occur if the associated KIRs or",
"    <span class=\"nowrap\">",
"     CD94/NKG2A",
"    </span>",
"    molecules are not bound by the appropriate HLA-class I molecules. By comparison, nonmalignant autologous or MHC-matched cells presumably express HLA class I molecules with the appropriate peptide; this permits binding to the inhibitory receptor expressed on the surface of the NK cell, thereby inhibiting NK cell function.",
"   </p>",
"   <p>",
"    This hypothesis assumes that HLA class I molecules on the surface of tumor cells are either downregulated or alternative peptides are displayed, characteristics that block the ability of HLA class I molecules to signal through the appropriate inhibitory receptor. Experimental evidence for the lack of HLA class I expression has been found in a number of different tumor types. Alteration in peptide expression is more difficult to evaluate, but it has been observed following certain viral infections. Alternatively, expression of NKG2D ligands has been observed on a number of solid tumors and hematopoietic cell malignancies which may allow for appropriate cell recognition and lysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     MHC-mismatched transplants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low incidence of relapse has been observed with MHC-mismatched transplants, particularly in patients with myeloid leukemias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/43\">",
"     43",
"    </a>",
"    ]. The newly perceived function of NK cell-mediated cytotoxicity provides another possible mechanism to help explain the GVT effect in MHC-mismatched transplants. Depending upon the donor-recipient pair, host cells may lack the appropriate HLA class I molecule capable of binding to and inhibiting the inhibitory molecules expressed on the donor NK and NK-like T cells. Alloreactive NK cells are therefore created. Such NK cells, which recognize recipient tumor cells based upon the lack of inhibition through the appropriate KIR molecules, have been recently observed both before and after such transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of such alloreactive NK cells would suggest that GVHD would develop. However, for reasons that have yet to be fully elucidated, GVHD fails to emerge in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, these observations support the concept that NK and NK-like T cells play a significant role in GVT reactions, particularly following haploidentical transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Adoptive transfer of NK cells has also been explored using mismatched NK cell populations, with early encouraging results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cytokine production",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cells secrete a variety of cytokines, such as interferon-gamma, tumor necrosis factor (TNF), granulocyte macrophage colony-stimulating factor (GM-CSF), and transforming growth factor (TGF)-beta. These cytokines may have some direct effects on the tumor cells and may promote recruitment of other populations of effector cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Activation and expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies have been employed to activate and expand cells with NK cell function. These cells appear to be activated with cytokines, particularly IL-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. To enhance the antitumor function of NK cells, different methods of administering IL-2, both ex vivo and in vivo, have been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many groups have used IL-2 for the ex vivo activation of NK cells, thereby resulting in cells with enhanced anti-tumor cell activity (termed lymphokine activated killer [LAK] cells). However, since NK cells do not expand effectively ex vivo, it is difficult to obtain the numbers of cells required for treatment, thereby resulting in limited efficacy.",
"     </li>",
"     <li>",
"      The direct administration to the patient of high-dose IL-2 is associated with significant morbidity and limited enhancement in NK cell antitumor efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, dosage schedules have been developed which are reasonably well tolerated and positive results have been obtained following transplantation for NHL and AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. In addition, the administration of low dose IL-2 to enhance antitumor NK cell activity is being applied to patients with minimal disease, a regimen that is less toxic and better tolerated than high dose IL-2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/53\">",
"       53",
"      </a>",
"      ]. Unfortunately, a randomized study of IL-2 following autologous transplantation did not result in improved outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/54\">",
"       54",
"      </a>",
"      ]. This may be because lower doses of IL-2 result in the expansion of regulatory T cells, which may negatively impact anti-tumor responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-2 has also been used to treat the marrow or peripheral blood of the donor prior to infusion to enhance the antitumor potential of the graft [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     NK-like T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The active expansion of cytolytic cells derived from T cells which share functional similarities with NK cells may be obtained with the use of specific cytokines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These NK-like T cells express both T cell specific antigens (such as the T cell receptor and CD3 complex) and NK cell markers (such as CD56 or neural cell adhesion molecule) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/61\">",
"     61",
"    </a>",
"    ]. These ex vivo treated CD3+CD56+ cells rapidly expand following mitogenic stimulation through the T cell receptor (similar to T cells) and recognize tumor cell targets without prior exposure (similar to NK cells) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/62\">",
"     62",
"    </a>",
"    ]. They also produce cytokines such as GM-CSF, interferon, and tumor necrosis factor, but do not produce IL-4.",
"   </p>",
"   <p>",
"    In SCID mouse model systems, NK-like T cells effectively eradicate human tumor cell lines and autologous tumor targets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/63\">",
"     63",
"    </a>",
"    ]. They have the advantage of being readily expandable and do not require the exogenous administration of IL-2 for in vivo activity. Clinical trials using these cells have suggested that this approach is tolerable following autologous and allogeneic transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In one study using this methodology, improvement in recurrence-free survival was noted in patients undergoing hepatic tumor resection at high risk of relapse where those individuals who received cellular therapy had improved DFS compared with untreated controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different properties of these effector cell populations that may prove useful in immunotherapy posttransplantation are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef59586 \" href=\"mobipreview.htm?19/63/20475\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CYTOTOXIC CELL LINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cell lines with cytotoxic activity have been developed which have phenotypic and biological characteristics very similar to NK cells and NK-like T cells. The cell line TALL-104 originated from a child with acute T cell lymphoblastic leukemia. These cells lyse a broad panel of tumor cell lines, but not normal tissues, and have in vivo activity in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The use of irradiated TALL-104 cells is in early phase clinical trials. Other NK-like cell lines have also been developed with intriguing biological activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/69-73\">",
"     69-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H970600276\">",
"    <span class=\"h2\">",
"     Engineered T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of groups have investigated the use of engineered T cells, which express novel receptors that redirect their cytotoxicity. An example that has demonstrated efficacy is through the use of chimeric antigen receptor T cells (CAR-T) where the T cells are capable of recognizing tumor-associated antigens, such as CD19. Early studies had limited success, primarily thought to be related to the poor survival of these engineered T cells. With novel constructions, including co-stimulatory molecules that improve survival of the adoptively transferred T cells, dramatic responses have been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. However, the long-lived T cells result in normal B cell depletion for extended periods of time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link&amp;anchor=H1037110587#H1037110587\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Cytotoxic T lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MECHANISMS OF CYTOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon appropriate stimulation, all effector cells use similar cytotoxic machinery. Two major cytolytic pathways have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One involves the exocytosis of perforin and granzymes into the extracellular space at the site of target cell adhesion. Perforin induces pore formation in the membrane of the target cell, causing osmotic lysis and introducing granzymes and granulysin, which induce apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]. The importance of these molecules in CTL and NK cell function has been demonstrated by the finding of greatly impaired effector cell function in mice deficient in these molecules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second pathway involves the expression of fas ligand (fasL); this receptor binds to fas on the target cell, directly inducing apoptosis in a calcium-independent manner [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/81,82\">",
"       81,82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MECHANISMS OF TUMOR CELL ESCAPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insights into tumor cell recognition have identified a number of potential mechanisms by which tumor cells can escape immunologic recognition (",
"    <a class=\"graphic graphic_table graphicRef71120 \" href=\"mobipreview.htm?11/39/11899\">",
"     table 3",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absence of donor- or tumor-specific antigens or the downregulation of HLA class I molecules, preventing recognition by CTLs.",
"     </li>",
"     <li>",
"      The lack of costimulatory molecules, resulting in anergy.",
"     </li>",
"     <li>",
"      The expression of both fas and fasL, thereby inactivating T cells due to fas-mediated apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. In animal models, for example, fasL expressing tumors progress more rapidly in wild type mice than in animals with defective fas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The heterogeneity of human tumor cells and the possibility of ongoing mutations.",
"     </li>",
"     <li>",
"      The appropriate expression of self-MHC class I molecules, thereby inactivating NK cells.",
"     </li>",
"     <li>",
"      The expression of soluble factors that inhibit NK cells, such as the NKG2D ligands MICA and MICB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/85\">",
"       85",
"      </a>",
"      ]. These factors have been described in vitro, but their clinical significance is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional mechanism that may undermine immune surveillance is the presence of factors that impair the ability of effector cells to survive or to successfully home to malignant cells.",
"   </p>",
"   <p>",
"    These dynamic interactions complicate immunotherapy applications. However, with increased understanding of these biological processes, more effective approaches will be developed which are based upon the underlying biology of the tumor cell and the immune system. Since patients harbor a state of minimal disease and relapse rates are predictable following hematopoietic cell transplantation, such individuals are ideal candidates to test novel immunotherapeutic approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POSSIBLE SEPARATION OF GVT FROM GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;With nonidentical transplants, donor cytotoxic T cells (CTLs) may recognize neoplastic cells as foreign due to the expression of epitopes unique to the host (and the underlying malignancy). CTLs may subsequently become activated, lysing such cells. This graft-versus-tumor (GVT) effect is very similar to that which underlies graft-versus-host disease (GVHD). This theory is supported by evidence that the timing and intensity of immunosuppressive treatment directed at preventing and treating GVHD influences the risk of recurrent malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some patients have developed a GVT response without GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/87\">",
"     87",
"    </a>",
"    ]; additionally, epidemiologic studies from the European Group for Blood and Marrow Transplantation suggest that these two effects may be separable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In murine models of HCT, the administration of interleukin (IL)-11 and IL-12 has been utilized to help prevent GVHD without the loss of GVT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]. In one model, all IL-11-treated and control animals effectively rejected their leukemia, but the IL-11 treated mice also had reduced GVHD-related mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another experimental approach involves trying to enhance GVT but not GVHD. In this model, recipients were immunized against their tumor (tumor cell vaccine) one month after HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/91\">",
"       91",
"      </a>",
"      ]. The immunized recipients showed improved survival and protection against tumor growth; the immune response was tumor-specific as no exacerbation of GVHD was observed.",
"     </li>",
"     <li>",
"      Administration of defined doses of regulatory T cells or cytokine-induced killer cells has also resulted in control of GVHD and maintenance of GVT responses in murine models of leukemia and lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/9,92-94\">",
"       9,92-94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This separation of GVHD from GVT, which has been accomplished in animal models, remains an attractive clinical goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/43/44729/abstract/9,62,95-107\">",
"     9,62,95-107",
"    </a>",
"    ]. The successful application of these principles to patients will be a major advance in the field of hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with malignancy who undergo hematopoietic cell transplantation (HCT) achieve an initial complete remission. However, relapse ultimately occurs in 40 to 75 percent of patients who undergo an autologous HCT and 10 to 40 percent of those who undergo an allogeneic HCT.",
"     </li>",
"     <li>",
"      The rationale for using immunotherapy to prevent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treat the reemergence of malignancy (ie, relapse after HCT) is based upon evidence that the graft-versus-tumor (GVT) effect plays a major role in reducing the risk of relapse following an allogeneic HCT. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link\">",
"       \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the recipient and nonidentical HCT donor are not matched at the major histocompatibility complex (MHC), GVT may result because of differences within the major MHC antigens. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Recognition of malignant cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the donor-recipient pair is matched for MHC antigens, GVT is initiated and propagated via recognition by the T cell and its receptor of additional antigens called minor histocompatibility antigens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link\">",
"       \"Pathogenesis of graft-versus-host disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2\">",
"       'Cytotoxic T cells'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Natural killer cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/1\">",
"      Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994; 367:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/2\">",
"      Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994; 1:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/3\">",
"      Sayegh MH, Turka LA. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 1995; 6:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/4\">",
"      Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/5\">",
"      Lanzavecchia A. Immunology. Licence to kill. Nature 1998; 393:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/6\">",
"      Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001; 193:F41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/7\">",
"      Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/8\">",
"      Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/9\">",
"      Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/10\">",
"      Ofran Y, Ritz J. Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation. Clin Cancer Res 2008; 14:4997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/11\">",
"      Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004; 103:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/12\">",
"      Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/13\">",
"      Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/14\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/15\">",
"      Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/16\">",
"      Nishida T, Hudecek M, Kostic A, et al. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res 2009; 15:4759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/17\">",
"      Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/18\">",
"      Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/19\">",
"      Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87:3587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/20\">",
"      Bosch GJ, Joosten AM, Kessler JH, et al. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996; 88:3522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/21\">",
"      Engleman EG. Dendritic cells in the treatment of cancer. Biol Blood Marrow Transplant 1996; 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/22\">",
"      Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/23\">",
"      Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003; 102:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/24\">",
"      Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005; 11:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/25\">",
"      Zheng Z, Takahashi M, Aoki S, et al. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. J Exp Clin Cancer Res 1998; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/26\">",
"      Schultze JL, Seamon MJ, Michalak S, et al. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997; 89:3806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/27\">",
"      Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 1996; 87:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/28\">",
"      Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/29\">",
"      Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/30\">",
"      Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/31\">",
"      Gumperz JE, Parham P. The enigma of the natural killer cell. Nature 1995; 378:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/32\">",
"      D&ouml;hring C, Scheidegger D, Samaridis J, et al. A human killer inhibitory receptor specific for HLA-A1,2. J Immunol 1996; 156:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/33\">",
"      Litwin V, Gumperz J, Parham P, et al. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 1994; 180:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/34\">",
"      Moretta A, Vitale M, Bottino C, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993; 178:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/35\">",
"      Pende D, Biassoni R, Cantoni C, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 1996; 184:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/36\">",
"      Boyington JC, Riaz AN, Patamawenu A, et al. Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity 1999; 10:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/37\">",
"      Brooks AG, Borrego F, Posch PE, et al. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J Immunol 1999; 162:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/38\">",
"      Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/39\">",
"      K&auml;rre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science 1995; 267:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/40\">",
"      Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/41\">",
"      Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/42\">",
"      Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/43\">",
"      Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/44\">",
"      Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/45\">",
"      Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/46\">",
"      Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105:4878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/47\">",
"      Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/48\">",
"      Perussia B, Chan SH, D'Andrea A, et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol 1992; 149:3495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/49\">",
"      Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/50\">",
"      Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/51\">",
"      Benyunes MC, Massumoto C, York A, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/52\">",
"      Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997; 89:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/53\">",
"      Miller JS, Tessmer-Tuck J, Pierson BA, et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 1997; 3:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/54\">",
"      Thompson JA, Fisher RI, Leblanc M, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008; 111:4048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/55\">",
"      Yao X, Ahmadzadeh M, Lu YC, et al. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012; 119:5688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/56\">",
"      Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/57\">",
"      Charak BS, Brynes RK, Groshen S, et al. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990; 76:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/58\">",
"      Agah R, Malloy B, Kerner M, Mazumder A. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. J Immunol 1989; 143:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/59\">",
"      Ochoa AC, Gromo G, Alter BJ, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol 1987; 138:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/60\">",
"      Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/61\">",
"      Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/62\">",
"      Baker J, Verneris MR, Ito M, et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/63\">",
"      Hoyle C, Bangs CD, Chang P, et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92:3318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/64\">",
"      Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/65\">",
"      Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell&nbsp;transplantation. Biol Blood Marrow Transplant 2011; 17:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/66\">",
"      Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/67\">",
"      Cesano A, Visonneau S, Pasquini S, et al. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res 1996; 56:4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/68\">",
"      Cesano A, Visonneau S, Jeglum KA, et al. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res 1996; 56:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/69\">",
"      Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/70\">",
"      Klingemann HG, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 1996; 2:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/71\">",
"      Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 1996; 87:4913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/72\">",
"      Hambach L, Vermeij M, Buser A, et al. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood 2008; 112:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/73\">",
"      Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/74\">",
"      Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/75\">",
"      Porter DL, Kalos M, Zheng Z, et al. Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer 2011; 2:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/76\">",
"      Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1994; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/77\">",
"      Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/78\">",
"      Nagasawa M, Isoda T, Itoh S, et al. Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: its usefulness as a marker of graft-versus-host reaction. Am J Hematol 2006; 81:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/79\">",
"      Heusel JW, Wesselschmidt RL, Shresta S, et al. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994; 76:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/80\">",
"      K&auml;gi D, Ledermann B, B&uuml;rki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/81\">",
"      Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/82\">",
"      Oshimi Y, Oda S, Honda Y, et al. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 1996; 157:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/83\">",
"      Hahne M, Rimoldi D, Schr&ouml;ter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/84\">",
"      Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158:4521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/85\">",
"      Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/86\">",
"      Inamoto Y, Flowers ME, Lee SJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood 2011; 118:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/87\">",
"      Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest 1997; 100:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/88\">",
"      Ringd&eacute;n O, Labopin M, Gorin NC, et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol 2000; 111:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/89\">",
"      Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999; 104:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/90\">",
"      Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymphoma 1999; 33:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/91\">",
"      Anderson LD Jr, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000; 95:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/92\">",
"      Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/93\">",
"      Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008; 112:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/94\">",
"      Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010; 116:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/95\">",
"      Sprangers B, Van Wijmeersch B, Fevery S, et al. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat Clin Pract Oncol 2007; 4:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/96\">",
"      Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001; 97:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/97\">",
"      Fontaine P, Roy-Proulx G, Knafo L, et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001; 7:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/98\">",
"      Epperson DE, Margolis DA, McOlash L, et al. In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation. Br J Haematol 2001; 114:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/99\">",
"      Andr&eacute;-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/100\">",
"      Guimond M, Balassy A, Barrette M, et al. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood 2002; 100:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/101\">",
"      Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood 2006; 107:3430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/102\">",
"      Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/103\">",
"      Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 2007; 110:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/104\">",
"      Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 2008; 142:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/105\">",
"      Boni A, Muranski P, Cassard L, et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008; 112:4746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/106\">",
"      Cai SF, Cao X, Hassan A, et al. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 2010; 115:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/43/44729/abstract/107\">",
"      Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012; 119:3361.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3546 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44729=[""].join("\n");
var outline_f43_43_44729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CYTOTOXIC T CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Regulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Recognition of malignant cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Self versus non-self",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Expression of tumor specific antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Malignant cells and costimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL KILLER CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cell receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Autologous and MHC-matched transplants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MHC-mismatched transplants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cytokine production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Activation and expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NK-like T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CYTOTOXIC CELL LINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H970600276\">",
"      Engineered T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MECHANISMS OF CYTOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MECHANISMS OF TUMOR CELL ESCAPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POSSIBLE SEPARATION OF GVT FROM GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3546|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/23/6527\" title=\"figure 1\">",
"      Antigen presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/4/15435\" title=\"table 1\">",
"      Cytotoxic T cell targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/63/20475\" title=\"table 2\">",
"      Effector cell properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/39/11899\" title=\"table 3\">",
"      Tumor cell escape",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_43_44730="Membranous Light";
var content_f43_43_44730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57841%7ENEPH%2F74698%7ENEPH%2F55226%7ENEPH%2F69629%7ENEPH%2F62937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57841%7ENEPH%2F74698%7ENEPH%2F55226%7ENEPH%2F69629%7ENEPH%2F62937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of membranous nephropathy, showing diffuse thickening of the glomerular basement membrane (long arrows) with essentially normal cellularity. Note how the thickness of the glomerular capillary walls is much greater than that of the adjacent tubular basement membranes (short arrow). There are also areas of mesangial expansion (asterisks). Immunofluorescence microscopy (showing granular IgG deposition) and electron microscopy (showing subepithelial deposits) are generally required to confirm the diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 294px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEmAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UqRGwNtR1KiNtD8YPvSYmNPY/rTKcBQQQcUwG1IE9aciHqelOPtnFS2Jy7CLleh4q5DeTRptVztPbPFVeAvvTJHyOKlx5tyHHmLZupAxJk5qpPK0h+Y5PrURJxzQMZ5pqCWpUYJahk0ZopKssUUqjJptPDYAxQA4IC3PSmsAp4yaTcc8UnfmlYVmSRRtM+1evvTnURMMEN/KkU/3ePcUx2zxnilq2Tq2O80nrSFzjGKdHbyyBSkbEMcDjrU17p13ZXHkXMDxy4ztI7UuaKdr6hzQTtfUqZPrUsSBlJOfrSrbSn+Bh+FTBRAWSRfm9D2ocl0CUl0Ilti2drDPp60kltIg5H5ipkcjlf5U8yOf4jU80rkc0rlAjBwaKdIcsaQYwc9e1amo2iiigYUUUUAFFOVC3SpvIIAOetJtITkkV6niZQec471EylTzTaGrg1cnklU/dH4VEGING1sZwceuKQ8HmhJIEkiVTkcUEA9RUWT2NPV+x6UrCaGsAOhptSOp69jTKaGgpfzzRnjFLjuOtMAzhvSm45wOac3zDNIrYpAIBk4705gdvHQdaGYY+XirEDD7NOMdV/qKTdtRN21KlFFFUUFTqf3QAY55yPSoK09O057tUKN94kY9KiclFXZE5KKuzPGVPPen4BORVjUrJ7C5MUx5FWrPThc26OrjzHfaB/WpdSKipX0IdWPKpdGZ6nsTxSGpr+B7O8ktpRiRDg4qDNNNNXQ07q6GvnPFKFyBntQWFBfggVReoj4Axnmo6WgdeaoaQlFLSUDFpduPvdKbSk560ABxnigAnpSUooAAT0rb8PaSt3fQi6IWMncVJwSuM5rHhUPMilgu5gMnoK6QyOmqrNYrGyW+1cKvDAYzn2Nc+IlJLljo2jnryaXKtLnZado0E0FsWXz7U75QIx5TBgOQAccdCK6/SPCei+IQsi3sKXJbMQmb95IB1DZryPxF4if+2Em08JFEmHVUJwpPUfT2qHXPE5v4Y/s0b2z53Mwck7sYOK8OeXYqsk4zcb9e3qjzVgak7Ntq/bp/Xoe9av4a0VI59PgaGBggPmSAYVweefTkV5d4l0TTbbyLpZIJiG2zJG4O4eoxXEWd5qd4GiSWSRR85DN2q8upWyglrdxIExsb7pb+dGGyythXrVcghgXRl7smxl3pcM14FsJljjdgA0nyqM9iawbjzEleOQjcpIOD3rstB09b23uHnjKllPlrk469R7Vm+MNIh026g8pwWkTLgHo3fNepQxCVT2UndnXQrpT9m9TmaKewx9KQEYwelegd1xAMnFDAqSD1FXre1RwT5oGR8vHU+lVZUKuwbgipUk3YlTTdiKrgsLj7Ms5jYQscBuxNWdG0x7u6iypEG4bpCPlX616Df2zS6c9nCloYosFGX5S4H1rjxOMVKSivmctfFezkox+Z53DaTqoxGWDEgVE+5Dgqc+9d3oIt7rWPsWpSrAjoSzxpk5xkdf8APFGtap4esr8qLGO4e0l+QrnZcLwCG547nPrWKxknU5ORt2voZKvUcuXkucCltNOXZFyFGTj09ans7B5TIjxy+aMBRjvnvV2/1qCe4b7PbfZ4N2VVTkqM5xmuh8LS6NqmqT/2ncywwhiyEvjCnr9TW1avUpwc3H9WbValWEb8v3GXq9tDFJFHpsM21YlEiyfwydCffnpVbVNNllAZ1IuEISQkcEnp+NbPiLWtMttauBpjNNbKgjicDhsdzmqlvezahHeXRmZcgOzPxlgO2K56U6qhGdrLz31MI+1glJq3ruczd2M9qxEqHCnBI6A+lVa7ddbWTwvfwXEayNI6tl1yQehINcSetd1CpOaamrWOyhUnNPnWwoYgUpGQCOaZTlOPpW5sJSg/WlbnoaZTGPDY6Ck4PXrTacoyfegQEAZpVOFb3FIc55oxx1pANooopjCug0aOX7IjhGMeT0PLc9BXP102keIxpulQww20bzozHey561z4lTcLQV2YYhScbQV2UfEW77YRIHVgoG1+o9qjs7iOC1D5/er0FVr65kvJzJJ99jk5qswwcelVGn7ijII07wUZEtzcSXNw80rFnbqTUQBJ96AR3zTgwyTg1qlbRG22iBU9etPWA7d7fdHr3qWCaFFZnUs3YVBLLvFTdtkXk2MfBPyjApRG5XcFYr64q1pMUM99Glw22MnlvT3rsddtrHT7OSS3nS8ikI2lMqAPcY+lY1cQqc1C12zOrX9nJRSvc46fS72C0hupbd1gmzsc9DjrVRlKnBrttJlm1CG3hjIQNLsXcx24I6e3NXda8LtBMy30axXCpkpjG/Pf8qw+vKEuSruc/wBeUJclTc86p4Un/wCvVm8hSGQrGdx7jGNp9PeotuQea7lK6ujtUrq6IxjkY5ptKRjkUFie9UUPtf8Aj4iywUbhyegrrriIFknstgt3IjkERAJ9f/1muMrZ0LUEtnKStgEqVBHyEg/xdyK5sTTclzR6HPiKbl70d0W9Q0oXAuLmwhxAjBSvUqcdfpnjNNfw6UmiR3YeZEJMnpnHTNbdnrX2u8uJ0ihSJ0x9nTIyB6enPNaXmxQ2cKsjSD7kImj4Rycs2f6V58sRWp2i1/Vv0OKVarT905bQB9muPOl2lUGGV+Aefu/jirGr2qqjloHMaHcLjnaQeij25qS+YNqc8slsZFYmTykOAoHOc1jape3BhZNpjgl58sZC59RW0FKpNSWhpFOpNSNXw/4nu4LyOGeRpbcL5SxAYGD2qfxpI09o0t4yfaTMrKvIKqRyMdOwrmtMaCJne4DMVGVC461PqF/DNZNFsLzM4k8wnlRjkfnVvDRVdTgrf1/VzR0F7VSitjMLA8Uxhg0owD0oJzXedqLGn+SblVuSRE3BI7VEQfMJINETFHDDGfQ1bCS3sh8i3PyLyEGcD1NQ3Z3Ik+V36Hd+ArTVLzQJhZtG0CTbRHkbiW74PUcVc8UeE9Q8OS21qwM73CCRGQ9T3HtUvhCeHRvDTQajHAreYZVlil/eg4AAx0wPrXWeHfE+j310bbVzJJ8mYL0oA0bDn5uelfK4nEV6dadSnG8E3st/O54c3U9pKVNafn8zyPXNlo0MdoJC7DJeRdrhu4/DpXLzHLnJz7+teg+MrSGWO7nsX8xYmy8uSAxJ5xn1zXnxQk57V9BgZqdO56eDkpRI6UHFTQQPNKkaKWdiAAPWugHhWaJ2FzKgKHa6pliD2Hp1rpqV4U/iZvUrwp6SZzPNaVjBKYXnQKY0IDKTwa6abwiLXTori7QxbwQrF87j2GAMitOw0/SrDS7driae3vJACyFMr1JBP4Yriq4+m4+5rrY5amNjKP7tXOO1XMNsFhVEiuAGaMHJUj3NYtb3ir7N/a8os7lp7dQNrH6dKw3xnjrXXh3eCfc6aHwIZRRRW5uKKCMUlPXHINADKeuO9IwwaQcUBuK/3jSUE5NJQAUUUUAFSKcIfrUdOB+XHFAmK5yelIATQwxxSocZIIzSDoIRzgZozwRT9wQHj5j3qKgELSUUUxksLiOQMwJXuBXZX84vtHtrW0MdtbSIvyk5LMOufT1riK1vD+oQ2Vz/AKasklthjsXH3scHmubE0uZKa3Rz16XMuaO6J9S0d9PS3kgvElDx+cNhxtH+PtUsPijUpbQ2VxK1zGcFS/Lgjpz1x7Vs+HtL0/UbW4tXvgLm5t2dEX7sbA5UEnufQetYOjabnULqGdZluYULIqD+IevoPeuZVKc1KNXVx7r8TFVU4yjU1t3X4lK8iKNvZlYsNxCnkZqAFTggV1+irafZ0iu4Q8/mMXiIwzcEf5Fca3yyuoBAB6V0UanO3G2xpRm5txa2HNtxkirIFiyW6oXErAiQt0Vs8Y9qporTSKi9WOBS3MBt52iZlYjjKnINbNXdr6mzSbtfU2vFnh3+wri3VLy3u0niEoMLbtuex96w0VtwOM47VKjSFVDsdg6A08HJIqafPCKjN3fcmPNCPK3fzJZLlzJ5sUYiOMEJwK6TVfEUep6Zp8dpb+XNb8ykcbzgAH9K5lSoXruOefQ1ImnXksoa2tZcdfunjPNY1KVOTUpaW2MZxpuzlpbY6PT/ADbtCsQYyMPmTqXNZdwrXepJaX0vkRKxXLdEqx4ZuYhfSLqhuCByDF9/PoDWm2hanrEsjwwCNHbdvf8AhHuetcjmqNR8zsu/+RzOSpTfM7Lv/l/wxnT6RYo88Nm3mskhEUmeJQMjp27GszUrEx3K+YoRQACAMV654T8FnS5b2S7tvtN/DjyimSHLLwB26ZOa8o8XLdQa1cw3aPFJG5BjbtUYLGLEVnThK9lv3Fhq/tarhGW3fcrappzWk5KqxgY/I55B/H1qisRbPt+FdR4MmsLmX7HrNwUhP+r3/cVuOvoMV0VzoGgvo960ep2sUySHyUzlivvgc10TxvsJezqJ372NpYiVJ8kot+djhdKgsrgtHdzeRhSVfrk9hW1ZW8gtJXszmM/Kw6HHFVLbSEkkZYpY3xnkckj2rWuLmSI3VvpNrJFpshj3iQB3BGOQfzNTWqc0rRf37EVZ8z91/ft/n/XQNc/s6z0+xW2lZ7mRPMnBJ+Qnoo9wKo22qWsavuDkrgoMdfXPNa3iDRtHcLNpV1PcDYu5ZB8zN3IA7Vy99pyW4LRzCQDnpg1GH9nUgk27+ehNJU5R5Xe/mdeLrTtWKW0cvlPJDlgw+UEdgfpVTUbay0ZUgvEilEqBl2EEgH3rjDkYJOKR5HkPLs3HGTWkcFyvST5e3/BNFhIp6N27f8E7jRF0aWd3VY40jViN/BPpVvxJ4gt7QGCybz8gFmHQHsf5f/XrgYE3kkghQOf8K0NISOS+WKbYVdWCA92I4FZ1MHDn9pNt26ESw0FLnd3boZ97qV3O6iW5lYL0BY8V13gzxIyIbHU4Yrm0mYIZJBkoDjPP0rMGj2VvqMtprSXNrMQNuBnb6kj+ldR4X0610+8vrJIY9TiMTPFKqksuR6dRwOaWMq0JUeXlv1XT5pjxNanOlZxv+X3nKazoDDXLuKxYSWySEKwYE4PSsG/t/s8rISCV4JroNU1OWC/Esf7t1Xb061zt5MZZWdjkscmuzDOo0ufax0Yf2mnM9LFaiiiuw6wpaSlGMjNAEyr5kZPOaiZSDTxIVyAflpZBkDByalaEq6ZDRS9cmkqigooooAKWkpcUABo7U7A25J/Km0AJSgE9KSt3wkkX9oeZcRsYFxucNgKMjk1FSfs4uXYipPki5GXHas0RkY7V6DPc1E0LgZ29K9B8S2djuxZSvPE20mbHygntjHH9a5LUNgnKxn7nHFc1DFe2V7HNRxMqm6sZFJVqWFmXeo4qsRg811p3OtSTNDRXVLo75Xj+Q4KjPOK0NVkns9XjmSQh2RHyvuM/lWJbP5cwYYyPWtXUGlmEL7W8oqNmRn6gH65rnqR/eJvZo56itUT6HaSy6S+lwXEdizyIGkeYDG8nGAcehNc5N4dMzKLWG4aQxCVhs9e/sMVmW+rX1tbyW0M8iQupRlHQgnJH5103h/W76O+ikt7uXc8YSbv8g7fT2rz3Sq4ZNwf3tnG6U6Cbg/zOUeyuNNkWdgh2Ps6g/N6V1uk6C2sQ+ZDZ+bM0Y3FsDax7479/yqlqtr9ouEnRFK4MhRR05xzXoulaxZeHvAMWo2kPm38cyRyLIe+GORjoKxxuLqKnF01ebdv+HM8RWqTjHk+J6Hn9x4at7W+aMyvJsXlccbs9PpT9V8FXNvJI/llEKl0Gc5AzxT4PF1t9snuLy0mJkl3mMN8oHp69a7mz1sa4trqsNmsMNsdjc5H/AAL65rOtiMXQtJrTr6mdWeJo2k3/AME8703SHSfzpI44oORGWOeR3qvBqNzd3UkdvKkaIThTwWHT+Vdr4jt7XSJ72DDGeRCYnAK+UGH3SOnevM9KDjUYijhMtjcRkDPrXVhp/WYSqPtob0H7WLnL5HTX3hqfS5oJpD80kYkVY+q56E/jW4t2+m6dO91cSTXUieay4yAe273HWs68ivxpkk9zLFLDCdkX7znGcgD1FZkutXdxZzWxbasowxPORWPJOulzNOz1MlGVTeV7fI7f4c/Ej+xpPK1CJZ4CwAbuo/rWD8WNZsvE/iZrvTowoKgE464rkE0+UYZS3rkCpeYism4KFXJJPU5q4Zfh6WJ+tUtJbeR0KnTU+eC1KK2FwjGSOJmCfNkLkcVPZXCOzpcR5R8A7eMV0fh/xCyR3VrBaCWOTPDHOFPUCsXxDHbQSK2n+ZHG+WCnt7V1xqznN06kbdmWpzlLkmv68yWyT+zJ0uXkVUaUoFfI3DHOR1xzXX6f4l8PW+jvafYvOvZn3Fy5AUHnH4dK8yvLya8dWnkLuqhAT2A7Ulr8k6MT0PWitgY11eq3fy0KnhI1Ferqz0TVYZ7vWWl062a1+RVSJRyRjHb6Vi3NjepDPHJZT/KT+82Ern3NS2fjCfTbwT6fvWVMp5hYNuX05H+c1uweJ73U7ZpYyULvmRivcEfhjkVwcuIo291cunXU4nCrSSdlb+v66nnbRFQdyEYH61V+62cV6D4i1SG4TetlarcK5fEaAg9sNXN+KpoJoLNoY1RgpDFUCDscYH1616GHxEqllKNrnZRrTk0pLfzMiK8IiaL+E9PrUDykMNp6elQUV3KCR2qCTujo4Ln+0ktktzcy6rvKkk53p2x71e024vxqLvY3E0ExJRlHDbRXKWs8trcRz28jRzRsGR1OCCO9dNqOsfaZ7bUFj+zXQUbkj6Ocfe9vWuKtRafLFXT/AK+78jkrU5KXu9fz/wAvyIfGFm1nKiXDs1wfmwecKeRn3rma2te1JtVljZ2d3VdpdjyazDbuITJtO3O3PvW+GUoU0p7m1C8IJT3IKmtYGuZ0ijxuc4GaasTkZ2nb64rovDOnyhmvVgaVYug2gjPv7VdaqqcHIdaqqcW7jp/CkkMeWlG9iFXjgnvzXPSQGN3Ruqkg16Ffb/sRRHYNJy8YThDnjPcfWuP1mzew1KaCXaXDZJU5FceExE5tqb1OXDV5SdpO5lLGS2KlRBggdc1Mm0c/xZ49KYwMblWGO9dvNc6nJshdMDnj6VGwK1K5+b1pp5WqTLTIqKKKosKepAB9aZRQA9sgYJ5plLUjtGYUCqRIM7jnr6UhbC2qI8oEhKp3IFdtqusWEHhm2stKs41dADcysvLvnjmuP06HzJlyMjPI9a6TxTqOlpbvaabaKBJHHlmzujYDnnvmuHExVSrCLTdtfL5nHXXPUjG17fcjAOsXrRTxNOximOWXtn1qkJGAxUdFdqhGOyOtQitkalo5SFpRGzAY57fj61SulAcOo+VufofStHQb23ik+z36r9mkPMm3LJx1/wDrVNfafG5Asy0sbH/WAcA9uaw5+So1JHPzezm+ZfMwq6bQWuLuxltlhEixZkXjkZ61h3ljNaSbZACM7Q68jPcV6T8LoxbR3012jCM2zDecgL9TisMfXVOh7RK/YzxlVKlzR17HBTozSOqA8feBHStPwtqEFnJcQ3SqBOmzzCuTH7iorhC1zKyH5WJwB0qouk37oJEt5GUgFWC5GO38qcuSpDlm7EtwlHlm7I7OW7tbB4ptPdmh8oq5bksT/EfzqPDatpGoNcyBUSDzQqnaA3JUEeuA1Y+lxw3Fo/26RoHzsUheAcHgita915bDRdTsojHPLexxxOwx8gUdvftXnSpOMlGmryutfmcrptPlhv3/AOCcZCWf7wTaOORXc6VGulWZt9Ou2l8wKZyuQhPXAHrmuU0eITRSKYi3zD5lxke1XrjV4LCN4Y4y9wH4LHgAetdeJi6r5I/cb1lKpLkj/Xqd1qWvzXeiy2L2Kzyud73EwBbaPQmuK1DRLdbaKa2mDSvyUXnYPeuf1DWru8kZpJnwwxgHAxVaC+uYdxilddw2nDdR6UsPl8qC9x262HTwcoK8Xb0/U6K4V4rSLzWlCj7245Xr2qS1vJZ4HRSY7UYRVH3WO7q1c4b2bfmR2Ynn5jmrMGtywW9xEscZaUghiPuc9hW0sPK212XKhJruzqlsGdZ45rpYVhVpAvRSR1Fcrq935oSCIKUiz8wHWoLzUrvUJN11MzDJOOgqLAGaqjQdN3m7sqlQdN3k7sbZXlxYXImtZWjlH8SnFWtW1m81abzrt1ZsBeFA/lVGZRnI9Khrq9nCUudrU6uSMnzNak4pcgdMZqEMR0NJ3qrD5SVmweOtXrFNTADwGdEY9QSAa0PDGhT34uLrZJst08xT6ntXW25EVk/2mQF5E/c4OMOAccenauDE4uMHyRV2cNfFKL5YK7W553cXE8bmMvKvZgzHmuh03WrKaxgh1CBZZoSRvdAwK8YFPW5sr4SRXyGSZASgGB9efbFcy0gt5D5W5XDdavlVdcso2aLsqy5ZR1R1xl0ye5kktdNtWilXY3BKRk9/UVmT+HhPci2spEN4TtEZ4Dn/AGTXPJPImdrsMnJwa07bW5ItjsgeePHlyZ5X3+tH1epT1psPYTp602XJ/BPiKG6e3fS5xKi7yOOF9fpUaQQ6bbbr0k3HKiPupz3FJfeJ9UvLgyyXc25gASXJJA9aitGm1XUGMrLvKltzdBgUL27jeu1byuNqra9WSa8lb9WWtLtreKZLq6ic2THGXHOPUepFGozWEOpt5Ei3MCMMkqR5nc/rWxrllcv4PgubqaVkSQqgY8Annj0FcMqFulTQSr3m3tdEUFGtebfkdPpmuWkMH2a9tZHtPO8wBHwV9qv3njeKLaNF02K0ZAVWQnc20jH51xJ3ZAYVMihWH0q5YKjJ80lf5uxq8LRvzON38/y2PUvAt3e+JrWdNRMTR27CZpX4eb/YJ9Ko6roFvPJd39/cZkLgRwxtwFzzz9P61X8PasdBitDJHlcgSRtwCDyfxqh4tufOuHubVnSCU7kUnOATXkxo1FiX7P3Yva34/eeaqcnVbj7qfb+upFe6ZDMrGMR27IuVAONw9KqJaosKSTWqyOcoI953lj0OKrW98WlU3o3KM4J78f8A6qvXkdtNElzbSSB4zjaM4HvntXoWnC0ZM6eWUPdbOdu4XgmaOQbWXsRgioh9w1NcyGadjIxZickmouikV6Eb2Vz0I7K5FRRRVlhRRRQAUo5IpKVfvD60AdfbRBvD7G0t1idASZX6uOMgH1rFsdPF80zST7WjXcQ3Vh3x7113h/VU/sqO2WWJHVvuTqCrZ4PJ6d6wrmVo9ZkPnRE52eYo+UADA4/CvKpVJqU42seZCU05R2+//Ix9WWxWWMacJhGE+YykElvw6VQrc1/Y++VJlbzCrBAOoK9fbHSsOvQou8Ed1F3ggrV0fVLu1xbw7pYnYHyuvPtWVU1rO9tcRzRHDowYGqqQU4tNXKnFSjZq50mrSRLp9sqEZdy8kTrhkbJGK6Ky8QxzWYtLWaIWhhCSxunOduSfzFc1p8M+r3shIEzuC5CuAcdx9elYl+jWt7NCUMbRsVKnqMV531aFb93Lda/ecEaMKj5HutenU73WorSFSyWL7p0DI27j3wPxq7pfiiwkRdIeJ/kHlRSFtoQ9sj69681bULlljV55CIxhPmPyj2p1rDLdTYhUs4+bI7e9KWXRcLVXt1H9Sgo2qa/f/mdZ4khCwEwjbwS7A53e9Zug6bHeee14+xVAKjPLN2H61et7a8u9F8yaHdGn7lHC4BI5OT3PIq6mkR6fa2dxezqPNJKgN0C9yKyVX2cPZ82tzBVFCPs09b9DK1eOTS2jhaHyJgpJ3Hh/SuWcmR/Unk10Hi/WItWuIzCr/uwVMjNnzOeD7cVz9u22ZTgHB7134WMlTUpq0juw8ZRheW/9ep1dho1pHY2hnjZ55fnY84x6VNJp9lZTnFsvmq2QSxZQo9RU0t6Y43a5fG7gBuoGelV9b1OznSIiOSIKvynb97PcmuFOrOWt7M4l7SctbtPzKPiC0g+xR3MSkTGRg4UfKEwMH25zXPJGXlCqMk10l7qEItBFCNyTRAFiehz1wKWwS3/ti2jhmQq+0M2AAPWuqlUlTp+8u5006kqcLNdznipXqKduAHWu41TTbaeG7fZHFtP7tegx6/8A164a6UxM6Y4B6g5rShXVdaF0ayrEcjg8CoaU5zzUix57HFdWx1aRIqkhKiVC+SoYZxV6w097sShNuIxuYk849qLm1SG4Tyd5XG7J74HaodSN+UzdWN3E67QL64vRcJYIwjY5eCFMsFXnII71zfia4um1A/aleKTaDtPHGODVmO5Gkut1pd3ICArKy8HcRyDWHf3lxf3T3F3K0srHlmOTXHh6Fqrmlp+Jz0KXv8629NS94akSPU43nBMY6kdverPiOxzq4WIKBKoZefX1p/gudYdV8mcIYLhSjB+meoP5ite20q4t9Vnknt0MYBLCUZATrkfhSrVfZ1nLy+8itU9nWcvL7zl5tLkSFXVgxPUdxzjmp7Pw7qN0krpbvsiAZzjoPWrnijWbe5uymmQrFbBQvTluP8axTqF0VK+fIFIwQGNbwdecE9m+5vD20o3bs/S/6o63R/BsU6K9/exQq6Ziy6jc3YH0pmj6XFaX8sUwYOpK7lIYY5H8643zHOPnbjpzWj4eupoNZtWiDSMZAuzP3s8YrKpQrcsnKd/K1jKph58sm53/AAOx8YQL/YdvDZQSxIDlw7ffYd8ew/nXCAFONtelapeQTzfYb0yK8LnAcYYH3IrktZtxPqbmytmCFQzbui+vNc2BquMeSS87mGFqtR5ZLTf+rmDIuFOTn0p8SCRoxnbkgE1bjtWdnbYWjQZcIeR+PNUgkkbFh0B59RXpKV9EdykpaJnbvo1xHbQJdSb4pY94bPJ49OorFlu7aO0XT7jO2JywbGTz2+lOtPFd5HF5dxtnUKEUuOUHtWVBC19dkF1V2yct3NcVKjUV/bbLsckKUo3dV6eRY1OSG7aL7JHtRVAI75rStre6/s/7HDGHBBm+XG7p6+lXUttJtbMQTttvDkGRxkL6Hik1i9tIdGjazvYZLgZVlQFW+v41m6rlaEE9+v5kc8pWjCLt6X+ZxtyQ0zHaFPooqFu3vT2cM5bAGaUjKk46CvVWiPTWhDRRRVFBRRRQAVJCMuPao62dAt4WkE15Gz2yn5gOM+2aipPki2Z1J8kbhYWV3qDrBaQtKWbaMDv6Vv2HgzVTLMtxFJGApL5BHyg1WvdRtorjzNHiNtAj5jBbJ/E1u6P4s1hCocxyxFfLZW/iHp615WIq4lx5qSSXnuedVdeUbwaj5Pf707f1uUvGPhZdC0aB3Zd0zZUE/NtwDnFcKI89Old9r+k6lqVn/aE9ykioVj2FuRxxgenFc/b+HtSubXz7e2kkjzjKjqfStMHXUaX72abvqXh68KcPenfzehz7LtzTK0dRsbqzyLq3liPT51IrPAJ6V6UJKSujvhNTV0y1p0nlXCMdwUMCdpwcVqeKGsri8R7C2eD5BvDNncfWqekWzTThVGTXWajpqoRcXEo8yOMMO+MEYArjrVYwqp9TkrVowqrv8/yOBIwcGr+lSssyqrshf5Mqeea6l9M0fVoc2syw3SxZkDcKz98fzrjSrwTcEgqeorWFaNdONrPzNYVVWTi1Z+Z2J1qWzghsd0hTdgxgYAyefxPFdZf6Nb+KdBtJYlks7u3j8kMyko+D39OK4bTdW+2SW1vOY45Fbf57/wATjJ5rsrLxJc6ZYvDdXFss0jeaG384b88142LpVIOLpK007+p51enNNKKtJev+VjzPVbKXTrya3uU2yRttYVUt3KToyqGKsDj1rpfiDqsOq6nFNDIJGEKq7joWHWuZiOGyOo5r2sPKU6SlNWbR6dFylTTmtToXlS41C7WeD5Crffzuj5/nk1SWwu7rTfMgileGNyrN1A9OPzqxaT3OoARwWwaUfecDlu/JrVs7WSWJfs5kW5kHKcKA35elcspukckp+y0ul+Jypt2jOHDDBxyKv2mkySlGkYwI3R2U4rSkvWvc2c6oGj3MZepdh2zV2JP+JPGJZD5hcqBuPy+2KdTETSV9GOdeaSvoy3pfha61CMRPfxSvIRHHuJ5IGSoP0rQufh/PNFHGrwFymQIySB1zz9aoQWVxBEslq4to1kDmbdkpnj1qnfvqtl8i6jOLdcvEzEqHHsua89utOf7uol8v8jkTdSWlWz9P8jCOjxTa8LG0mIjyMvIORxz0rv8AQ/CmnWVx5d5DcXLoC6Sxr8snGcAHpXm9nLOl8HhHmyOCCMZznrXYDX/IS3iSUpJHHnEh5Ddx+NdGNhXklCEun9M6MVCpO0VLT+tdNTE8QW9nFeTS25lgWQkpHj+E9B1rMsrxoJYzIolijJIQnrkYrY1i186C31OfzRHNJh0xz6kj86wL5oBeSGzV1tyfkVzk4rqw9pw5Xr/VjahaceXcsQE3ERs4kRfNYNuc4wQPWq9pDj5mjd0H3ivarsWnyR6dHfMyEO3ETfxDOP51cxBpuYrqECRCCwH8YIyP51bqJXUdf61G6m6hqaXhfTrLU38pomF04Owg7UT0z3rK8Uy6hbai9peXTTNAAilWONoHAqzaas0k08kCpCjYARQB06VI+nvqk0lxLJwEJ+bksfTj/PFcsb06rnU27b2Zgm6U3Ob07b/18jj2JJyetDYzxW5L4a1HepS1cRyPtV8Hb+fp71izxSQTPFKpWRCVYHsRXpQqwqfC7nfTrQqfA7kdbHhLyx4hsmlICK+7JbbjHPWsetrQoo1SSeWLziCFEePXvU1/4bXfQK7Sg0+p0nie5soL21uowS7HzN5bcx56N61uXfjTSdR0gae8C2hdcyTwoAWPoQe1cB4ikie+2QGQpGNuH6giq+lWTajfR24lWLd/G3QCvOeBpTpxlUb93U4lhqTpqVRba+h1t5Jb6Z4eiFuRLcTNvYgHIUjAB/XiuKnk3tnnHp6V28Fyk0Fvp80CSSW4G1uQTgnB9/WuT8QwRxXYkgUJHKNwXdnFaYN2k4y3etx4V2k4tavqQWUUdzdRRTSrDGzAF26KD3NdePC8Nneu6XC6haQBXklg6BeM/SuCyc1cstSu7JZVtpnRZRtcA9RXTXo1J/w5W8joq0JT+GVvy/z/ABOx8d6RYq0l94fnaXTMgYc/MpP8wOma4NupruvCmtebY39ncwpJCbdiARxv7Hnp/wDWrhpBh244zWWB54Xoz15evdEYVSi5U5dNtb6eYBSRkc0ob5SD1pI5GjOUJB9qbnv3ruOuwlFFFMYUUUvbNACVs6C5klFpJIUikPTHftUvg/TIdU1dIrnIhUF3x6Cu2uYNH0ma1v8ASwsd7FIGEb/MpAPB5z7etefi8XGEvYpNv+rHDicQr+yUbvv0X6/gzlr+MRT+T5JjZCQQ3FbelNawxLHeKVkPIkGTg9QMVL4slv8AxFqcuomzWFY0Uv5fAxwM1TuLUCKWVJGn8lUYOg+Vc9Qa4ef2lOKlo+ut7P1OJyUoqMnr1s76+v8An9xqXl4IrV4rTJgxtZyuCSan0pGgtn8wThCVkhKcBiOv6Vn6ZqVhBcKt/MXtXjbeIyM5x7+4rK1DxDNmA28m5EGAuc7f8/1rJUJz9yK+ZKo1HolZdzoviNeveaL5Ai2kTecFb76jbjmvO9L02W9bcAfLDAEjrz7V2i61FqcloZFLTID8sgJBPv61DbWCWKs9vO6XMgbMWz5QO59q3w03haXsrWZrRnLDwdO1n/X9XKdpp/lXks1r8kaKMqeACDgj/PrU+u3lvFp6tDOJJ5SCVPVOvetPW72JLD7Pb/PLIM7V9O5PPtXB6yFgnEEcgk2cluOCQOM1eHi8RJSnoVQg60k5/wBepe0a+jiusNBAzMCQ0gJwcZ6Zq4/h6a5jkvYZIXjI3uitgrkZxzXKqxz1/Oui037VHp/31EbDPPcelddanKm+eDszprU+T3oyszAmUqx7EHBqMsxPJJ+taetM0l6VkABAA4x6VUFo+3cQQK6oTTimzohNcqbKxOetWLaBpM4pFiAPXNTJJ5aMoHBxmnKWmg5S0si7pd1/Zss7GITB0KAliu0+vFdFdeLra608QvahZY14K8HPqa493Yrg9AKbYwiaYJvUFuMk1y1MNTqPnnujnnRhP35rVGhp4llvkeBMZOCe1dD4it/7PhVmjVmfDBkbIAre8H+HvspkuXBlihXeDuHzNx0FVPiZqEVxY2MUcKq6ll3Km3IGP8a814pVsVGnBXXU4FW9tXShsjjbS6uJpFt/OCpIwB3HA/GtnU4JL+YQ3N7lbdAibRkFQO1cqCcjAOa0LC4kU7HYFBwVboK9GrS15o6WO2pTfxRZrabp8ptwYlPnoxXAXJKnPPvXOyyzRag0q8OpxyPwrpJPEt5ZqV08JCjIFby+On/66h8OWcF7PNNfAMhBPXHNZQnOmpVKq0/Ezi5U1Kc1e/Q0bywvZNKtdSvrhNsw/dxE+grC0e2hvb1Elj8w5+6vV/Su+1TT7aXwjY3Ecu4RTNbMjYOOhyPzrgPsUlrcTvY3BzG21WjPLH0xn61z4St7SElezu12tqZUJ88Wm7P0sWNevDb2p0xlCtA54H8PtXPXN1PcuGmkZzwOT6cCllZpGZpCWdjk570yLBJ9K9SlTVOPmehTpqnEFaRRwce1WrPUrq1c+TIykjBwetPQAxZC5Zeue4ptxbEshhDOXHAUZptxlpJA5xekkdPD4zvJ7GC1llEJtw21sfe3dc/hmnWv9nas12sltFJPImRK0hVgR3rk/s7rErsCu4kDI61ErPCRIhZSp+8OMVy/U6evsvdfl/XcxeHhL4NPQ3lTSra2ZHg33iNxvOVPt/WrsOo3lqftKwQIsaDYyAJt4xx6965ia9aQg424AzjuR3qaXUZZbFbdsbEOR61UsM5fFrfuKWHb319dSuztNcF5cszsWb1JNd34V0az/s4S3sETNM/7mQzbSoHXP1rD8EaeLq9nuJAPKt49xyM8k4HtWzqKRLLE9viFcFiM9xn8ia58ZU55exg7f1sY4mpzS9ktPQ1vEdvJYWEdxLYQIyjCMjhsj8O2K8vvZpLmYyOSx6V6BdXiXW23DTKjDylLDK7SOWHvxVlPD/h200i4N08s9zIxFuY2HQeornw1dYWP7xNt9jOhU+rq3K232/4e34nl1X7bTpZ5UihQyyOcAIc5P4U2+tWtrySCRGRkbGGGCPwrT0jU7jS43+yqCjkFiy56HqK9epUlyXp7noVJycb0zaj0W+0a0kW4EaW0wzJJuz06D2Oa42VSc45zXU32qXUvh+XzWZFnkA2jlWXk5/OuejYeWw46VzYXnXNKpvfoYUOaKcpO7uZ1LUkqgNkVFXoLU7k7hRRRQMKXJ24980lFAHVeAdYtdG1SWW8bETwOh+XIyegrpL2a11eGNrCEtgM4MK/Mozjkdq8yqxaXtzZyGS1nkicjBKNjiuCvgVUn7WLtL8DjrYONSXOtJHTavqk1mtutvI8bJglWHOR61mwX+p3yTW0MsnlztueNOAT+FN0q1uNQnFxcZljQ5O9j83tXpGhSpZX7+dZW0EU0YVXRB8ox1rmr1YYaNlFSkc9WqqC5YpOX9fM83/sa9czLBC0phGXK9h61kukkZ5DCvbLI2Gn6PFJDumu7pz5jOBtOPase80201W+l+yxqkp++SAqD6VnSzV8z546dzOGPnFvnjoee6DLdf2hF5BBcdAzYArSuvETtdSloVVmG0HuKn1nSjpz7LXcssZO6QHg1gXMEyr5ko3A/xDmu2Psq757HVGVOs+do2YpzqFrdIzIJSoK9ieRxn6ZqrYaI8jmS5GIwDyOc1kxtJvURsdx4G3rXaRXo0/SwJGLt5WBzyG9PzqavNRVqfUmrz0/dg9zh5YtkzIcjBIxiug0aJ7ixkCSKojI+UnrmqMsc2p300sUD8/Mw5OPUmn6TO1rdqp4DEKfbmtqrc4W6o1qtzjZboqaiGS9mDEsdx5PNOjYyLtLAA84qxrylb6VW4cHk+tZqyAcNxVw9+CZUPfgmWdqAqoycjrUDuq9eT6UrOFXIyDVZuSTWkYlwj3JnuGMYQDioVO1gfSm04KT0BP0q0kjVJI9G8KeIBJpIt5pQBEWLRgYMnAwPzqh4gna/ngS4AMCAuixnoDzXEAsh4JU/lV6y1GaBiC+5SMfNzivP+oKE3UgcUsIlJzgb0915elQ2XlKGjmMkbFAGI/3u9WrmH+0I5LqOFI4wu7hsk4HJ/Op5biTXWtZLkGNgoUHbhVQDr161RvbVdP3PGxaNGKgHgMPX0rmi1dLaRyq1+XaXl/SMK6lV2AQcCuo8Gwfb1FrHjz2YKq9yTxXJtZzfLMF/dNznPArofCEt5o2tWeoCHcgbI56dcE104tXotQevT1OiuounaL1/U6/X9NvNPhGlKsN0d3nbUlB2EDnODwa422OyCVCkkWzJZlJI3c4z6Z4FWPiFD9n1zzIZSonTzGQNypJ5BrmJZpSpHmuVOMgsTXPg6DlSTb3126/eZYejzU077+X/AAbC3kmWMalSmc5Hc+tVFBB5pSwyQTzUtpNFHdRtPF50QPKZxmvVS5Y6HopcqskX9N0q8vIGmijIgGf3jMADjsM9a3bjSb2O10u5aOS3V1Cxg8Fh/f49a51bxi7LGpEeTsjB4HNdb9uvJNHR9XP+iAqoctyuRxgfSvPxMqqaelvxOGvzpp3Xp1/Mx5mEcssNwpIDfKDxh+nNZuo25hJeQ7S3IU9SOxqC71KeZJIt+9C+7ew+Y+nNUXkdzl2LH3Oa6qVGUdWdFOg46tiOMMcdKWP71DnPSmg4PFdJ09DsPDU01oBJZrIRICHUDO4Cuo0bTbjUAXe3gVPm5kGSGGcfhxjpVLwCtzMtsI1wpyEZMEg5PBrrJNM1CC4uJbuGSSJV2h42XkH1Gea+YxuIUakoqyfc+exVaKm4tpP8Sj4ogsrLRxLcQp9sZApKHq/t7VycMkksdisqsqw7mBIxn2Per8Vnc3upJBceYLeNgMj+ENxn8K5zUbu4trm6tVnLIrYL5P0rbC0rL2ad3v8Aea4enG3JF36/12KeplrvWp3RC+98gcnP8624dNku9JllMDuIYyNyZ6nnpWTpWuPYSIZYYrhUyQrjufeuy03xnpj2037p7W5mXYy5/dEfTt3/ADrpxTr00lThdK2p0V4V9OSN0vP+meeSrcJGqSHCEZUE9qWz027u4pZLeGSRIhl2QZCj3rp9RtNKlaTzr6COTjYIssMYznPXNZOmTXVnFczWNz+43+Wyq+1m64OPSuqOIcoXirPzWhuq0pRvaz81oYdxC0bfMrD1zUIFdTrNtcva2l5Iqv53IC+3XNcxKDvORj2rpo1faRub0avtER0UUVsbhRRRQAvWrNvCXIAGSTTrG3MzYwfwrp7LRxGAzrn3rnrV409Gc1euqeh0Gj6Re2GkIAyqlyA2wHqO2asahpEyaekw8xm3DAHQV0fhwefpyRSozOh2xtnpiuxstGaS0KSxHPoea+OxGYulNuW9z5ypiZwlfz+88t0lYpF2ahK6IgLBOg47Z7Z5ro9Im0W0Vp5/L+UeYSzck44GO9aviTQLa3jLbQG69fzryDxKz20ksRbGDjGa3w6jmOkZNXNaCjinaV18z0CV7HUrV7xbfzI1JKhFzg++PoOtcV4l0S88hLhUEUMvzOFAAA+lc/o/ia/0hpFicNDJw8bDhhXQad4gi1tWtr24+zuqZjL52E+hIr0Y4Ovg5c0dYr56eh2/U6mHlz09V97+45qOylsLhJ5UzErYzmtmC7tpDbxt5UhU7RsJyfqPXjrS6rZySRtuZc9fLHp61ziQSLKOCCD17V3q1dc0nqdEeWsryep6M+tWuhXEt1FDGv7wxtERk4x6elcHdalA+uyXtvbqkBlLrEeQB6V2djptlfaHdXWqTpLO0JEaE4w3Y5HX6V5tOhSYovY4rHAU6Tc7X5loycHTp+8uXXa/df13+Ru64sd3DHeWqPsIHmZbJzWCVDPwCFzW7oLqFkS5QyQhSDjIwe36017KCeUi2DsWPRBnb71106nsrweyN4VPZXi9kZwtDKyhSvT16VXngaEYbrmrUMgDFZPvDgHpRdhti712k9B7VspNOzNVKSdmVrO1e5fj5Yx95z0FbVsbfT3gkEbMVG7gn5u4zTlEccEFsisiE8swPzEjn24q9BYxoqIyCQg8ENnIx1+lc9Wtzb7HPVrc3xbFll0/UoovOhZZSpZyy8DPOeOenviud1XQ5LSJJYSZInXdyMEetaMckkbPGEZC0ZBKgcjsM+marrdN9qjN5I/kAlGVDnA9M1nS56b916diKalB+49O25n2ur3EESwu2+IcDcMlR7V0R1CO8gitkmEsYOdrHnp3+grnNUiJlUhAF5AIGM80w2E8Myo2UYgE8dM1vOlTqWlszecKdRJvRmjOywzTIm0KQBjdkYzWnd31tb2sMn2k/bAu4xx/dGMYGfpWZBZLNKVZi74+8CckevNUr7TLi2B4LrjduHPHrWfJCbSb/wCCQlTlJKT/AOCOvr2bUrpp52ZiRgEnOBVSRutRxzOkbKDweKYzk12Rhy6LY61Cw2nK2KI0aRwqKWY9AKtjTZwyBwF3DOO4781UpRW7KlOMd2QLKY2DIRkHPIzSSTySZDMcHt2qf7HwjZPltkB8cZ7j60R2m9ZmDBRGu7D8FuccVPNDclTitin2xSquTWvo2g3erPILZVARdzGRwoH51Sm067icq9vL0J+6TwOp+lCrQcnG+qEq0HJxvqioRg+tA4NKwxj1ptaGp23gPVJY5DZwNtuj81u2e/dfxFetz3Mk/h+Lyp2a4/iO/LNnH/1xXzlBM8EqyRMVdTkMOoNdronjq4t4/Kv08xQMLImFcf414OZ5ZKrJVaSueZi8HKb5qf8AX9djrp7Oe4vZra2uFCKq+bI3ZvTPr1rHvNHhSIQ3MPmXG5gCo5b3rR0XWbY+GjM97At5d3RJDH5wAOM1Q17W7yG9lnbyftnl+Xnrt7Ej8K4qSrKbgtLfLVfocEadVT5Nvw+e23/APPdVWKO6dbdiUBxVLcfWtq3tYru0u2lci63DYBjkmspbeQXAikRlYNhhjkV9LTmrcvVHuU5q3L2IssfU1q6HaLdXSQNIIzIDtZzhQ3b1rpYtP0u0jn+xLJJcICgeQDBB749etYiQPbWxmcrsGfbJrneJVVNR0MHiPaJpXX5m7d3dxF4MEErxM0M7w9iSDySPUZ71wzjqec1Ya4dk2MzFM5254zVZ23dRWmHo+yv5u5rRpezv5kdFFFdR0BRRRQBf0qby7mPkDkDmvV9KiivLdY8YVccnuf6145H98eldFp/iG9tFQJJwo44rzcfhZVknB6nBi8M6usXqfR/hSxtLK2DuUyOe9Ta74y0zR7YgzRyTHOFXnA7fpXgT+KdVuY9rTMEGAQvGPriuZ1Ga6aYkySFe5z/n0r52nw57Wrz4ifyOCjltPm993Z6lfePF1TUTC2Fjk4Ge3vXGeM7a4e6eckvG3IcdCO1YulREXkC3O5YiRkev4V3N2Nlhqtu0qQ2ojBhjB3g9CACTxnP869RUKeBqR9iv6uazjGjUTp/1+v6dzzExkkkgmoyNrcZzW7ptgbm4VCTtz0UdeQP610lppek2OpQyXMDThGJMJzhq9OpjI09LXZ2Sxag7JXZH4JlW/v7aK+g83aMb+Qdoq5r66XHdSxpIiR5zguCeeo4/lUGo6zb2unSG1svIn6IynbgHk8V5/NI8jFnLEk5JNcdHDSr1HV1iuxz0sM603Ul7vz/pHd2flXJWHT5UMn3QidW7Zrm9csGtL50c5ck5wMc1l2UssEwkgdkcdCDVqWeW4uA8hZ3Jzk11woSpTunodEaDpTupaHSeGvDuoXdpPKzm3tdoJZ1PzA9x7YzUeoKuj2M0EE8LySEFJI852+nt1rqY9be60ZrKKLyGCBWkLbhkDoPTNcOukXMs5+0EIAerHP6VxUak6s5SrOyvsccJOU3Ks7eWhRS2Ty2eWb96cYUDOatJYMUEjAkIRw44NXtRNnb2jMgBkPyrg46VVh1t5o445hGAgVB8vXpya7OepNc0UdKdSa5oi4VtqyHau8DOM/rV+xilhVZInEkDBm2k8kZxgj6VsXGmxGz+0b18uMhwU+63IyRj61iNcW9m+5zJHxlMcZHbj3rlVX2qtE541HVVol6/FtdogtlkjfZyF53EZ/z1qlqOmzy6bHNbpvi3A4C/MpI5/Cmx6rA2xpC6xAFduMEZPbHWrfhzXI5NQjswoiicjErtyMd+wo5atKPNFbD9nUgrxWxhSSeZcKLhXkWIbV9x2BrWs9LF9YfJNtuoySUGMlfzrWu9PjuLqZtHlSaTYVdI1yQO7CsLxDp0qXbCzDkRKA7Z+YtjnjAqo1lVtGL5WEaqqNRvyv8AL5PuQ/Z2tXOPllQ9Se2P1rUW0MmlRSBQPNDo5OeOx4rlJbm5iHl3O4kdA+ciui8Pao12y200ixx44OM89OlaV6c4x510Na1KajzJ3OWvIGt7h42H3TjI6Gq9dtr2mxzWcQQFpdpKSBCSxH8J/E1xhTDYJwa7MPXVWNzqw9ZVY+Z0Hh2K3ns5IY4yL52OJWGRtx0Hp71Y1OI2U6pPcxlm+V9oDAZ69KoabfRW9rHHghy3zMCBjnt+n5Vu3miWerwrPplxGkqr+8Ejja2OpHp9K46suSreekX8zlqPkqOU7qP3nKyTi3uGCBJVVyQSDg/hU1pIbq4iWXaEbKnrxn1qGbTbpJHAidgpwSoJFTLY3dtKiXEMkJPzDcu3g96624W0ep0t02tHqdXZXZ0rR2LRIrGdRuz95QvT6dPzrcutch1SyiubCCOD7IpQru+aQtnP1Hr9a4SLT726mWO2hmuBnkKN2e5ro9Oijs452uUe2byzsAGQTjGDn615OIoU7817y/roedVp0vWX9dDkdatVi8mWNcLIuSB/Cc4x/Kso/jXWPILqwuIyq70bcuMYx3zXP31m0KRyhXCSAkZXA/A969WhVuuWW56FCr9iW5SpelJRXSdRIHOAMnitfTpH1BzE0ha4C4j3c7sDpWL0PPNOjkeKRXjYq6nIIOCDWdSHMtNyJw51ZHX6XphguQ9xA7tG+ZI2Hat1rCzl81wdsm7cm8DOPSuJbxJqjiQPdO3mEFs8kkDFNl16+k25lGQMfcH+FedPCV5u7djz54OrN3lJfibV9ceTIZ3G2JzgAdWx61zl9evdzMzZC54UdBVee4lmOZHJ74qIda7aNBU9XuddKgqer3JSfY0zbwevFPHJzxSNgLitkbIioooqigooooAcjbWBFTCcBgQOlV6UUmkxOKe50cGt3IsPslugVCSzEHk1etba5vNN8h7PBViWmJ5Ax0xU3hPT5I9Cu9TktPNgDCJWPY9TV1fH1/p1tJBZWVrGr7suYwxOeOp9q8erKTk44eKbT721PJknUk4UFHR7t21+V2N8OeH5PEesrAn7mKJeWAJBI4H61f8AHrwaYF0uCLDQt8zEknsMc9Oad4R+Jcul2rW7adaySFzIZMYLZPTiub8Q6lNrmp3WpTiNfNkJKq33fYCueFLEzxN6ytCO2u7JWHqqpzVWuVbJP/gIueGAscrSycKBwadrOowprsUrEyRRyfOQcbh0rLtLwRzpCp+XjPtU3iSxlkha/jKNEWwOeT7muj2a9tefXQfJFVLz66G9cmx1O3ja1tlaRDjbISS47CuJ8QWH2LUpI0UBM5Cg9PanaRqc9pLHgnCnpn3r0d9D0rXb2G6vLxI7i5AfahJVRgcHHfipc/qE/eu46+Y3fBzuk3HyuzznQ7MzXSpNlI8ElgOlWr6xWNZFtd7FSNx7n6Cui1eBdNnmNtCkvlxbWYDgH8fas/TJY7jzZjiJXYbRgnmtPrEp/vVsP2sp/vF93/AMi2uns7AkOd+8Ec9CKWfX769eQzyAl12scdfT+VO1i0nVfN2HypGJXjn6/rVS8thEsbRIQAo3d+eua6IqnP3mrtm8HCWrSbZWlikdN+Cc06PTLhY1lkQ7DzgH5seuK0NCtpr262hd65wwz0zXc6po8l59nOFI39d3HToOelRXxioyUGRWxnspcrZTtrmzj8IyQTrKZYF2kZwE3EYPI56Vg3WnCeJXt5FuEChi3Pyn+6feptdaCztL5Ip5lkmby9mPlYBge/piud02SfzlijLZdhhQeprHD0XyyqRdru+pFKleLqJ26jJllQ7ZMjnoTUYZll3KSG6g10Ws6Pt8pgzRzMPnEnHPtiqkejt9heeaQBkBIX1x711xxEHFO5tDEQcUyrYapeWl4tzasUnXuvWtKDxBcNu3RLLPI5Ylhu3E/wAqoWVtAyGVmLbDnaOv/wBar0cSad4hjF3EVVV3ohwf4cr0rOqqUm/d1t+QqjhJtct2dJq2hrqloAixf2gil5XZiNgA+779cD6VzVp4VvBcws+PIYgl1b7oz39Kv6/rCWcshtA8dxMgWRScgAjn9awbbxBqFtHJHFOdjjBQ9MVhhqeJVP3Xo+/9fcZUKVZQ9yVk+/8AX3HbWs0supPp4md7a1ibLqei46155eqRcyHBwWOCe/Ndf4Q1NnkmN7FvjeFowQuM8fzzXL6ihS4eMrtZeCPfNXhIunVlB9l/wSsPH2dSS9CgBznNXdMvJLK6SWN9p6HjNVCuB70uAOvX0r0JJSVmd71VjsbDWpxp8tupR4ZJCwDbQTxz7jiqVpPPrE6xM4JwQu7+DHYVh28kQ4YMGyDu7AeldH4Ov9K07VWn1GD7RbbG2KXwUbnB/lXBVoqjGU4RuzinR5U/Zx1+S/r5m1oWoX2lENZsFZQQy4PI/kKp3cF3fatBHdTqEnUENuGAxXNbUevtewiOxS1t0RMOxI3cdTz35rA1NJbqQojkPHzuJOCMZ4rgpXc3KUVF/ezigpKT5kk/vf32/wAypoWnS6neXVtbMscsY3lmbACg8ms+6HmWM8bMAIskYOckN6duDVvw1qEljrklxbBJGdWj2sOCCMHiszXi8N3LAsqshIJ2cAnFejCM3W5Xto1+p2wjJ1bX7MxaKUjHWkr0j0RSc9aSiigAooooAKcvWm0+P71AMkAqJjkmnu2OB3qKkiUgoooplBRRRQAUuTnPeikoA7HwRrv2dZdLuZCtnctkgtgbsHr+lbcOhRXEMpM8JiDlC+QxH09a80BIOQcVvaHrc1pDJAXJjfgg8ge9ebicJK7qUXZvf/M4MVhXN88HZnoJ8NaBpWoWQkRbm2uIN+9yThgOvGO/asrXPC9vJpyzaYx80LukTdkH3H+FZdvfHz1LSPtwMDPSuu0LXooBJGsSfvMYOMjdx19uK8uosRQtNScmjzp06lNqUJNvzf5nlpVoZvnzlTycVux3ZNk0bgyRYBHpUvi+ylbULieNVKMxciPkCufguJVUopLKe1esmsRBTO+L9tBMvXVqLO1ScmLEoJTnk4NW4fEN9cbbayYoWjKMxxyuORmsu5mFzHCkjPvAIA7LzVzw1pt8+uW7WEcU7xHzQJPuMAeR7+lKcY8jlVtdX32G1GMHKpa677GjdXjS2ENta3GQxKzb8KPqe5rKsdYl0+GS1aJHKS7kPdD0OO2K2b3Tbe/1SW4cLplo4ydikoD9M56iuTuYSl15SkHnAbH3h2NTh405xcX6/wBMVFU5ppq/y6+q0Z2NnfS6po9ws4K5OyN8dupH8ulVNNtLO4gvhdybbsKTGrH5SAPbv+laFtFaaPo4uVuRKwXCg5GWIyeMVyN/q8kyxpAPLCqVJA9axo03UclS0VzKlTdRy5FZfcW/DFyIdWiBbajEAnGce+K6jWtUubGKKNLotGGJG7rux1Pft3rzy1uJIJ1kjbDA11usql7HHdefFM7w+a4XjYQcbf5VriaEXVjKWxtXppVFJ7f15fqYGpXk2o3Ku6rnoFUADPc0+3hkjZZCE4OCCeRUuk2b3UoEaeZJ1VO5xWva/Zokdr3godvl9yc/yrWpUUFyRWw6lXl9yC26HbWdnpWracjSgWpC5Vn6Mcc81Q1izibS76Tz4vNMixiFeAq+o7Y4HSsqfxNataR2drGQqfdLE8n86Nf054dHfUIZNjnHmRLyMEdevrXjQozhNc7au9E/X9TzlQ5JLnbTb06/8H1M/TRD56bNjKPmlDqcAL+PNYmoXxu9VkulRVy2VRRwB6U3+0glhNB5P7525l6Hb6YqpayKJAWycdBXtU6Li3NnpwpON5MueIAv2tGQ53Rqzc5wx61mqOa9Ak8EXFzottqstzEqz7mKqM7AoHf8elcXPZyRSyADcEOCRz+NLDYmnUjywle2hNDEQmuWL2NTSJSbUxoSoHzFs9COaTVrNvMhuZWUpMMqQ2Tx/e9KzrIN5mOgzg5rZ12JZreJ/tEeyJABxz9KmS5Kqs9yJe7UVuphyoi7/wDx0ZqGO3keIyhD5YYLu9/ShXQsRMWIAIBX9KfHdJHOkiAoUwwA6bh3rq95LQ6kpJWR0uk2WlMjW2oQzfagCAYnA/mKzdW0SSzuJQN/kAFwxHIXOOapahrE93q01+MQzSNuwgwAe+K9E0DWLbWNOjtL6aJptrIrPwVPUH3HtXnVpVsNarunuu3ocdWNWhapHXurt/ccTa21vJcp9nZtmBlu5OOf1rY+zy5uJolAMa7izSZ4xggev0pbjTRZqZYBxjcflwFPSljvGXR5VhUfO+Mk559PepnUc7OOvQzlUdSzi9NtSl4VsY7zVpRK5j8uJpGPUcDNUtTs2dZ522KobIz1OfSt7wxph+0XLb3U+QxYleG46Cmx6Fc3yvIAFhIL7jypA/rTeIUarblpoJ14xqOTlpocxFa2U8I8yVo5vRRnP61U1GxNmyYYurqGGVIIrtYtG002hW3lN1qykOYUP8Ht6nnpWffx2k1tPHEku9QpQscBD3BFb08XeWl7f1+BvDEvm628/wA+9uxxlFPkUq5B60yvSPSCilFGDQAdaeeF46mnAYHSgjIqbk3GZ496bSsCDzTaooWkoooAKKKWgBKKXBoIxQAlKDg5HWkooAsQ3LxuCD0rorO5MWmm4mPLfcwepB5FctTjIxUKWO0dBnpWNSiqhjUoqZ3VhqcNxa4uvkQDZuGCSD7Z5rGvbM7ZXtlZkCksApwq/wB6ufEjLnBrc0y9drdk37TIfLfnqO34VyvDui3KBzSoey96JHZW8zxr5SlnlJCAdeldFZQXY8i0s3dbmMZUKuCpI5yw/rRbaYILVjAGeRj+7TvjByRWHe6re2Sy24Jjd+JGHUjHT2rFt4htQt8zGLdeVoNJ+f8AX9dzV8XSW2nTW1ksq3WIgZyshwXyeD9Kz/C1vFK97PMSDFCduDzk8fyrmnZnYsxJJ7mt3w5fmGO4t9yL5u3JPsa3lQlSocqd31+/U6KlDkpcsXcg1uWExxRRszyLyzbsjnkj65rHrtNS0q1v7eN7ZY45ifLUR9GOe9Uh4ae3wL2SKJ+PkY4I571VLE04ws3qKniqcY8r0fY562haeVUXuQMnoPrXTaiiQ6DDtwzM3l7guOnvREn9kLItpeW0nmZByw25Ge3071nnUZL2K0sZmRbeJzgkdz1JxzSnKVWSlHZDk5VpKS2X3/kaen4j0hGhhK3cWWDpnOM/xenasK8upJ+XJrs/DF7PpereTGV8tmUsQx2so56/1rjfENzDdazeTWq7YXlZlA9M1nhm5VpJrTe/qRh7yqPTTe9+/wDXcZp+2S4RWcjnqBmut0fU7i1uLi3iR3a4iMHluoYMhHPX061xen3BtbuKZeqnNdx4h+wWP2aWCV5fMiVwwckjOM4P04oxiTkoNXuPEp86ja6fzXzON1LyzPKNpD7yPpVaHh8MMiruptBLds1rEVjJG1Scmq8Sx7iJNyjBwV55rsg/cOmDtCx3Nx4jtU8JW1hIrNIsu4ENj5cc1j6bctPMI41wGyFLN905rmXJ4xnjrVvT5irEIcbup9q5Vg4U4vl66mEsPFQdjtfEOhTMiX9rbmKB1ClRyWIHLewrntV0WZbf7VbbpIMgEk8g49K04vE9xb6fEvnk7AQgBPHb6d6bZ+LxDaNDPB5wIx8+CBz1rlpLFU1or2/I54UsRT/h2aXy0+f53OO8l2Y/KeOvFXpNKnitBPIAAxGF749fpxXdWF5oepkQW0KxXW3cGkUZZvY1k3iwIZTcSPvjODCTndjPfsOmMV0LGzlLl5bWNPrNVy5XHlf3nHiIHqK3vD/h7UNWhupbGEstuu9mDAbR/X8K6HR9L0TWPsSM4tn/AHjzMCMbVGVA96swfabOx/0KQtbMmJiMZAzhc1lWxzacIaS8/X/gEVcXN+6vdfdq6/PW/r1Rj3PiO4h08adLbQqFXYTs5z6/X3rLWTyLbzF3tIfmJ7AVb8XW6wXCGM7geCSOc1k2CtcSiEn5SD36VpRhD2fPFWT1ZdNQdPnSt3NHUdbnuLSMRMqFQUO0Y4/rVi6nnm8MWDreMIkYwumCNvJOT65rnb6HyZtgzkdec5qJ5HEewkhCc4HTPrWyw8Wo8ne5vGmrLk0tr0NK1tntbuKeO42SqdytggHB45966HW74aneNd+TtDFDw/BOPmP5j9awrS5VrBVaQ7kO3y25DLzmrNrrcNklzD5CNDKhGF6AmsasJSlzWu1p8jGpCc3e12jBuwZbuRmGDnkZqCVNp9qnY5JYjGegzUbcjBrvjodkXYjUAj3oOByR+FKeMY60HaeTVlCqRgUxjk0h6mgD16UDsLktgZpwj4+bINLIAu0oGAxzmhZMsN+MUegnfoRkYJFJT5BiRh6E0ymUFFFKKACnLhhg9aZT4+vGKTEw2NjODj2ppBB5GKsB9pwRg0MQ2QcDHNK7J5mVqKcwxjkc02qLCnI5Q5U4NNooA1bXXb62kR45RlcgAqOM1BcalcXCTrKynzmDudoyT/TrVGlxWapQTukR7OF72QlFFFaFkiTSRsCjspByCDTpriWdy80jOx6knJqGilZXuAuT61YsFR7uJJX2RswBbriq496KGrqwpK6sej3ukPp3hm51CKRC7ssShV7Mp9e+BXBGykyM9CSM4NdBo3iULoc+kagu6KR1aObGWjI/mMcU3UtctZHdVjMoXARz+Hrz26e9eZh1XoylGSvrv5aWOClTr0W42vfqYi2RHVxnGcd63NbeJPDllbzTvJeQnCANlVjPOPY5PSsy51l28xYEEaNJ5g9Qcdc1mSyvK5aRizHuTXX7OdRqU9Lam6pzm06nQs2SRyhhJKI2HIyODT44ldpFZm2hTt2LnJqipIORWpA0aRbjMVYrkbFzg9uaud1qiqia1XUz50eF3jkUrIDyD2qe3tZmg89EPl9N3Yn0HvSuwldicu7HOT1NXFvJrIxxTAbUBIUg8ZpSlK1luEpStZblJrVvK8zcuS2NoPPTOajKckDn3qSS6dn+Ukf1qEtySTye9XHm6lLm6hhkO4ZyO4p0skkpyzlmxjJOaTJ24pAcUyrsu6S0onYRyFCVOT6j0rutJvNPtbu0VpWMUgXzfMGQv4ZrzyBikwIAYngA12vhDSotS1NftiOljGN8j5AAHpmvOx8Y8rlN2Vuhw4tRtzS28hniPUotWurS2s4V/cs/PUNk9cdquR+HJY4rG+W3dsvh0U9R047g89KyNfubCx8VTNoxZrZH2xt7Zr0PU7yLVfCVp9nDx3MAdy+7qAMnGPzrz6050IU1TVoy7+fc5K0Z01HkXKut9/z/AK6HMz+A3uZ1mtJJJIJACvmLsPI6ZJ9c1wviCzOn3725yChwQa7ez8ai3SSxBaSN4QoZz9xwO38q5bxdex3+oLJGS5KDexOeenX8K68E8VGry1vhtodGGhiKdT947x6f8E57c2MZNKBg/NRtI5p2Cxy3Jr2Lnpjg2eetNLc4HJpC2OBQvAzilYVhVBzkmmucng0M31ptNDSDtXX2qaK2jwycLOqZkB5OR6Z9c9K5LPy4AFNyecHrWVal7VLW1g5YS+NfiT3c/nzM/TJzwOKjZQrL8wOeabkE5/lTa1SsrILdh0h3SMfUk02iimMKKKcBnpQA2lBI6UUlAE6SK2PMzx3ApsxXdhCSKbjjIP1plJIlLW4UU7HGQKbTKF6UlSFlxgKPqabjp70CBDhgTSyHc2RTelJQFuoUUUUDCiiigAooooAWkorU0nQdU1eOWTTrOWdIwSzKOBj3qZzjBc03ZEVKkKceabsvMy6KUggkEYI4oOO1UWJVuGdFtmhZeSc7s/zFVKWk0nuJxUty/CbeOYF33KOenWpXia9DXH3U3BATWdGm7Oe1dda6Tay+HWk89lukcARn7r5x09xmuatNUrNvfQ5a0lSs9b/eUrnSLWEW5W4UrIpy2eQR7elZN3ai3nKMT+IrrW0q5/s2eaBYZbe0EXmKR824nkAdT1xXN3aTSKWdWPVQPTpWOHrOT+K/9XMaFXmfxXt/w5mNwOKkUZU1FJw2OmKWOTaOeRXc1odzWmhIRtYZrs/DOuWX9njT9TiUqgKqTxuyc9RzmuIL5PApe/HWsK+HjXjyyM6lKNRWmdp/wjcMt0ZrRpGtC+Q7dAPr61J4i1GTR7dLGxulkDhslH3BQRgjpxXJPc3SQKjSuIz0G44qv52Sd5JOMAntXPHCylJOpLmS6GEMM+ZSlLmt0t+Y5Sygkke/FMl4UCPPvShhznvSMc12nStxEU7eKcQMYAyfWlVgBzQML3oB3EVFAJ796gY5PtUzvwccVXqolR7sWkooqixwGTSMMdsClBxUpQHnPFJuwm7ENFPK4WguCBkcii4XI6KU9TSUxhT4+p+lMq7pcSzXJR2CKVOSamTsrkzfKmymetFPlxvIU5x3pgJB4qhig47UNyc4604IWNPI9aVxXIKdtbGcHFK6gdKdG+3A7UX7Dv2EWNmxx1p5iYYAPPetGwjWWNiCM54B4pxhVMocBh7f1rF1dbGDra2M0xZHOM1GUIb0FWGYAkZ4HelRVc9j/Wr5mi+ZrUpkdfakq00fJwMHvUDKVPrVp3LUrjKKKKZQUUtJQAV02heM9V0S2ggsZdkUe7K9m3dc+tc3y2KcqE59qyq0adaPLUV0S1F/Ek/VX/MW4laeeSWT70jFj9TUVOKkdQaStFpohq3QSiilPFMZc0qOGS6UXJIi/iwcGtwRzTMkMAZgrCOJwMHueR3rnLSdradZU+8pzXZaX4nWS8hc2sW9UKZye/GcdM1w4pVE+aKuceJjUvzQV/mLq1xLpVjbm1uNz3MW64ZHJCtkj9RiofBltPqGqra2cTTSuS+CQOB1OTWc1v5mk3V79owyuY3iDAFlJyCB3GapaLrd5o98t1YStDKFKBlOODWSoOVGUafxeffoRGi6sHTi9drtP+rLyINZjMWpXETIUZHKlSMYINUanuJXlmkkkYs7nLE0zBI7V6EFaKTO2K5UkM71ZhcxyK4AOOxGaiVATyal3ALgdfXFEtdBS1JLm4e5ILgZHTAxVcx7fvZzUkErQzJIuNynIzSTzNLI7ufmY5NJJrRbEpNaLYjzt4phzu5605eeSaG6jNWWKCU4P500uSaaST1pKLDsL1pKKKYwoopR1oAs2llPdkiBMgdTnGKtXdlNaQJ5ojAJ4wwJqCC7ltoysLbc9feq0kryNl2LH1NZWm5eRlyzlK99BxYDHahRGBlySccVFjmlIPetLF2EPU0lKeDSUygqa3JDnBxkEUUUpbClsDoMmox1+lFFKIovQlt/mlVT3OK0dW0/7E4G4NkA/mKKKxqSaqJI56kmqsYrYzCMnrxTSBtyKKK2R0Jk0chCDHGKk+1yKwLHd7Giip5U2Typ7kHmKTkg1YtXKNuUdeOaKKJLQUkrWJZQrIsgyCTjFV2TDEH9KKKiLM4MjIHTHFNKiiitEbIYwA9c09FBbHeiiqY3sPKYQ/pQU5AJNFFRci7GzNlhjjApEXfkmiiq2RW0RjDBxTaKKotBUkUhjcMAD9RRRRa4blqW6kuFRGwFGeB+dRsoC0UVlZR0Rk1Z2QjsM8jpUO7HTpRRVpFRFB3HuKfRRQwYoGc03AoopCGuccCo6KKtFoKKKKBijk0lFFACjrUiICRnpRRSZMiWaEBhyeRxUTJgZHQUUVEWyISbQsIBByO9JKNpx1BooqupX2iKiiiqLP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in membranous nephropathy showing diffuse, granular IgG deposition along the capillary walls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph showing membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph shows stage II membranous nephropathy. Electron dense deposits (D) are present in the subepithelial space across the glomerular basement membrane (GBM) and under the epithelial cells (Ep). New basement membrane is growing between the deposits, leading to a spike appearance on silver stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Silver stain in membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph silver stain of membranous nephropathy shows a spike appearance (arrows). The spikes represent new basement membrane growing between the subepithelial immune deposits which are visible on electron microscopy, but not with this stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stage III membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in stage III membranous nephropathy. The subepithelial immune deposits (D) have a lucent, moth-eaten appearance and have been incorporated into the glomerular basement membrane (GBM) as new basement membrane has grown around the deposits (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44730=[""].join("\n");
var outline_f43_43_44730=null;
var title_f43_43_44731="Bleeding risk GI procedure";
var content_f43_43_44731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Procedure-related bleeding risk from gastrointestinal procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High-risk procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polypectomy or endoscopic resection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Argon plasma coagulation and thermal ablative therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopic sphincterotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumatic or bougie dilation of benign or malignant strictures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous endoscopic gastrostomy tube placement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopic ultrasound (EUS)-guided fine-needle aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopic hemostasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Therapeutic balloon assisted enteroscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue&nbsp;ablation by any technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystgastrostomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of varices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low-risk procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic upper endoscopy, flexible sigmoidoscopy, and colonoscopy (including biopsies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic endoscopic retrograde cholangiopancreatography (ERCP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary stent insertion without endoscopic sphincterotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endosonography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Push enteroscopy and diagnostic balloon assisted enteroscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteral stent deployment without dilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capsule endoscopy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Anderson MA, Ben-Menachem T, Gan SI, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44731=[""].join("\n");
var outline_f43_43_44731=null;
var title_f43_43_44732="Types of vasculitis PI";
var content_f43_43_44732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of vasculitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of vasculitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Affected body part",
"       </td>",
"       <td class=\"subtitle1\">",
"        People often affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms can include",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Takayasu arteritis",
"       </td>",
"       <td>",
"        Aorta - the main artery that gets blood from the heart",
"       </td>",
"       <td>",
"        Women between 10 and 40. Not common in the United States.",
"       </td>",
"       <td>",
"        Pain and weakness in arms or legs, belly pain after eating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant cell arteritis",
"       </td>",
"       <td>",
"        Aorta, arteries on face and head",
"       </td>",
"       <td>",
"        Older people and people with a condition called \"polymyalgia rheumatica\"",
"       </td>",
"       <td>",
"        Headache, pain in the jaw, trouble seeing clearly or seeing from 1 eye",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyarteritis nodosa",
"       </td>",
"       <td>",
"        Kidneys, skin, other body parts",
"       </td>",
"       <td>",
"        People with lupus, rheumatoid arthritis, hepatitis B or C, HIV (human immunodeficiency virus, the virus that causes AIDS), or a cancer called \"hairy cell leukemia\"",
"       </td>",
"       <td>",
"        Tiredness, weight loss, fever, red bumps or purple bumps on skin, numbness or tingling in hands or feet, belly pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kawasaki disease",
"       </td>",
"       <td>",
"        Heart, other body parts",
"       </td>",
"       <td>",
"        Children under 5 years old",
"       </td>",
"       <td>",
"        Fever, swelling, and redness in areas with inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary central nervous system vasculitis",
"       </td>",
"       <td>",
"        Brain and spinal cord",
"       </td>",
"       <td>",
"        Middle-aged adults",
"       </td>",
"       <td>",
"        Headache, confusion, stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Churg-Strauss vasculitis",
"       </td>",
"       <td>",
"        Lungs, nose and sinuses, skin, other body parts",
"       </td>",
"       <td>",
"        People with asthma",
"       </td>",
"       <td>",
"        Asthma, allergies, sores on the skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"       <td>",
"        Nose, sinuses, lungs, kidneys",
"       </td>",
"       <td>",
"        Older adults",
"       </td>",
"       <td>",
"        Fever, joint pain, weight loss, runny or \"crusty\" nose, ear infections, cough, brown or dark urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Henoch-Sch&ouml;nlein purpura",
"       </td>",
"       <td>",
"        Skin, kidneys",
"       </td>",
"       <td>",
"        Children between age 3 and 15, but can affect adults",
"       </td>",
"       <td>",
"        Belly and joint pain, skin rash, brown or dark urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryoglobulinemia",
"       </td>",
"       <td>",
"        Blood",
"       </td>",
"       <td>",
"        People infected with hepatitis C",
"       </td>",
"       <td>",
"        Red or purple skin bumps, tiredness, joint and muscle pain, swollen glands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity vasculitis",
"       </td>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        People taking medicines that cause a reaction",
"       </td>",
"       <td>",
"        Red or purple skin bumps or other rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beh&ccedil;et's disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Adults age 20 to 40",
"       </td>",
"       <td>",
"        Sores in mouth or on skin or genitals, eye problems, joint pain and swelling",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Vasculitis is inflammation in the blood vessels. There are many different types that affect different parts of the body. Some types are more serious than others.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44732=[""].join("\n");
var outline_f43_43_44732=null;
var title_f43_43_44733="Survival in hep C cirrhosis";
var content_f43_43_44733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Survival in cirrhosis due to hepatitis C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 302px; background-image: url(data:image/gif;base64,R0lGODlhzQEuAdUAAP///4iIiICAgAAAAICZzMDAwEBAQAAzmf8AAP+AgP9AQP/AwEBms9DQ0CAgIDAwMKCz2XBwcBBAn/Dw8BAQEKCgoFBQUDBZrNDZ7LCwsMDN5vDz+WCAv2BgYODg4CBNpv8gIJCQkP/Q0P9wcP9QUP8QEP+goHCNxv9gYLDA3+Dm8/8wMP/w8P+QkP/g4FBzuZCm00RERP+wsISEhIhISDBDaYgoKFhidXOGrIgICMTExE1NTUhISAAAAAAAAAAAACH5BAAAAAAALAAAAADNAS4BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxseMBQ1DExUCFRNDGQIhHsjX2F8NAgMGQw/dAw9CEeIUFNbZ6utUBgPdQhkDFgAWAxkTAxQAIQMRThBwBBhIsKDBgwgTKlzIsKHDhxAjSpxIsaLFixgzatwYUYeeAvAAcBMgcoAAkN5QGikgoKVLATUO3AhAI4cNGjQ46tzJs6fP/59AgwodinBHgI8hR5Y8CU9lEZYvWxqoIQHDggQkFKxAgACEAgUjErRYsIAFu7N/BiL1xs8fgHIhGogDII9ek5YQqhoRQTZBAhRfuSL4isIvWRFoE8dRi6dBvwcFJngY4KCAgwHWLmewV8FJSwB5MTxhQbZFghFfQXBdoYCEXxNkFcsew/iOu3cDCgCocNlBZwANwFH455kkaL1YyJrwm3Vr169hx5adTZ1KbUyfhYQWw/fq38BcCRtegLi6+SLXL2UXwkHChjWkF5hGrUA1Atau/SaQQbZ/+fPXpGfJeuxd8B4dyumXwFcM1ieYYKw1mJ9f/P0H4CwCVkJggQca0v9ff8vpl9pqChSWAFkuXLhKhpRsyOElpZ32VQkIlACdWLGpCAqLk7j4oicu9PWdc14pYFiKOlrCoyQ+/mgKXzLISCNrCcBm1ikumGbClYCIoIAJeiwZSZNCXHABLAssR8JWNhZGXigmPKgAHYMxsQACCYR5lCZkArDBBRzUEmQLqKlG5VhcWuJCjQsAIEKeLKCGQnlVLmiCCCSQYNZVC2RaXqdgmVVlCyWaFelXeZrwFQkyABAnCAmkqKoCLQjBAmAk4KnnJn36CeguC0SZVXiFyWDhIy0gMEIRK5SQQLMprkYjCFuhAEACgyVQQgkAyIAACSN8C8BqqlkLgrMjgAD/ALgJqOZCuDaKEO4Iuda61Qgo6JqHmJD06mugvwy6oGpe4YikItjmOYQIynaLQK11YttoxAg0Gm6neLaLwLhzslDntoWl6MLAFXMsRAmwYqsAw9beqTAe/D7i77/GiBAlYOG5xp8hcc4pRJC6umyyxEOXLLECGftlssmYqlbCAiWsYEK+E/vclX6wBa0vzHtmMjPN2JBmmlbPjTDWwX2oZmRWAKCMMWIUV33twzJsC0CyJARrbZ0mf7kA0nj/XXJXC7iQ64nLseB2uC/fEbMjX/spAcBn8fXdlK7BpofhXIFQqwhbgQBm0XJjSzCl9pGwdJ25dgVmvlEbzZUIt9Lo/6yrNCLduB2PNxI5ABhIAEF1pC1Hto1hnXgYIkSn0jsjvwMvvI5B+kWfg50zmLzyb+LRPCrPLxK99MMnmUR33sk4YvY3jtc9deErMj755l+Bvn7X2/dc+9wfO0z8iZgf/eo3hvtZj0H6KxJY9OOfXAAQEQIE3gHKR8A3GFB92NvfArfkigceIoKgOYAGKugHA+aKBKNThQcNAcLjiIaEgshSs1DQKvB1DTvGscJ2YDiIkZ1rBP7b0Q3Vk0MdIoeHg5AXCEAAxFGssBAtHMIOkUiIBaAgai1AGyeeSIgoSvGIVCSEDPIltURlgouD8OIQ2qOCMB6CBSY4IQfPOMQBFf8xCxwwkBsRAcdq1VBJddTQHfGoxz0iQoYlQEGjKIFGQaixCHnskCEPoUQmBnERjQzEIyFZyEkmQl4oi9UjMgmITXJSkp5ExBixqEUqoO9DQtLPWMRAyj+YsghmQmUqERHHbynoeg1a34MEo8BgLlA/KFDbCC7VhVr64ZZE+BPldrkIOCqIe7B83xVIg5VtGUkGZpyCM8OwjZMMoZzLgAI0o/krau7CBTJATVdcs0gpjPMLFaDMZUgiDwdoRp2D9II03fkLEUxtKytAATOdcE8vuCMDKgFHA+QyjiesswgDJWgwrkICZcqglURoaBfySQEDUGAZ7xBCSo8AlagYIKD/X8ioRoXBgigpYFv0NKNIuVAACoBjAJ1Z6UpXEhWpwDSmk5vpMQwqTxAoUgg73QIFBgCclE51AvnYh0WP+oXgwUCp2JDPIqOqhcuEoB8OAEAHTMKNDgA0DcGjIFixQdYsBOcdFljGBOwxj2hsVQ1xnWs26lqHiyohsIJFBmHpYNjDTi+xxljsHBp72AlCthiSlQNllQABEV72f4FsEVfLMMXP+iKzcdjsEkpr2l2gFg6qXS0YW+vA0PZotGdgLW1t8do3xJYJut0thmzLJNyigY3CvUVv3fDbJkQyubWQbAV0Q5cMsKG5zu0kdGEh2ZeSgy1qwG52dbndFRG3CyDB/w1er2vcNTy3vB08LxcaYFIHGMAAeWVvHt4LX/OmYbqwbS8bctlf/6JhAiFwyW/CK+A1yLTAp+iuesGbBvFC4cEQJoVkxVGADqeTwXzAcIZDIdkHNBgMFo6CiEfsCclGwAEK1m8fVsziTUgYNxRGQ4qlsIGk1vgTkm1Ahz0sYz949cctlm8XJhABAzTAAtZdw46ngFgka0KyfC1AB+wC4kBU2cqX2HAIDMCSHJ9hylT4MpgZqWQu3IPM+C2ylx+7ZjanoQPnuMyCK3xiOmDgAF+t8yQku1d9EEfKfaZDCi4gAQK0UdCjbPMWPKCbCURGzoTQAAcOwIEXQhqTktbCA//oMQEHuBXRilABASTAALl+2hAbpq4AzGwGNHNhAxD4wAcIQN5XpyXUWaBACIRgAS7z+REaeAGnPe1rQEh2rQ8Ax551nGg/qOAErE5Bs50NbCxMYK3DaYOtxYBrXcOg19umQ5A/HIVyUhedUhg3GVLAgMk9eh0b0MAIh0BvBjAbCgRgQKv9DeRuX+G+U1irffmpz3tEQd5lUEF7GKBtdZzgAAeouAoOcAFHH4ABUejsCwigAUcz4eORkGwGKgqFfBpbohR9eLUNsQEY6BoC6A7GBzAOsE23urO7biMEBB5oAkAAAwQYggoYwGl9m9zoSAceBxjwAggA3eSOuPE7aH3/BHu4gwK6ESpV38oJekvgBPcmRgoALYEDvOcCB/jACS7Oagxc/ATK/uoB2n6AIWBg5xeAAAE8u3eMb7zjHHgB3QmedYNbocn3NcChl+COs1IGAGJPQktf4l1PYGDTL9j3MDYtcctq4ABJBwDKASCBXQ8e5Bw3wuBHOHvVn0mCcj+36kEOicxa+vdOsEfYqXrVrGq+qLOeOSM2QICb5/wWG8A4AwAPgNOnfvVxJ4D2h7d6ItS+9t03e+y73/j/vqMAD5i8ElzeD2+stSUDOPVfRzH0Rqd9FzDgtPZ3jgHrCyHuGqACykZygrd7sudZ4Md7mpYCGiABEqB6HxCAkZYG/w7wAJUxa08QAVNlANFQaH0lc6bweU2XBf2nbyZogtqXggRQcZEAdwdyd/4HAIN3ABiwAe2xd0lHfkLwfYTHeyoAdxwnGjP4b4oQa2TWZJg2CqomAR2XgicgcFAYhTuHcVRIhR8QhVh4Aip4cbr3apJlaiYWbqimCoKngid4hkQ4BSmgbFX3aSqHG+iQhGhRbh/gakiWWdtQDeKmfMOQa3W4Zpk1DXooh7MBAYyGdaXAACcAGowHBYrYCC4Gh+xGbUmiaSNICihXcveHBDFodJDoeFUwDwWQARRgbJRoPksYeIVwbVSnbZ+niO+haikwdRhAb4sogxAAAwxwfSCnif9+oosM8FVPyACdBgA+l3SeCABrGIzasYIv8AJpyDVpABlCgIFjSEB+aIch5oAEMHUqwISrdian93F7p2uWtXd4B2gGWHtMN3cPuGvY9gEAAHdXaIBrp3gHsIhM9wH0+Gtp0GRS8VLTVgYQBwvZ+Hx0kH/lowL5p20X13+oBwBMV30RiXLRB3sgN3t/BjBtpAFP2HYUyYsAoGxv94ATOY995wdah2NdxkOGODnRWAe1t4MIKEL+N5H+h30YKYM2GZFCcI+L1ncxiHInOZFFmZJ9EGRDNmSTSJB8mBifx4Ta6GccpwEQAI0HEHof8IA3KZQVeQGWqHcZ6VkOmAKLNnj/K7hzFPkC2oZy+beCWSmRKXmSSQmKLPSUikGHUykHQRmRuRaEISmXgbl3bXeLKFd7GKBsH/cncaeWcvmAq4dtWfkeR+mPfIKXhXhzj6CDEWaXUISZ1JGNjcCZprBce0hQoplYr6Vl1NWS7pSaYPVactENTUkGBQkMfqiCurmbvNmbvvmbwBmcwjmcvsmCsOaZV8ASA2mboKkjZUic0Bmd0jmd1Hlxe2mZXtOc6eYGaiYIhKVeLHmN23kI3cltZxB56Kl+Z6ad49kGwXOLg2CahNieghA802SeaPBkkaeetcae9MkGNLYHJTZh8/mfgRCg+4KcUQBUVNUB/nkXD2qg/2rwJwyAkOqmoFCQG5WBhOIpoTRHYCqJoU8AY2s1DwXqoYBgg9q1K/nZAHtlAX7lmih6CPzFomdwab4VoTOqBnkUk3MgYR0QZSe6o4DQHj66GCLqBBXwUw4wbB1KpIYAA7NVB6hFXyEho1BqCMElB9L1U8I2pFn6B3lhnBeaBu4QpMylo2GaBp11nW0gWTgqBZbWmvAGgmuqCClAZz+apEsgAB7gDDH2BCUaDw0npMVxp4tQnm7wnQVwG1v3BPKwUjA3F2SHqIlwZHt6oxMgZEzpBBNAAdwwdpmHBJvnEp1nqZfqY0iaBiFgqME3DqM6VERVVKeKqoiAAe0EBxLmAP8RkA5NAJ7ENwBYpQ92aquJgKBnEGQR8FPytwRDdn5qxVbxV6zGigjSZKG0xKdN0AzuwHVJsFIeCKPUWq2H8CcrmgaRiFeteWzkqggbwADnmqzaSnkPAA1p2q6MUKNoAKe1ya74qgj6agbd5a3r+a/5OqVkoHIsd5oGuwjYdqResJIEKwa32bBGBLFc4GLpCaYWK6YICwby+aQdq6X5SJ3EuW8au58cO7J+kAIme7JQNa9K4KhX6q8sy10y2wQO4KoFe7Ox0FsPMLFhULE+a6NmAHngYIo9W7TxZaa44QD9ypxM+wohi6VTa0NnkAFkNgHgwJ/9ebWtQFgdMA7l8A7/y+mUYMsKhOVd4OABxbayabtFOWsEkpcPaWWNVhu3TjS3RfAY0/q2Iqu3okBYXKsPHjAZTpq3gitEB3ZplBajNru4e8sraiq58cm3eEC0lvummHsHmru5a1C1kQu6SUa5pDu4nWsHn3u68mq6rFtwrvu6nSC6pyi7chu7tntlqVtYlZu70niZvmtju8tYvRu8VDq8VjAN5iQEdVqpxgtIfZBe72Bd/fRPzvu8dsYHlNYW3jCpCwuh2BtmyHsF+eRWo8pSyFer4SsJtLsEpRaH5zurLlW86/sG7ZsEDeAAJyUExUes11u/E8gHPRV/n/F+bTWuAFx+fBCquAEA4Qq5/+CbwCk3vqlFvxKsBveLthccwNm5wRyMQx6swB0cwoyQwVJLwqCGuyh8CCY8Bqu7wk/QwhRrwTAcBjI8tDRcw19wwyiWwzrcTBQcYD98nCo8xPg5wkbsnUGco0l8uUXcxHzAw1/wwlCMHkt8r1WMnSCcxSH6xFzsOFfMsF8soGEMt2PMBlLsBVT8xWncBWvMxW3MBW+cxXG8BXNcxXWsBXcMxXmcBXvcxH2MBX+cxIF8BYNsxIVsBYc8xIlcBYv8w41MBY+sw5E8BZNcw33sAQnGs4d6xkbrBx5wDl1ryT7syTFcxlIAFwBwVfFWyqbcBHnsDrohy638yr8LCLRMy/8IbMurGgj2YF0SVcu8fLyC4HL95KzpGwNCMQMzABTMHBTP7MzN7BPR/BPV3BPXjM3TTM3bDBQ8MAODoIHiELVCUKpSocxBEQPo7BPqnM7rzM7vvBPtDBTzDM/uTM/xzM6ujMUz3M/+jMMA/c9TrKaGtVmXLMwCrcYEvdAB3dAD7cI6atD7LMYOrdAQfdE9jNEZndBu3LsHvcsdzdEhLdJ6zNAVbdEn/dDAq9EqndJyHKGNVdAmvdEsTUQnTNM43dIo7dIlXdMj7dOCdNM6PdQ7XdRE/dJAbccePdFs0GFk4NRhANVRva5fINVeYNVVTdXopdVbLQZYDQZfPcxiPdb/ZF3WZj0GzfAMEHzV5FwFmkwNa70FjqHWYiBkvqoFS8nVWpDW7DmnQxbX3uYMIQDYgS0AnIwFysAMzmCvlgAO7vC988UNQjsFjgrZW0CgYNAAU6Wd4JnZG5hW6AWeem0Fhft1hF0FhTvKci3Z3xAOlv0IdVEPDvcFtzHZUoAPpZYbYNAZkzF2X/BTnJ0bYZ0Fl9HWqN1h+YQZVz0XuswF/fAPl3HXB/eodGGiv6whJrEUUV2zXhDdUV0ODyoAw5HdbtYNFjDaViAX/mSiYLBWzboFqW1qU+wWzZ0FTqEUStEi2Z3fVc3dzu0WYVAB7uC1VyAX00DeW2ABAgBu0m3f/xwmbV/Q2w2eBd9GAZfxAKdNBb1tUrq9Bfe93wguCc/9FgOQuMtt26k8rWRQ33oMnv7J4nYFD/zNBe4NBv1AEvbgn9vAG76N1yEx4qpMCZNRGd6tDY8Rp1pgDzC2vOhlYmU74VdAaVoWf1A+Bei34PqQ4VSgGeCA3lSQXlVOvg8OVPhUAPZA4FPgGBwmGZRhGcpdCTzuG2FAs14uBS4e4Ux62C3enB7wUw9g3FRwVxRwttON5lggzjAGBu+Q6FxA57vRG4R+1pI+6ZRe6ZZ+6Zie6Zq+6Zze6Z7+6aAe6qI+6qRe6gTVYelg12OgtU52cP/AoWEA60/wbZKXBAJOzv/0FelHkOv1y9qfSgFabgWTYWKTgeJGAA/OMAbJHgVrFQGEzhJhDhIn5gFMjr25feDDNgGzBmXfZQAdsAws0QAANmaSd9eQ9+3RagAVkE8wZg0CbgDDRu2jOG2ztlbesOznnk6zFgHPsBuGXWzptBnwLgRMdl8ksewC3wHrWvDo7uZ+SgRa5u1C5qfyngEVUPHT5Q8ASfBNhu50YQHeXgDyDhwdgF+6vrn9RKkPAKrBDGMaeLf6YBLNLgDUOAQub+EAAA68Wg4l1QDlEAH2EAIgsYFEUA4KDg/uIAQ3n1ZGz9ruUIGXVxc/DwD6KwAvBgBJ73ICoOBEsPI0jw4VsIH/HwYSJvZS3NBhMU9maZ9eHN4ZXr/yfzoPW88UfioOC660snsbyyAXL/V+AFAATTZVJRFl9qDgVA34HP735B0SFg5/aq+eOI953pD0fx/4VHV5ko/1YwcOsh0NK7/KFOCg1pD0j9Hv5+QW8jBslD8E9pAO1C7cAA4SxCHt1S0AcvEPqV/6nSHt6h0Bg/28ToESLjGK87ByVHX2BD+20ysNxc/5tJ/5mLfkz/D8RBASSE9VdWH80H/9QpD0lJ/0T3YZ6ED5s/YOh0b7tL/63d/jZ//87p/d0o7++30bEUD7WjtVr826TgH60wUEoYpgIMg4BgBiAQDohAqRQaipLB6T/4Vic+AoeCzFwlArqFYNg0xlYACkrUYk4KFmu+HvZOg6sLwrCtIa4EIixvzOKLzCGvTOAPg6CgQqBwrKmjIBMjMXCxoNES3KCjoyCigoIFlbXV9hY2VnaWttb3FzdXd5e2W13JoawroyJuoc5paaBCgGKCLOjrvmNokGGiY6nCkENs8akNLwkqaTk8Lb2h7ZI5wtJgCIHSoesfziqxqQ69nPBJBQyLBkU8EtmfZ1qXcPXhkPdQY8cOSLYkWLFzFm1LiRY0ePZwqgIhLtY0mTJ1GmVLmSZUuXVdg865DvZU2bN3Hm1LmTZ0+fP4EGFTqUaFGjR5EmVbqUaVOnT6FGlUM6lWpVq1exZtW6lWtXr1/BhhU7lmxZs2fRplW7lm1bt2/hxpU7l25du3fx5tW7l29fv38BBxY8mHBhw4cRJ1a8GGsQADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a series of 384 patients with compensated cirrhosis, the three, five, and ten year survival rates were 96, 91, and 79 percent, respectively (red line). However, once decompensated cirrhosis occurred, the five year survival fell to 50 percent (blue line). Deaths in this study were liver related in 70 percent of cases, and due to other causes in 30 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fattovich, G, Giustina, G, Degos, F, et al, Gastroenterology 1997; 112:463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44733=[""].join("\n");
var outline_f43_43_44733=null;
var title_f43_43_44734="Toxoplasmosis prophylaxis";
var content_f43_43_44734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Toxoplasmosis prophylaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 391px; background-image: url(data:image/gif;base64,R0lGODlhCAKHAcQAAP///4CAgEBAQMDAwAAAAPDw8DAwMODg4KCgoFBQUNDQ0GBgYCAgIHBwcLCwsJCQkBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAIAocBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PQAMBk5SVlpeYmZqbnJ2en6ChoqOkpQNhB6Wqq6ytrq+wqwg/AQKxt7i5uruutmEDDLzCw8TFsQsCtAGQgJO/ycx+A9A9ztF91l/T133bPtnceeBd3uF55Tzj5nXqW+jrde867fBx9Fny9XH5OPf6bf6u8PvXZqCNgATTIKxiMGGahjQWOiwjcQrEiWUuyqiIMQzHKBo7PlMm0s1HKCFL/3pJ+eKkSi0unbB8qWVmi5g4CgzYqeCEAgGztDSghuJnUBYIBPRE0WApE5xMbNIUSHQHVBsDCGglYKBAiVSntAggsCLrshaSDpyYJOCBAK9LriqROpVh1Xln5xJIloDAA7AOEIAFIMlBggQFagUdKmBBT0kKEAx4cDbAAxIIAkxb4DXzgb8A3CZwICLzZq9jDSdQkHhWKgdmCScQ0BaAggCkb8MOoFYBsgSzCjQgwCBs3Lwr79YVQ1eFXBpZkwUgoJkAhL2xp0MwYN3AdbXBGkBgAEA79QUEFCggsIDE2AXDEwAYe33A8AZ9Sb+PP584d/IMQBAaAZJRV94CtRA4H/8EAxjAQGIEDHAAVwEsIB8CDDBgwFtPIUeOcj8UkFkATvUgQANQJFXiCUO9cKIUzaXw3AxZBfNdVigSZuB0p+xVXoSEDXXdj6Tp2MBwJY4lAnf9wbUdAAUQIJ+SADBJJZPTOeCdjssU8EAC3HUZYHo/DrAeAw084BVrAuzUxIxHxOiCAhBAIAADQPrg4xM8rkDlTUc9IedaHsZpnQAJnBIbl2UC4COPDkipJVl9ihCghiVQqeSfe/qoKVmfAjAhdyjG5t0DDxgIAHrkNeqAANcZMAJrTsBpxKAspCaCAz0dgIxjpc3WgFeiFRkAAm5xJkIt6CUzwGy1AYaAA7wBkBn/XKLiNhRp0tqGzLCEaXZYT9M9gAxp1Kp1rZK+0jZsYpfBW15Qbp2o1rOJ3griDbbCEB0Ji2YH5KMRTocbno0uq9Vl7kWY6pRkiZBfuf1NJmV/InxKZmzE2WcgAlKyV+YAC8BW5xT9EoHrCuhBkABoB2wXwMnTJRBAcffl5yhXeLYX33TSIThWgdcB5RcA4wFMXADcKZBV0TEbMLOsQM8soHZjEXAAyJclreQ0FYo8HQLo9eQjeg0wLeFWWhexMgkpu/DvCAHvOLB0ERbwH8KViqoVthkTtxdqEUPZFwQ5joUnh6Fay5UIsYG8F3V04p1ZhAdwx9WKtRbqzr48FICe/1YQKJCq0BEmDWUBT0Ypn49RJqM67F+GiaMIrBsQKcOQGxhpdTmmShqSfQ4nCZDG5747xtYis2cC1zHsY182nzLdVp778PYIcVMRaXuZFu7CnyoMF+ga3QexPQpwTUPddAhOMiFRnSZTv6PQ+HhqqtXlhR53gIuNWRbVJx4VsGBA6tP/CEA4ANxnbpJTC/6gtADNBYZt54sE6GqQPin0xTgjIF8LRIiCOgEOfdnDxwZ10BjYcMdMXIFNU/rygGc9iwDUOtr9UgMy++GMOovS0cWUtoAGpWdR60lUgH70AAfQLIFAysoQN4XDHtrGTtvxytlqOJzLZG2FOlhfeVK4HP8vdPAHYjTBAzSnu12x8QCiuw4D4Hi4HN1PAYvzkeTG0j8S4KlIdBMcBGYRRAxt7kd4YgC5oBiWPwbuipN7i3d0IrJHXQdxs+Kc+sC4ETKWkQtn1B4n2RClVinNkyXoWwpKiQYx2uowBTjATtzEvhGBsAlGKUEuhdCiEojIMmqR5U4kCLABnPAbqLSLHvhngiDeJE8qYOYZXJlMFxxwK0WJVZigMJg+DUYIIqQT2360FQ6VRisgTEU1qmmRUX7SCtTUAevApyNoiM4WmgEAnoKiAECKoF4NuJewOsMb0BRrWcjyBZSGAixvIUowmjnAeyBqzGNli1u/WhFjgFWYc+3/ClEI8+PRDoAigw0IGjFDp9LWOZJ3jiGeOYiUceZGKvSQ6HEoQJvaIpUA/tAnQjnDoaMQR8MqQYBpEDjAqCqUKMrhyQANiM0SUyUYmZ3MjwEQD3mwppUDREpqIRXBemQFN1XhqSe0GQsIs8JSMKSxBRLN0Qp6+YQXEYGuJCjAYZoA036I719Zac8APaUV5FAvn32ZBMLG4iRZuW6CsVsPinZ3pjRRchl9EphhIOAl9iRorUKiFPIi1Be1kG9u3FOVWh+QVLUGjm3sXEEoe/DWXHG2BZmJAQlxsKch5NYnqpqLO1sSW+f81UcCpE6UOOub4FLQgnykBPMmOMH6JXcZ/6+KlcAUZaAJoac98KMEMXk6qUbxqHEimNBtRfWjs+BJomwDktNSNUy8tFQvQTFNYwj6ma2dxTcn8gpkJEM3POXTMLWRl4IZupRjueUsyIUWwwAMHGvhJsDIWAqCeQdQ/+5qNkUUwQLWm4S+3gBkS/kMV4zZseEsYzgCcIBNSbAALvrlYQOQ8XQnpkMDkOxo47mh00o2gDoJTDOL0twpxipDpxjMAXxj5JPDKuKljfhHRewLipxmRDUFsq3aGO4OhhNC9vjUOhFil1Wphua8IKBo05LSfX5ENjJ5B6lqsQ5+dBi0BAmGQhbqT4YORRwA8HTOOvWxkkBmM5v1zp9xEv/zTYqbgglVZpxvnlxl8IQduF0yRzfTCsRGoFc9i8A618mRAv7jGjY6rbt4aupZQGbKSXGFmHojTpStlzfFUXmhlwTvVoIRPhD+BMzJYQJtyrwkUDHwkcJzYHqyZAIq9cUrWwIA9I4mWUPzGUo+oh2YKEccy2IsNkq6tlG1LaV8KilVUguUcyNNEh2MmJiY2YnOiNDbf8yWB7VVwbIfibE/KemAx7sl8xoXQUZxLH/2S8b+fAerx33NQFR8pOigG7EEEUCu89ZXvXOQu2OOjthF6Lc+/r2DgKfgyoGz2KgfmURgXA2aZeYV/3h6RVh1BWnF6YvZfIyey4T7h5oh8sn/Lr6Md1OH5zX2mFvI8oCoMlqsChLuyF0KBpaHUdI5AFlYFDe46VLJkAZYpMKdeDTxSKkAeuNsYG3D6lPX6eOnTsYeqZM5raT93BiPmNsRU55PYwzKoobLdPBNb2RyXQxez4HLU4Cp6U5B5VGYZ1TALltKo6RE1ALNroApgxepSOC8o4HpjgWXoTAeZZ6XCedxMPfdPgHzT4j7MUXu+C3oRKxAG8FwvJNUaRP/9SsgmMJHIPYbsM2eDJi9ECJPe+k/Xuu9xwJJ7fRae1pnQMP6fqrkCrmMyibAE+wTgkOcMVMeSzEKgGW4VJMYoJTGb4VrvhWof4PJX7/l1kcoWPAq/3sRKHMDWNiBXP2WFVJjC4d2McrHaAHgaH7DO34nR9whbNvRHd8BOS5GAni3f7HHVwH4f7yHbFPQF0rRTHuCgG2igERRWumVWKGWfg5DIUcxHNiifDbYI3gTFkkRghlTgijIBf5ngtW3dVMwKfmiNNAwVt62Go/Dc8xWZpXQg+WRNTnCAPIxAjz4hT/YMMYxcFXAf1hBhEgoBCbGEKzCT/BmTPqEQ30xC380hyRwOpJgGVKSY+2hfFU3AFcXKf4Eho2ifA2SVV01AhBAT1RghjVwhGn4iGjIPSNoBIkBPlmjUqtmanTHiXCDJxBAGqEGgT+IeG+nbaaUd4UYhsrXd//EAUhZkUFR4IjQMYmRKEpKyAiWBk6p2IiVuASQeIsysIaMcBvIZ28454v3JYzwZItjxIxYQIs04ozQmITZV42wt4zYCBLOKI3bmEq/iH3fyI25OI4doo3muHnlmI5J4I0xEIzs2EzdGI7xeBD0iATwWI90M4/6eI5uRY39WBb8GJDteI+NR5AHmQ4GiZCTho4MuUnr+JDX+CES6TbdiE/GkJEauZEcWQsL6TbB0JEiOZIk6QrIgEYlmZKYQBsq2ZKUsHxakAou2ZIsOZMqKYsd4Y4VKYI7SQY62ZPZCJQe8ZFCaQY/WZQNiZTNQJRKCQRH2ZTHAZWgxJRSaUZUWZX/9oWVevCUWkmJXSkOV/mVHBSWYlmGZFmWMcCVaBmRa1mQbTkHatmVcfmWWUmXb3KWdumPeRmVewkQeNmXJjCXgDkDglmVhTmYMHCYUKmYiJmUjVkEjPmYzvGXjxmZkokCllmUmXmZ4MiZQ7CZnrkslNmYoBmapbmTtMSZNukJNbmam/ASeeiargCT4/g+snmboiA+OYmRuEkKCqWPutkRwTkRp8kCxQkIwzkRyZkQxzmZAbmcCQGd/jaabtmP0vkP11kPzSkj1BmdNJGd8LCdmNmdBAGe8GCe5iCeAmid3/kS6hmY5Imd7akSEjFLs2QbTqEeUHKfJ0AtJAI5xCQh/7+HO7TZec9pBJ/BeigADa9CfiWAAK5xjCSgVFGAnuEgEWyBTwviFazjLOHxcySAH4DYJtSFbmdBgZ10oERwAAwgGfiBAmTBonDHndaCk5hho0hgodzAEdnQGMtANs4CDWlTAuKjRSG2AAgCJUn1KmOpop+ZF50RTEFBKcEwogrVLr7gJknhCzLpDFqqGhLELLunJ+4ZWz0KDFWyDd5QY5kyGsSUHglwADZzFq8yR03KnioDATUUQoqSP9biY7LkFRXmY6uCWcsAh8ChE/ZBNU03LObiQNgFkCBYpomZF23ikWoaDBUkIrQRHF+iIVo0H5eaFwbAiCmKpyozFApCov/eQBbekAp3QiJk5QzOAKsoh0de4QysKjuUoKMz4KvRwKOWakwPoqY+pkk0tgyuKh2V0QCEGhHxqQ/AWgMTMh99emqEkQwsKoqaAQ20yhsMwK1Q8qy6eq0Rwp9DMK2QIKx8uo/ZmgK8U2Hi4wy4SidjapzRWg/q+gIOIEF4pG2kkRTYaqwiFgCs4xVDOgkNUrCrwjvl+q61YRspR6nE1a6QE6QvF31Sg62UWADFsSxdeKrA6TYGsCErCAyN4adruiGOhgAGcBiGuiosWx1p9Yy7ajglG7JCsK+O8J6diaolwbON4LNwk6/nOZ8lQbReCbQiIbSMoLSi6aRBS7EugAD/chVLJiBMt+SfnPNLR6G1pLYalSq1uCVXcHQCkmCjmhSbOPoDt1EttrETAlZfpeGgLOC0i1ARetM+v8k9tuCsi5EoSWFsLSoJP+eRgCtW7gS1doCeewslUKZwDUIyhbI1w1khPIEEFpJjBjALGLIAeTYJswEXTegCeKsIFWFRy9K3UTuuPZJXJFBhInYZ1qA3YcF+jlmP6Km6qfCxJdAArdZM07GeWYsM+bQTEPos+0UYMqYUrwI+rxJjJPCv6SUg1sqx1oJS7nS6iVARZLW0Rct8U+KmJvBsH/WMweKBFcu0K/C9GaNwJOooMLoW0WewJUCoSTozwKsAavGotXAA/3QyC8CBq1sDN+RHqPErPoqUMfdavlSbKz8bvhcLJZ8Kotj7rtlQDqPEuHWAnlURv+4RFmSxpUcxnGohOuS3alFbu7XDrBwrP3p6S+BAogkcwstSoET6wH4SweBrtSWQpCNgp/8EXm4mVxtstOvgwZmicE1ovQ6cAujgDd+6JGqyDdbQccuQChuCGYxYfDUcxIqHw5NKn+xUFepgDXjUvyMguyCLOwuMxkLsK+s7si6yxNzTv5Ols2O8LPeyLOR3sJCKvs8msFcsmhQaJXlVOv/UhV+8KnIFui/AvYhQEbh7J9GXShortquisYVSC3diLJnsZG0rwXTsAuz3E9thR/+nUAC08XcPOhb25yjWk7Mn5LKzEbPWEn0nWchjlDkC0Lm6NBsvi7DbYTatDKXue7c6rAISFQTUu0rJbKDsy8ySukoiNso1wMbGic1euMzlY6o84Ky9SGptNMe6GwMNAM5EUEFQJQSrxron4LIxIMmHwLgcTAf0fAj5XAj2jMTmsM+FANCD0M9kuwXVvLPerAb3PAcC3QMNHQQPvZT24M/hENEz4F+x7KphQae0AWlUYNF+4JG9WQrwnI4g/Y6K5LFmI8i28SAFjAUnzQexSQytWQxiXI0x/QJSrKwsHTN7mgU5nbQUXZsqFLWUAmHpxTQHXQNBLRILXZ5FXSUrXXX/fiMqJ9zUyryTTy2fWFBkv4zUHnsiMbohwAzTPbnV0hrVaYDVGIHW+qrWaMDWxDnU3yjXjXvWdL2Ndt3BeB2aksxlEjoCFDoDCmC3Oq0Ee00Qbn20JoIgZZ0CEDrPE0wDS53DWp3X2CjJJBolkZFel4EApnOf0wJLtTBhs0EaZiEZthCxWzpr9FfayyIqmRGx8Se9Dt3XnqnZpxAzgJxV81GluuqoPuaxSmUAcNQmE2ImwECs9yKosxBga8Tc8rvcxJ05x33TMJDY0+nXPuCjLboqdGhaG91012qtD+aR8vuu12ur5K3eJLqs73veJW0D2r1ymI3T3V1DcIFHhvG+/1F7s9aKufUVMd6A3OFqs+X93u4tCUVEtztQ39p539Co25niu/H7sAW+Ew8iVo4iYNDQJgtbqNeb4dP94Rq+37d92dxtIrckz/6N4Av+p78silBF4hWEKO1N4vB9vS474ylekYudxEWwANwcBxAenhLOjA3NosiJ25x55G8A5emZ5MIo5W1g5TtK5bf414RHLQjQPpRwPoqauV16j6EHF2OO5prMA1h+DUH+z939GFHVSwK+Il16kpObmjWgN5qBIY8Rku1sG7bY5sGq5ZHIvSTzxAhB5OptAqONGLAtGzaDb4+avuUAxLirA4TODHoumdwbVSWApuVRv2Mq6l4Nyf/uIdzMbd226x6AhMjlEDPqy+ahKZTcWxWtzl4o7EC04RSxPKNrZMcZTtXXa7EDSz8h9OO1XpG3nleP7a7NNM7p3a4Zbg0gDN6zQh6x/r2TuOl5MKC2YdiS95bci+p6Y4B+fAKxbBsClswA3iZMmqYAs+HadhneoDdFIse0fov0NcHPUTiVndk98Fszk1bkQsvRTgJa8ssr8u6n4KwL4LsjEL0o59U+jlDKjoSaOsEsqRZiShiAKBizzTCMgdrUMQvLIHqgnYXKUtuGzg2SbMFKABdCbALFB81kGomrxjoTjKTGNKRMqr+SURzEbWhQMkfJvdJsijQkFalIwxqpx+z/PqAlDSwEGmujLvusvlTO+56GaQKwGHwWRzUJRz3ZrCokr4ut/0o2SNOr+hRVVT/NynmLGnInguXCsnyf1pDhWoJWaZ/ebZIv5+omXgI9cX/OL+HtdqDCSorBiTNh6FvtKNLq5hsxSdEqtE0YS4Ld7Kj4AZ/zSPj1EgMb2rohrAEmLxv5Jq43iEKoTIMihTNIuIP68oH64o6Qiq/4lr3sUq99sz2lIB/bhtbRQM37OynlwMAaC1z28kvARY7Yxt/7VGHUPR3DWqD7jdDpj4n83srTvKzFny/ZKp7bUf13VIci1XrIUo79T/vySIj8drKx8hvWZObLz14F7J+37m+C/9wPAoA4kqV5oqm6pgT7wrE807V9p0GA873/A4NCkmv4GwiMSlZx6XxCnbootWq9vprYLVek7YLDyqm4bD630Grhd+1+k8jwOV3Zfg64igL4Xv+DyQEOEsr4LR0+NSj0FTpuCT5KTiYafQUILPAhHAAcIIg4CCQ4AAwkJOQ55JmWImR2AgQczHLKii5cVU7y9kT2AtftspE07IgCCOQhATgYFHweMBxIfyaIJCAgJBQMMHgJzCoDEIBmWw0Hq8P8rrufpQNpQegEuIwzk4487Mg+AECg9i2VCAGMmowr0g7Ru4Y1FjqMqGviCAIDLubBl2ScCDJTdPBLxirhCJKy+v9RiSexIcSVLp2o9KFFwD8AjPS9kpXLpgIDBRlJmwbgQQMABb6RK5lHIcooMV8Gawl1qjxdAq4iKJDAgIFr3jIlKbDAQDhZXFEm2CmWa6mkBZd2bArlKdVJUuvitUE3r0y+Lu/6Dbxir2C9hR0CPqzYy+K5jdclfiyYsGQmlYFFvpyXMgoF3ERAI4EgAKsSCgI8iEWr3g8HqPkYxQhbKyNimu3Kvb2Y8wmDIpCgDLBggIHSI0ghgMCHOMYeBQyQRsCAkTcdBoraTGJbt6PM3KHyLjFgp6yyIgx0QoC99zLtJhA4QFUAU81TCWaReEB+myn3C/oNt913g3g34ErhFWP/nBxFMHNCAQGZAgEsJQjQQAEPFHcUNeg9Z5wAbRnlQoOeQPDbej8gaCAVBaroUIoFlbDgb0k0cFVtAPwHGh8YUtjeW0S9RQJHjI3oVjICGjhaPUsy2aSTT0IZZZNXSVmllVdGGUuLDAXhXlwjlGjKNSYsQB4RPfb3FhlD4giKCAp8M+IBPsEYxItTZYKlnnvy2aefVzJg3JZD3LmAlicdV0oDNZFQJgl7mEKnUmmKhAwAxZHgDWwJ/NPgc20dYGZfW7I5qEim2iHEaCUxwIB2PV0F2wgDEHCVAKA4I4ABNwbZ4DgNGLBAoCWIIgAD/Qwgoa4gBuBmVaQKOmipqKI4/8QzXcAm1AkQpvAcodJGCy213wrhjKxXuGqAs+9xFe6n5LY4rbjj2klvDHdCJW+84dprWL+WzUutvv/OgK9mBrs0sIEKEwwDwpU9LBHD303c8GAWpxGwEgdgdNEB3cw2AB8KeHzCaQGAWhrHNmmpwKFKVIwxChE/RrNDMd8wgA4E6HARzx1ZlMx/6hJrgAMO5GjPSCIqZ1PTT+Ascwk2D3GRI1S/EzUOTSBx7VUZ5VHAF0PyIVwSoSqUC6ZQaC21F3/CHTeVcdPNJ9butO1vfw88gMAD44xzQJgjBKDujTokoMACCjTR1YlO5C113ZPrOTfll0cJbkqzCvDcM4D/x/8AKLaKgMBYEDDS81VGOkDAy0tE7nYhLMoOM7/wMjMF4A+IrEJOusNlFAN/UxF77YDQfrwQxhvCuZBgo5CVCPohWhE2/9wXBfPKz5E89z9s77Dzk+r7QLqaVM8Y8Uahzvbt3/PiPfw8hC9Y/fOfIT/+NtzvV//7h0F/AJzB//JSwAFCIjcIhN37BnTABVpBgBBkAUdoMwJejaAAo0mNCA7AD+mZRgdawsjrZoDB2FzkXCcD0W86NgCOvbAAtZEhaPaQuElNUBISzGEKOIKaN9XoBNAZgPk8IboBNGBMI1hAKpzhJp4FIAGdq4ECgiieYxUOO844Wo4Ih4lwkOZrYpv/XpiApAD3PJCHT9ihGk0wDm+VbgFemlEG06dCpJCIMaWbY6huVToF8E40cjTBiHJENhPIgQy7AoAUb9KWAJ2qjYRgoyQn5ZpMzZF9DehdhAIZoxNhSgvTIUGgtDK6YwmqSHTsYIkKh4ATfimWP1TXP56GxCBVEnkKzCUOxkEaTJ6AFgKAwE6QKIByxKEpJsFldn5zDXmpklJ6NJ0B2hej4CArcYZKnJe0k0ZeBoGSufSlcaJZgmGN4ABaMB0JICRKWTWIGdDMpJwktUdEYhNMfbvUqkrCTHDCQZyVHIc2gGkaVmjIAbGAEwkeVJsHjKkJC3hc0344T0Jq510gpN41/714HKGMRWU7+SZAfSBQSQbOPcCSEK8OkIB0lYI4ZPHNo6TYFdjUSle5cUaw+DCtldL0N8oy2vTOd65YSkd0RS2dFpr1z5Ku4aRt5Agkh3COdcAxklB1g1TVyBFpwLIHsNplId711K3mj6xofQFJX9LWtdKgqzx860roCtcYyDWHdo3IXu/KgrxOsK8NEaxfU2C1wsqAsHhrIGIb6wbFrgOyjp0sARnLHckusBsXfBwQLAtQzAIDtAN8QNDSJECETDZPmFstay+HTsrS4FjF3Eg4OoEJ9F1EG5+gjwhq9CFT8AwUO+AgAF5ZHvQBVEmtXS5z/VRC2K6gJw+iY5lEZv+MZiQhABBoAAK8ITKhlEJD6hzAQXBUk4Bc11LQXe+/FsXImGa3H/TYWfV8tYwaQSB4SWEoO+drD/YC2F4MIAsDcpG7flikOWSwrzMYscwiKIMgCT5sgCu8pZ6ApkS5ww5N3lRfb+qsKB0iB073iJQO28TCKlaRe7GxirORxYZcucaCQfycUWAqi0aCgJu0MuMVAznIQh4ykYts5GBQ+MhKBiBgl+zkyjT5yVJWTJSnbGW/VPnKWqZKlrfs5ZV0+ctifkeYp2wfVswCP2OOn1rXzINqVIMctXUzbuhshJD4w0h2fkSZn+yRHdxtz0Pos5MxnIzyCprPbU70DAoHHT3/MnqSi440paFC6EpjOoCTzjSn3XHpToN6RZsONakVXepTk3nUqF5191TN6ler4dOwnnWjXU3rW3NB1rjeNQqSzOtfAzvUym0usYtt7GMju0nPDfYVVJvsZ0M72tLG0muZ3QXRDhnbwNZ2kLnNa2+vGNw1GPa0y12PZT9G3BZWNwH/Y+53V/s27A7wvGNQ7yrcuwz5hu6+V9BvqHm2MP9ObcDnMHAGOrDgDtpgekABqRQUFAgPVwF30ykr14DwQmo2hVN5EIBzZXIF1IDBImxy1N9QyN/0U/gbDm67hONgTtH5xhRKngNbUzyssxpTARyATiQasyAP8PlyitNFG2QV/9IwiDgF82DzlJ9JBZxxuRtZzlerGxDr2HBW2XZgC5RlooNyLMspMrEcpBkEFzZxkwdtIsV/fF3tFFJNAOKdlKOIYAGKAsWcSgAf+fBWTPeJRcRfsYAi+LYUq/gNC6329wS8zD7D4sTiWyGLPR7+TVJsi+GnrnU09I+EjqB6sz9PgKMCjxzmAAWmcuSyoeQCEwdQAI8ZmZWKNgCsFzoVMq8KmjmWyhuUSr2ek2EhDH13Qx9b27XiA40ihHcalvqtRyt0ITPNaflg44/tk+J8dXqCQ8r4vueD0T8oSvHkBv88VYzXhtQzxdBTuNBW4qvHKSwAFNMA0qSYkim5sMmINf8I8Y2Nj4gE/wXOTuiDWxhTfgHANEhDR2lEfnAY9AREBCbFArrA3+hAOGjgypkf+03NCOREH93QbvlReZygHLnJ48XCbanfDZCeFRjPKCUT78XFAO6AATxAN9ifW0wBnMRH+uAgEeoMmoAG0TRTnhEEQKCJfa2J07UFR7hAg52KfrRY9RlgLAFOHoAEgkWSCwgHCVEhCIaWCEadCEzH7NlEnEzHUQDSNShAKZTSOVgf9aRXyMkgGrrV50URbPwD/MXFg/DBdZ1ecf2g/yXDsAhfipmEIIQKEj7HujTNIgHJED4PpYyfdmCKSu3AGAWAiGHKUTAA6u3ABI6ApXRiHgT/RSy4wHWNkaYA0SeW3xnWy6SYzjENX7MYzhKewqkwg3+9yAziG/sVzlXE3ikGzxQgQFdkj3SARfUoYjMSDlk80zLKxbVkBwRchywoi280YzcaxVUsUibaFwAAi7BcxHoUAJW4wI1tBStMFD4B4xyl4ypiA3m8ozuWDlkYTTuGQy32wvmRUgE0gKEkhQ6aQgOgknbIk49MGB+e1WX8W/7dQD9VQbaEis6hgLaoAzFO5A1IVFH8Fvg1yK5ACjJU1D9MIIpxJA2ApPZIJBRg4A0oIRWkCyisywuw02KFoJ2QYz/ASYUwjU41gz8yAk+hzwT6WFd0yUxKDFS6WUz2lTmJ/0FMus+3SeUWVKUehgFWAtwLPJ0NqIcRVBH4wMDI8cBZNpQcvSQMaIcocBYJ8h26dZBd+ttWYgFYmuFlWdb2NGEQWCUNJAIZFJS+SIUqLcA/xGDBGFEBNCYz7uQJMF0NUKVejh5m+qRhocKw9JGbFEtbwKDbmccB8NFo3IpnQJ6YmN18EA48QUcKegb1XZAU7cBhIdgraNFVlAKVwJA0JE0LJcOcjeZ8jIKXAKfXTcgnHGFtkh2aMUbdRQeViB11Oh51rsYUOF58rCZ23VAPaWYxIt0N6YwOuInOTOYNuEYPgoZsjEDF8U94fuTtZN+I1eErleInoOMxJAHq7F5BnP+Ldx3Fx1HP61EPphBHpkwDHNYnm/hnIIIhOeQBp8AJNIBCdc3Hx/EgNuLIcBgkf+4nIjbUhm5DN8QJBGQPmOwBhOqRCzTjC/XOObTeDmgnH2RDNyCRT+jO8eXC95UieP7kQ9TEGJJXpIwHzpXAc8wcdWCROD5HY+YlzKEAApKXQ0IeBHiSMD7gJsnKL40PU0IUWRRXLljk+IAEGJmHGnKpNOoREgiOJ/1ZGH4JGWhp06jSODShQUQTA6wpGRSBiGiHMB2L/NHoDgiqUP5o6uWDu9kdDg2k1WWVIFRc32UK2s1h2AnexsEeCXqFf/QDRlaWlJ5AFMbT2RyjhDYH/T3/jZeu0gTyoA+KAOoMzirVw3CUTAZBlHL4aZuaqpjGaRkiip92DAMCH/SIRDSpaoa2aJpIQymozpzOAgM46yeujaJuBO+kEJDaIg1cUke4ysfJaRwIwOzVXjbU59oUBIjEonsIzgjYU2LJZ5CegCrmwUqO3Bi5pCmchzweyjkywyHmhCwci3hwIsn8aIrNyr4CCfi5xaLcqxhih+60RdMkDYfVBCNginoFCZDgXTSxQnEs7J+mSYLiyMc1zXX1DJ3kyGJqoWnx3LJd5kOojFHMI7B6FBCiRgVmovUUCWpZZrxuKwrcoypwhSbMia6AQlNew1Y46bv6axJA4yB5wiFm/4qEPFpx+SMLMa2IuUoD/KmuGK0/8l2MTUGuDIWrZM/RyphT9kRaFCvNsoU0HQdXcC1REol2jMUoeJ0zFiqOWCNp5JT9oSKw6ArMAm1YxlW05AMrzCqbnkQUNoqzMFQ9+dPPiioUdBxZispdxSwNMB2aFcUlKlEsMQW9KuimdEpGEVWdwOTh8gJdUSMOeGRhde4MmGY13tQ46goG7SqipGO8FcvARgg5gsh4xOfl0lrtzkBV+YBGogC39BBeogBfItyuKa8MgBUQ5CTEtQsKzOPxUozrStn1Bgb1vpz1iu/5Hob5GgH78hL5VgFb6lv6PoL7jhP9DgFkDeZe4m8h2P/vQPXvU1bBAFhqmtiCfoqF2Yln+GqlvGJu59BemkwgpzTDWwLB/15wABsZ/I5BPyjDQ6YJEykUDWowIGDwVJWwD9gVqW6EAZqOAxZPCtfBCXuVDPcl5n6ihiUBTiQBK1xXDDuQu73bEBNxEbuWDffS4dbdsoysqwzSMU4REH8HuRlxFVvxFUuJ9M6wEiOpTFpbt3ExHNDwFwscEoPBGJNx+Zrxta1xGjfMxLhndEGp76TnC6hlErvxujEWFNlgCozlX/UD7VQm+OYxgE0M9H0IKxCwLNBCNNyC9ckRK4jCDflmKEayJ8jRCaLmK6FCJ2xnJ4fCKLwlGhdyXRxy6ZD/gjeVQq2Iw1KYA+QxlI+KhYfKHkOx4eSW0rFcH6LcYY9ygzTMMSmXMp7scSiOEgQiBUJwaAYyanmSbhzp4tPyso+khQ406s4OM7/tMYVhYU0oM84yBk3IRpwmxUF2AqD2iuD6iDhnqwoIczYnzB4naauUWJAoohi+bCg+c0micz1Os8uChl2+MzxHJcA0ynp88z33lj9uiEHs6lB6rSb6iLUudOFGKUFTVt7MrgNjNGK1TU9uZkc31kCzh0g7FklXnUmP9PtYkHIpcuaiQWXCp7aqtF8pzA8lA7Z6stF18RIIwpO6cxvXNPKOqKOi49j6HXcaZ32ggqYi4tF1ROls/0InTHJtVDWinMYmqBVKD/Xr3k63JgNZuInNFsTxZQgEcgi6FtcvF+CDgEIV/nIpyrII1d55BHVXc+7tsGonzElvskIBSjSVksAHJtNocBMjNXM1112I3eSR0DReb9XAsKpHNWHjoqIyQC4OfYF9tOOqsLPIfPZ8QEAfO/b0CjVka8bAfG66DkVRYOKkMBgnGgcstkGwDEWO5XM+BwDt3YhXahVql9TA3C420O3v7e4Tghg6Bku1AWREl8A5MKxyWzThogczto/xPjZwg5PCMK9zqOFzIcy43rV2B/f7ZO8PbO/MGMH3Zjd5A/BicLV7/0F8G7V8o1T/yu9VnrZ9r/9v/+5v6fH3/Q5wATPDASetHCGXFwf4fVcBJsiQDvszBTuABYPPfi+4/4TxsbZwCJOCFlf4haNwg3vwRWx4g7zw4dI3iINeGE9XPrhCD/dWT4eqiuuVEsNUE0cjFM+xANN4YGX4Y1l4jxOziItxkAt5H8K3kR95XSl5Vi75ABkPDWGBlGfwk0P55/23EuS3Cje5lWcNlntJAgeycB4XIxheJxDXKxknuOYWJ4ACAV8yHns5/hhPkWCKIX7JQdqEA5So8LEsQIQKjcbednVXdo0rQ8n5nMNPnbsHnOjAIPnf0zDSSCgAf+XC4LQSsiTiDSu68jD6rBTHRSDaFMzESID/jYRZT4057h52+qKDeQZZEyNQ7Cm6CSBxrYm5mJh82KoTcqsfT51/Y6X743Ch7Q6cEW+uxeoCRK3bSupoOq9brq97epdDDrVLuySk+G9fu9Rke7Zve/X297fLjsJY0GkQV3bKuBHIdB3Xt7i/8fvgNHLYaaiv8U9ro2m7O7ffTtKlc/QodeDZh1Mbnlx86lR7p1WLMlaDK6imdL5jzMCAdYZ5soQgpJCYdfKdq3GUaHS/hVt7X1z3HMjTtbO8KxI6/LvngKB0EWTeNnL/iM4mitKdhGGfEWJb8yk0cyg2tm97+8l/OApMtqOYAGBD4Yjv7GbLx62cIraCNtOLNmnztby1+/z6QZyzCP2bFJ3LV4psFwMtmoBtI58s5HZA6wBvVy6+T/2/CLdDBi6uIKXW/8pyG0dztwF0NwF1dwLeWzd1bC42pz29cPdMOu8JhDe69fzfs3oKnLcPpDfhr/dc+j3io0q3S73kr3iSW/64UH7mC0zl56/nc/5Xgj6Ph77G2M/olz5XCjEWG9s1p/5tUDHrE5uHv37t2/7t437u6/7u837v+/7vA3/wC//wE3/xG787hAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Prophylaxis should be strongly considered.",
"     <br>",
"      &bull; Prophylaxis is recommended.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44734=[""].join("\n");
var outline_f43_43_44734=null;
var title_f43_43_44735="Appendicitis ultrasound";
var content_f43_43_44735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler ultrasound of appendicitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this doppler ultrasound image of appendicitis, the appendix appears edematous (9 x 8 mm) and hypervascular. The layers of the wall are still detectable. Continued inflammation may be followed by localized ischemia (which may be visualized by color Doppler imaging) and necrosis. Sonographic findings were confirmed at surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christoph F Dietrich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_43_44735=[""].join("\n");
var outline_f43_43_44735=null;
